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Abstract 
Low-grade inflammation has been associated with the risk of chronic pathologies 
including cancer, atherosclerosis and type 2 diabetes. Epidemiological studies 
demonstrate an inverse correlation between diets rich in cruciferous vegetables and risk 
of cancer, cardiovascular disease mortality and circulating levels of pro-inflammatory 
cytokines. Sulforaphane (SF), an isothiocyanate obtained from broccoli, has many 
biological functions. The aim of this thesis was to test whether SF was able to suppress 
pro-inflammatory signalling using in vitro models of chronic inflammation.  
 
In human monocytes (PBMCs and THP-1 cells), physiologically relevant concentrations 
of SF significantly suppressed the production of LPS-induced cytokines IL-6, IL-1β and 
TNFα. The suppression was also observed with all genes induced by 1ng/ml LPS as 
measured by whole genome arrays. In addition, it was demonstrated that SF could 
directly interact with thiol groups of cysteine residues 609 and 246 within the LPS 
receptor, TLR4 under non-reducing conditions, to reduce the levels of inflammatory 
mediators that are produced in response to LPS.  
 
The anti-inflammatory effect of SF was not restricted to the TLR4 pathway, and 
significant reductions were observed in NF-κB activity induced in response to TLR2 and 
NOD2 ligands. These findings were translated into a more complex in vitro model, 
investigating the effect of SF on lipid accumulation within adipocytes and adipose tissue 
inflammation in response to macrophage-conditioned medium (MaCM) using human 
SGBS adipocytes. SF at 10µM significantly reduced levels of lipid accumulation within 
adipocytes and increased the expression of carnitine palmitoyltransferase-1A (CPT1A), 
suggesting a role in energy metabolism, a process often disrupted in obesity. In addition, 
a significant suppression in SGBS adipocyte IL-1β and IL-6 expression was observed 
when adipocytes were exposed to MaCM from SF-treated macrophages, when SF was 
used at a concentration as low as 2µM.  
 
This work demonstrates that concentrations of SF that could be achieved via reasonable 
broccoli consumption can suppress pro-inflammatory cytokine production, induced in 
response to a number of signalling pathways in addition to suppression of lipid 
accumulation and adipose tissue inflammation. The relevance of this data supports the 
concept that consumption of broccoli could lead to a reduction in the chronic 
inflammatory status in vivo as well as a suppression of lipid accumulation within 
adipocytes, to reduce the risk of developing chronic disease. 
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TXN     Thioredoxin 
TXNRD1   Thioredoxin reductase 
UC     Ulcerative colitis 
VCAM-1   Vascular cell adhesion molecule 1 
WST-1 4-[3-(4-iodophenyl)-2-(nitrophenyl)-2H-5-tetrazolio]-1,-benzene 
disulfonate 
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CO2    Carbon dioxide 
Cu
2+/1+   
Copper (II)/(I) 
Da     Daltons 
H2O2    Hydrogen peroxide 
HCl    Hydrochloric acid 
kDa    Kilodaltons 
µm    Micrometres 
µM    Micromoles per litre 
µg/ml    Micrograms per millilitre 
M     Moles per litre 
mg/l    Milligrams per litre 
mg/ml    Milligrams per millilitre 
ml     Millilitre 
ml/min   Millilitres per minute 
mm    Millimetres 
mm
3
    Cubic millimetres 
mM    Millimoles per litre 
m/z    Mass to charge ratio 
NaCl    Sodium chloride 
NaPi    Sodium phosphate 
ng/µl     Nanograms per microlitre 
ng/ml    Nanograms per millilitre 
nl/min   Nanolitres per minute 
nm    Nanometre 
nM    Nanomolar per litre 
pg/ml    Picograms per millilitre 
ppm    Parts per million 
rpm    Revolutions per minute 
V     Volts 
v/v    Volume per volume 
w/v    Weight per volume 
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1.0. Summary of the thesis 
This thesis contains the results of a research project that was concerned with 
investigating the hypothesis that sulforaphane (SF) would exert anti-inflammatory 
effects on a number of different inflammatory signalling pathway using physiologically 
relevant in vitro models of chronic inflammation. Cell culture models are often used in 
research and have both benefits and limitations. Cell models, either primary or 
immortalised can provide an alternative to in vivo experiments with few ethical issues, 
which allows for initial studies into the mechanistic details and efficacy of the test 
compound to be carried out. These models can present an indication of potential 
biological activities and can behave as a basis for designing in vivo studies with animals 
or humans. However, primary and immortalised cell lines are often homogenous cell 
populations which are not representative of the in vivo environment where a tissue is 
supported by multiple cell types. In addition, they are not cultured under hypoxic 
conditions and are not subjected to certain growth factors and proteins that would be 
present in the blood circulation. However, in vitro models are practically simple to use 
and can be well-controlled and demonstrate reproducibility. 
  
Initially, human monocyte cell models were used to investigate whether physiologically 
relevant concentrations of SF were able to suppress lipopolysaccharide (LPS)-induced 
cytokine production measuring selected pro-inflammatory biomarkers interleukin-6 (IL-
6), interleukin -1 beta (IL-1β) and tumour necrosis factor alpha (TNFα) in terms of the 
secretion level and also the transcriptional level. This was progressed into investigating 
the effect of SF on global gene expression induced by LPS at a low concentration of 
1ng/ml, relevant to that found circulating in individuals with chronic disease. Next, 
investigations were carried out into the mechanistic details of the effects of SF and the 
aim was to determine whether SF was able to directly target the LPS receptor, Toll-like 
receptor (TLR) 4 via modification of thiol groups of cysteine residues present in the 
extracellular domain of the receptor, the area responsible for ligand binding, using cell-
free and in vitro models. The scope of the investigations were broadened to investigate 
whether SF was able to target additional important inflammatory signalling pathways 
namely TLR2 and NOD2 (nucleotide-binding oligomerisation domain-containing 
protein 2), by measuring whether SF could target nuclear factor kappa B (NF-κB) 
activation in response to appropriate ligands. In the experiments with cell models 
expressing the individual inflammatory receptors, the two commonly studied forms of 
SF were compared, the L-SF and the DL-SF. The L-SF is the natural form of SF 
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extracted from broccoli while the DL-SF is a synthetic analogue of L-SF and it was 
hypothesised that these would behave to a similar extent.  
 
The final stage of this thesis involved translating the multi-targeted anti-inflammatory 
effects of SF into a more complex in vivo model of obesity, a condition characterised by 
chronic inflammation. Firstly, it was investigated whether SF was able to exert effects 
on lipid accumulation and metabolism in human SGBS adipocytes, followed by studying 
whether physiologically relevant concentrations of SF could suppress SGBS adipocyte 
cytokine expression induced in response to macrophage-conditioned medium (MaCM) 
from human THP-1 macrophages.  
 
The purpose of this general introduction is to introduce the concept of inflammation and 
how a low-grade, persistent state can impact on the development of chronic diseases 
including cancer, cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM). It 
will cover how diets rich in cruciferous vegetables have been shown to demonstrate 
beneficial effects on the risk of developing such pathologies, and will describe how 
glucosinolates (GSLs), which are found at high levels in cruciferous vegetables, may be 
responsible for the observed health benefits. The breakdown of GSLs to biologically 
active isothiocyanates (ITCs) will be explained with a particular focus on SF and its 
known functions. As the objectives of each chapter focuses on different aspects of the 
anti-inflammatory effects of SF, each results chapter will also provide an introduction to 
the literature relevant to the research aims of that chapter. 
 
 
1.1. Inflammation 
Inflammation is a complex adaptive response that occurs in response to harmful stimuli 
in order to counteract the insult they are trying to exert. This process behaves to underlie 
a number of physiological and pathological disorders and while a great deal is 
understood about the cellular and molecular mechanisms involved in the response to 
infectious stimuli, much less is known about the instigators of systemic chronic 
inflammation. Nevertheless, a common explanation for inflammatory responses 
irrespective of the cause is the drive to restore homeostasis. 
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1.1.1. Acute versus chronic inflammation 
Classic triggers of an acute inflammatory response are infection and tissue injury. 
Macrophages sense the presence of the inflammatory stimulus leading to the recruitment 
of neutrophils to the site of insult [1, 2]. In the majority of cases, this process occurs 
over a short time course and is beneficial to the organism. However, if the process 
becomes disordered and the inflammatory response is unable to eradicate the pathogen, 
the inflammatory response persists replacing the neutrophils with additional 
macrophages and T lymphocytes. If this course of action is still insufficient, a chronic 
inflammatory state develops, with detrimental effects [3]. While the causes and 
mechanisms of localised chronic inflammation are partly understood, the development 
of systemic chronic inflammation, which occurs in a wide variety of diseases including 
cancer, CVD and T2DM, is less well understood. It is suggested that it is associated with 
a tissue malfunction where a number of fundamental physiological processes that are not 
necessarily directly related to tissue repair or the host defence response are disrupting 
the homeostatic balance [3]. 
 
 
1.1.2. Inflammatory signalling pathways involved in chronic inflammation 
Thus far, four different families of pattern recognition receptors (PRRs) have been 
identified, with the most commonly studied being the TLRs and the NOD-like receptors 
(NLRs). They behave to recognise exogenous microbial products known as pattern-
associated molecular patterns (PAMPs) as well as endogenous molecules released from 
damaged cells, collectively known as damage-associated molecular patterns (DAMPs) 
[4]. Each class of PRRs have a number of family members which allows a certain level 
of specificity towards different microbial or non-microbial structures. Most relevant to 
the studies within this thesis, are the TLR4, TLR2 and NOD2 pathways. 
 
 
1.1.2.1. TLR4 and TLR2 signalling pathways 
The TLR family of PRRs consists of 10 family members in humans all of which are 
characterised by a common structure consisting of an N-terminal domain of leucine-rich 
repeats (LRRs), a region that spans the cell membrane, followed by a cytoplasmic 
Toll/IL-1R homology (TIR) domain [4]. The LRRs extend into the extracellular space of 
the cell and are responsible for the recognition of each specific ligand, which leads to the 
activation of the receptors and downstream signalling, a process controlled by the TIR 
domain [5]. A diverse array of the TLR family members are commonly identified on 
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cells that are involved in the immune response such as leukocytes and cells of the 
spleen. In addition, they are highly expressed in cells that are exposed to microbial 
pathogenic components such as those in the lungs, small intestine or colon [6]. TLR1, 2 
and 4-6 are present on the plasma membrane, while TLR3, 8 and 9 are present 
intracellularly on endosomes or lysosomes [4]. 
 
The TLR4 molecule was identified as the receptor able to respond to LPS, an endotoxin 
that is present as a component of the outer membrane in Gram-negative bacteria [7]. The 
lipid portion of LPS known as lipid A is responsible for the pathogenic nature of this 
endotoxin and is the causative agent of septic shock [7]. When LPS is released from the 
cell wall of Gram-negative bacteria, it binds directly to the LPS-binding protein (LBP), 
present in circulation, which in turn interacts with CD14, a glycosylphosphatidylinositol 
(GPI)-anchored protein present at the cell membrane. This complex then facilitates the 
transfer of LPS to MD2, the co-receptor for TLR4 (Figure 1.1). The structure of LPS 
consists of six lipid chains, of which five bind within the hydrophobic pocket of MD2, 
with the remaining chain able to bind to the TLR4 [8]. This binding results in 
homodimerisation of two TLR4-MD2-LPS complexes which is necessary for 
downstream signal transduction [5]. 
 
The TLR2 receptor is able to recognise a number of different components from bacteria, 
mycoplasma, fungi and viruses, of which lipoproteins from bacteria and mycoplasma are 
most commonly described [4]. Unlike the TLR4 molecule, following ligand activation 
the TLR2 receptor undergoes heterodimerisation with either the TLR1 molecule to form 
a complex capable of recognising triacyl lipopeptides, or TLR6 in order to recognise 
diacyl lipopeptides (Figure 1.1) [4]. This specificity is as a result of different structures 
within the TLR dimers. The TLR2-TLR1 complex forms a structure where two acyl 
chains of a triacylated lipopeptide are able to interact with TLR2 and the third acyl chain 
is able to interact with the hydrophobic pocket of TLR1. In the TLR2-TLR6 dimer, the 
TLR6 molecule does not have a hydrophobic pocket and as a result can only recognise 
lipopeptides with two acyl chains [5]. 
 
In addition, TLR2 has the capability to interact with other cell surface receptors such as 
CD36, the principle receptor for oxidised low-density lipoprotein (oxLDL) (Figure 1.1) 
[9]. CD36 has a function analogous to CD14, in which it accentuates the response of 
TLR2 to diacylglycerides by binding with the ligand directly via its ectodomain [10, 11]. 
OxLDL is known to induce pro-inflammatory cytokine production with TLR2, CD36 
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and also TLR4 being necessary for this cell response [12]. This emphasises the 
important role of TLR2 in the recognition of endogenous ligands such as oxLDL which 
are crucial in chronic disease, most importantly in CVD.  
 
Following ligand binding, downstream signalling is dependent on the recruitment of 
adaptor proteins. For TLR4 signalling, two pathways can be activated following the 
recruitment of MyD88 (myeloid differentiation primary response gene 88) and TRIF 
(TIR-domain-containing adapter-inducing interferon-β), while TLR2 signalling is 
specifically MyD88-dependent (Figure 1.1) [5]. The MyD88-dependent pathway is 
responsible for the activation of the transcription factors NF-κB (nuclear factor kappa-
light-chain-enhancer of activated B cells) and AP-1 (activator protein-1), which control 
the expression of pro-inflammatory cytokines and chemokines [13]. In TLR4 signalling, 
following MyD88-dependent pathway activation, the TLR4-MD2-LPS homodimers 
undergo endocytosis which initiates the recruitment of TRIF. This MyD88-independent 
pathway ultimately activates interferon regulatory factor 3 (IRF3) which is responsible 
for controlling the expression of type I interferons (IFNs) and subsequently IFN-
inducible genes [5]. Even though the TLR4 is able to activate these distinct signalling 
pathways, the expression of pro-inflammatory mediators is dependent on the activation 
of both pathways, for reasons which remain unknown [5]. 
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Figure 1.1. Overview of TLR2 and TLR4 signalling. During recognition by TLR4, 
LPS binds to the TLR4-MD2 complex with the aid of LBP and CD14 accessory 
proteins. The binding of LPS to the TLR4-MD2 complex results in homodimerisation 
and activation of an intracellular signalling cascade. This can be MyD88-independent or 
dependent. The MyD88-independent pathway occurs following internalisation of the 
TLR4-MD2-LPS complex, where it is retained within the endosome, leading to the 
recruitment of TRIF. This results in the early activation of IRF3 followed later by NF-
κB which controls the expression of type I IFNs and IFN-inducible genes [5]. The 
MyD88-dependent pathway stimulates NF-κB and AP-1 resulting in pro-inflammatory 
cytokine and chemokine expression [5, 13, 14]. The MyD88-dependent pathway is also 
activated as a result of lipopeptides binding to TLR2 heterodimers with TLR1 and TLR6 
and also in response to endogenous ligands such as oxLDL with the aid of CD36 [11, 
12]. 
 
 
1.1.2.2. NOD2 signalling pathway 
The NLR family of receptors consists of cytoplasmic PRRs that share a conserved 
structure of a C-terminal LRR domain involved in ligand recognition, a central NOD 
domain that allows self-oligomerisation, in addition to a varying number of N-terminal 
caspase-recruitment domains (CARDs) involved in protein-protein interactions [15]. 
NOD2 is mainly expressed in the cytosol of antigen-presenting cells but also by 
epithelial cells at a lower level. The expression level of NOD2 is augmented by pro-
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inflammatory cytokines including tumour necrosis factor-α (TNFα), meaning once 
activated following ligand binding, NOD2 is able to control its own expression [15]. It 
behaves to specifically recognise muramyl dipeptide (MDP), a breakdown product of 
peptidoglycan (PGN) derived from both Gram-positive and Gram-negative bacteria. The 
ubiquitous nature of PGN presence, allows in principle, for NOD2 to respond all 
bacteria [15]. The way in which the cells are able to encounter the breakdown products 
of PGN is unclear, however one suggestion applicable to antigen-presenting cells is the 
notion that phagocytic cells such as macrophages are able to engulf the whole bacteria 
and digest them into their relevant peptides [16]. The same mechanism is not thought to 
apply to epithelial cells and instead it has been proposed that MDP is delivered to the 
receptor through a peptide transporter [17]. 
 
Once MDP is available to the NOD2 receptor, it is able to bind directly to the LRR 
domain of the receptor [15, 18]. Unlike with TLR signalling, there is no dimerisation 
with other members of the family and instead it is suggested that ligand binding induces 
a conformational change in the NOD2 receptor. It is this change in conformation that is 
responsible for the activation of the receptor and recruitment of RICK (receptor-
interacting serine/threonine kinase) via a CARD-CARD interaction [19]. RICK is 
responsible for targeting the inhibitor of NF-κB (IκB)-kinase-γ (IKKγ) for 
polyubiquitinylation resulting in its degradation and the ultimate activation of NF-κB to 
allow production of pro-inflammatory cytokines (Figure 1.2) [19]. 
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Figure 1.2. NOD2 signalling. PGN from both Gram-positive and Gram-negative 
bacteria is broken down into MDP. MDP is the specific ligand for NOD2 and interacts 
with the LRR domain (purple) of NOD2 in order to activate the receptor. This results in 
the recruitment of RICK which is able to interact with the NOD2 receptor through a 
CARD-CARD (red) interaction. RICK targets the principle regulator of the NF-κB 
inhibitor, IKKγ for polyubiquitination and subsequent degradation. While NF-κB is 
sequestered in the cytosol it is inactive. Degradation of the IKKγ leads to translocation 
of NF-κB to the nucleus leading to its activation and induction of pro-inflammatory 
cytokine expression [19]. 
 
 
1.1.3. The importance of chronic inflammation in disease 
The complex signalling pathways that are necessary to maintain appropriate homeostasis 
of the immune system following an inflammatory attack may become less efficient with 
age and this in turn would lead to disorder in immune responses [20]. This lack of 
regulation presents itself with an increase in the levels of circulating inflammatory 
biomarkers including interleukin-6 (IL-6) and TNFα, observed in an elderly population 
as compared to a younger cohort, which could lead to unfavourable health consequences 
[21]. 
 
The link between a state of low-grade inflammation and the development of chronic 
pathologies such as CVD, cancer and T2DM has been widely studied in recent years. 
With the risk of developing these diseases largely increasing with age, it is possible that 
the elevation observed in the levels of pro-inflammatory cytokines in older populations 
may have an important role.  
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1.1.3.1. Cancer 
When a chronic inflammatory state persists, there is a cycle of consistent activation of 
macrophages resulting in a continued process of tissue damage, which in turn activates 
cell proliferation. A continued increase in the level of cell proliferation lends itself to the 
possibility of neoplasia [22]. Inflammation has been consistently associated with cancer 
development in recent years with a highlighted role of NF-κB, the transcription factor 
responsible for controlling the expression of pro-inflammatory cytokines including IL-6, 
TNFα and C-reactive protein (CRP) [23-25].  
 
The role of circulating IL-6 in cancer was reviewed by Heikkila and colleagues 
involving the findings of 189 studies. Across the majority of the studies, there were 
consistent findings of elevated levels of circulating IL-6 in cancer patients compared to 
healthy controls, however this review was unable to determine any diagnostic capability 
due to few prospective studies included [26]. Aggarwal and colleagues also aimed to 
understand the link between pro-inflammatory cytokines and cancers at different sites. 
They identified an important role for IL-6 particularly in multiple myeloma, lymphoma, 
bladder, lung, breast and colon cancer risks, while with TNFα, the main association was 
with pancreatic cancer [25, 27, 28]. Furthermore, Il’yasova and colleagues discovered 
that the increased level of pro-inflammatory cytokines were more strongly associated 
with the risk of cancer mortality rather than cancer development [29]. 
 
As previously described, activation of TLR4, TLR2 and NOD2 signalling pathways 
results in the induction of pro-inflammatory gene expression. Interestingly, in patients 
suffering from multiple myeloma, a higher expression level of both TLR2 and TLR4 
was observed in bone marrow-derived mononuclear cells [30]. 
 
 
1.1.3.2. Cardiovascular disease 
In terms of CVD, a widely accepted risk factor is elevated cholesterol levels which are 
highly predictive in younger populations. However, when studying elderly populations, 
this risk factor becomes less reliable [31]. It was hypothesised that this may be as a 
result of not accounting for the increased levels of pro-inflammatory cytokines within 
circulation of the older populations. This suggests that a state of low-grade inflammation 
has a more extensive role in the development of CVD in the ageing population [21]. In a 
large population of elderly men and women, it was observed that those diagnosed with 
sub-clinical or clinical CVD had elevated levels of IL-6, interleukin-1β (IL-1β), TNFα 
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and CRP [32, 33]. Additionally, these cytokines, in particular IL-6, had the ability to 
predict the risk of CVD incidence [34, 35]. 
 
Also of importance are the elevated expression levels of TLR2 and TLR4 that have been 
identified in human atherosclerotic plaques isolated from patients [36]. In combination 
with findings of significantly higher levels of endotoxin in patients diagnosed with 
carotid atherosclerosis than those observed in patients with no diagnosis, it is possible 
that the endotoxin could activate the TLR4 signalling pathway resulting in the elevation 
of pro-inflammatory markers seen in CVD [37]. 
 
 
1.1.3.3. Type 2 diabetes mellitus 
Similarly, the development of T2DM has been linked to inflammation, due to the 
involvement of pro-inflammatory cytokines in the development of insulin resistance 
[21]. Elevated levels of IL-6, IL-1β and TNFα have been identified in subjects with 
T2DM compared to healthy controls [38-42]. It was also determined that those 
individuals that presented with the highest levels of circulating IL-6, were most likely to 
develop T2DM in the future [43]. Additionally, both TLR2 and TLR4 were up-regulated 
in obese patients suffering from T2DM compared to non-diabetic obese subjects [44]. 
The relevance of this increase may be further explained following the findings presented 
by Creely and Al-Attas, where levels of circulating endotoxin were elevated in those 
patients suffering from T2DM [45, 46]. 
 
 
1.1.3.4. Inflammatory bowel diseases 
Crohn’s disease and ulcerative colitis (UC) are collectively known as inflammatory 
bowel diseases (IBDs). The innate immune system is largely involved in these disorders 
and increased levels of a large range of pro-inflammatory cytokines including IL-6 and 
TNFα are often observed [47]. In addition, there is a significant increase in the 
expression levels of TLRs including the TLR2 and TLR4 receptors in patients suffering 
from IBDs [48-50]. 
 
Principally, the gene most commonly studied and linked to Crohn’s disease is the NOD2 
gene. Three polymorphisms in NOD2 were commonly identified in Crohn’s disease, 
which collectively account for approximately 82% of all mutated alleles observed in 
sufferers [51, 52]. The Leu1007 (3020insC) insertion polymorphism results in a 
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frameshift mutation leading to the introduction of a premature stop codon and the 
translation of a truncated NOD2 protein with the final 33 amino acids missing [53]. The 
two other single nucleotide polymorphisms (SNPs) result in missense mutations 
Arg702Trp and Gly908Arg with a single amino acid substitution within the LRR of 
NOD2 [53]. TLR2 and TLR4 polymorphisms have also been identified as potential risk 
factors in Crohn’s disease but with a much lower prevalence and the results are 
controversial [54-62]. 
 
 
1.1.3.5. Involvement of obesity in chronic diseases 
An additional independent risk factor that may play a role in the increase in levels of 
pro-inflammatory cytokines within these chronic diseases is the coexistence of obesity 
[63-74]. Due to the knowledge that the likelihood of suffering from obesity increases 
with age [75], it is possible that this is in part responsible for the elevated levels of 
circulating pro-inflammatory cytokines found in elderly populations, which in turn, may 
result in an increased risk of developing chronic diseases.  
 
In terms of the link with cancer, obesity has been consistently associated with cancers in 
many locations and it was found that with each increase of 5kg/m
2
 in body mass index 
(BMI), a 30% increase was observed in all-cause mortality and a 10% increase in cancer 
mortality specifically was identified, highlighting the enormity of the obesity problem 
[76]. Further support for the link between obesity and cancer comes from evidence 
demonstrating that with weight loss as a result of bariatric surgery, the risk of 
developing cancer reduced by around 20% [77, 78]. A relationship is also observed 
between higher BMI status and risk for developing CVD [79]. This association as with 
cancer and obesity, was found to be also affected by bariatric surgery with individuals 
who had undergone surgery reducing their risks of cardiovascular adverse effects, 
specifically myocardial infarction (MI) and stroke [80]. With CVD, there is however a 
paradoxical nature to the relationship with evidence to suggest that in patients that have 
suffered a MI for example, have a better survival rate if overweight [81]. However while 
this may be true, this positive impact of obesity is at an endpoint e.g. after a MI. 
However, if these individuals were not overweight prior to the attack, it is possible that 
this event could have been prevented.  
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1.1.4. Characteristics of Obesity 
Obesity is characterised by an increased fat mass, thought to be due to the hypertrophy 
of adipocytes in combination with the proliferation and differentiation of preadipocytes 
within the adipose tissue [82]. Two major processes involved in the symptoms and 
common accompanying conditions of obesity are disordered lipid metabolism and an 
increased inflammatory response (Figure 1.3). 
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Figure 1.3. Overview of changes in adipose tissue in obesity. In lean individuals, the adipose tissue is able to control lipid metabolism for the body. The 
adipose tissue in a lean individual is composed of approximately 10% macrophages and they are found in close proximity to blood vessels [83]. When 
skeletal muscle tissue develops increased energy demand, lipids are supplied from the adipose tissue for β-oxidation and subsequent adenosine triphosphate 
(ATP) production [84]. In the adipose tissue of an obese individual, the adipocytes are larger in size as a result of increased lipid accumulation [82]. The level 
of macrophage infiltration can reach up to 40% of the stromal vascular fraction and they cluster around the adipocytes in crown-like structures. These 
macrophages secrete increased levels of pro-inflammatory cytokines [83]. Lipids are deposited into skeletal muscle tissue with the rate of uptake outweighing 
the rate of β-oxidation [84]. This results in release of free fatty acids (FFAs) into circulation. 
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1.1.4.1 Lipid metabolism  
Adipocytes are able to store triglycerides intracellularly as an energy source from dietary 
intake. The adipose tissue principally regulates lipid metabolism for the whole body. 
When energy is required, the adipocytes are able to induce the rapid hydrolysis of the 
stored triglyceride molecules for conversion to FFAs which can be transported to where 
they are required in the body in order to be metabolised as an energy source [84]. When 
these mechanisms become disrupted and the levels of triglyceride storage expands 
within the adipocytes as a result of increased consumption of saturated fat in the diet, 
lipolysis may be induced regardless of energy requirements, leading to increased levels 
of circulating FFAs [84]. A significant positive correlation has been consistently found 
between the elevated levels of circulating FFAs in patients with obesity and insulin 
resistance in addition to an increased level of fatty acids accumulating in skeletal muscle 
[85-87]. In a lean subject, fatty acids are deposited into skeletal muscle when energy is 
required from an alternative source to glycogen, which in some circumstances can 
account for 90% of the total energy demand [88].  
 
When FFAs are taken up by the cells they are esterified into long-chain acyl coenzyme 
A (CoA) molecules, and require transport across the mitochondrial outer and inner 
membranes. This involves a complex of enzymes that enable conjugation of the long 
chain acyl-CoA molecules to carnitine by the enzyme carnitine palmitoyltransferase 
(CPT)-1, the rate-limiting enzyme which catalyses the production of acylcarnitines. 
Acylcarnitines are transported across the mitochondrial membranes by carnitine 
translocase. Once inside the mitochondrial matrix, CPT2 catalyses the conversion of the 
acylcarnitines back to their respective acyl-CoA and carnitine components. The long 
chain acyl-CoA is then able to enter β-oxidation [88, 89]. 
 
During the β-oxidation process, the long chain acyl-CoA molecule is shortened by two 
carbons each time resulting in the production of acetyl-CoA, NADH (nicotinamide 
adenine dinucleotide) and FADH (flavin adenine dinucleotide). These intermediates are 
able to enter the tricarboxylic acid (TCA) cycle and ultimately produce ATP following 
the electron transport chain process [88]. Due to increased uptake of lipids during 
obesity as a result of excessive dietary intake, the rate of lipid uptake outweighs the rate 
of β-oxidation which in turn leads to the export of FFAs into the systemic circulation 
[88]. 
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The link between the increased level of lipid accumulation within the growing 
adipocytes and a heightened pro-inflammatory status may be due to the ability of FFAs 
to signal via the TLR4 as an endogenous stimulus, resulting in the activation of NF-κB 
and subsequent production of pro-inflammatory cytokines, as demonstrated in murine 
3T3-L1 cells and BV-2 microglial cells [90, 91]. 
 
 
1.1.4.2. Adipose tissue inflammation 
Elevated levels of pro-inflammatory mediators including TNFα, IL-6 and CRP have 
consistently been demonstrated within the adipose tissue of obese subjects [92-94]. 
While this elevation in pro-inflammatory cytokines is well documented, it was not until 
2003 that Weisberg and colleagues reported that there were significantly higher levels of 
macrophage infiltration within the adipose tissue of obese individuals [83]. In research 
by Fain and colleagues it was determined that the production of particularly IL-6, IL-1β 
and TNFα, was by cells present in the stromal vascular fraction (SVF) of the adipose 
tissue and not the adipocytes themselves [95, 96]. Adipose tissue macrophages (ATMs), 
were found to constitute around 50% of the leukocytes found within the SVF [97] and 
Weisberg was able to provide some evidence that the pro-inflammatory cytokines 
identified within the adipose tissue were primarily produced by these ATMs [83].  
 
A potential explanation for the observed increase in macrophage infiltration into adipose 
tissue of obese individuals was the induction of hypoxia [98, 99]. As the adipocytes 
grow in size, an increase in the tissue mass may result in the vasculature becoming 
insufficient to maintain normal oxygen conditions throughout the expanding adipose 
tissue. Hypoxic conditions thus induce an inflammatory response which leads to the 
infiltration of macrophages into the adipose tissue and subsequently the production of 
pro-inflammatory mediators in order to induce angiogenesis to improve available 
vasculature [99]. The notion of hypoxia-induced inflammation was confirmed via the 
exposure of stromal vascular cells to hypoxic conditions in vitro which resulted in a 
significant increase in pro-inflammatory cytokines such as IL-6 and TNFα, with the 
production dependent on the ATMs that had infiltrated the tissue [97, 100]. An in vivo 
study with the use of an obese murine model was able to demonstrate that the hypoxic 
conditions observed in the adipose tissue was responsible for up-regulating the levels of 
pro-inflammatory cytokines including IL-6, IL-1β and TNFα [98].  
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The adipose tissue of lean humans contains around 10% macrophages, compared to up 
to 40% in obese individuals [83]. While in lean individuals the present ATMs are 
identified as single cells in close proximity to endothelial cells [101], ATMs in obese 
subjects appear as aggregates and form ‘crown-like’ structures surrounding adipocytes 
[83, 100-102]. These macrophage aggregates were also found to exhibit high levels of 
intracellular lipids and resembled foam cells, which have distinct roles in the 
development of atherosclerosis [100, 101, 103]. Furthermore, the macrophages stained 
positively for CD68, a marker for phagocytic activity, suggesting an ability for these 
inflammatory cells to phagocytose adipocytes within adipose tissue [100, 101]. 
 
Evidence to support the idea of targeting obesity and its associated pro-inflammatory 
status in order to reduce the risk of developing more complex chronic diseases come 
from studies investigating the effect of weight loss on the pro-inflammatory status of 
obese individuals. In a study by Cancello and colleagues, a significant reduction in the 
percentage of infiltrated macrophage as well as a change in the macrophage phenotype 
was observed, where an increase in the ATM expression of the anti-inflammatory 
cytokine interleukin-10 (IL-10) was observed in patients that had undergone gastric 
bypass surgery when compared to before surgery [101]. Further support for the 
importance of weight loss came from several studies that demonstrated a decrease in the 
serum levels of the pro-inflammatory mediators including IL-6 and soluble TNFα 
receptors, in combination with an increase in the levels of the anti-inflammatory 
adipokine, adiponectin [104-108].  
 
The findings discussed in this section provide support for targeting pro-inflammatory 
cytokine production with pharmaceutical or dietary interventions as a potential 
mechanism to reduce the risk of developing chronic diseases.  
 
 
1.2. Epidemiological data for fruit and vegetable intake and 
chronic disease risk 
It is not a recent concept that what we consume in our diets is able to largely influence 
our health. Currently, chronic diseases such as cancer and CVD are the leading cause for 
mortality in Western countries. Development of these diseases may involve genetic 
predisposition, but most importantly are dependent on a large array of environmental 
factors including physical exercise, dietary patterns, smoking and alcohol consumption. 
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Development of chronic disease as a result of these lifestyle factors is largely 
preventable by changing these influences, as demonstrated by the analysis of over 
100,000 men and women where there was a significantly reduced risk of developing 
chronic disease, in particular CVD with individuals who closely adhered to dietary 
recommendations [109, 110]. 
 
A high intake of fruit and vegetables within the diet has been commonly associated with 
a lower risk of developing chronic diseases [111]. A disadvantage of these analyses is 
that by investigating the effect of fruit and vegetables as a whole, it may shadow 
potential specific associations with certain groups of fruit and vegetables. A 
considerable amount of data in the last 20 years has demonstrated a potential link 
between the risk of developing cancer and the consumption of cruciferous vegetables 
such as broccoli, Brussels sprouts, cabbage and cauliflower [112]. Based on the studies 
reviewed by Verhoeven in 1996, a more consistent decrease in risk of developing cancer 
of the lung and the gastrointestinal (GI) tract was observed [113]. In more recent studies, 
breast, prostate and pancreatic cancers have also been associated with decreased risk of 
development in individuals consuming high levels of cruciferous vegetables [114]. 
 
While the effect of cruciferous vegetable consumption has been studied widely in terms 
of its associations with cancer, there is very little known about effects of these 
vegetables on other chronic diseases such as CVD and T2DM. In one study by Zhang 
and colleagues, it was determined that increased fruit and vegetable consumption was 
inversely associated with total risk of mortality in both men and women. A more evident 
association was observed with cruciferous vegetable intake demonstrating a dose-
dependent inverse relationship with the risk of CVD mortality [115]. Additional support 
for these findings comes from two studies that demonstrated a lower risk of MIs in 
individuals consuming a high level of cruciferous vegetables [116, 117]. In terms of 
T2DM, one prospective study demonstrated approximately a 20% reduction in the risk 
of developing the disease with men from a Japanese cohort who consumed high levels of 
cruciferous vegetables. This reduction was however, not statistically significant [118]. 
Furthermore, some indication of the involvement of cruciferous vegetable intake on the 
risk of developing T2DM came from a study where it was found that a higher incidence 
of T2DM was observed in individuals that followed a dietary pattern which included the 
low intake of cruciferous vegetables [119]. 
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The most recent supporting evidence involving cruciferous vegetable intake and chronic 
inflammation came from a study by Jiang and colleagues who investigated whether there 
was an association between intake of cruciferous vegetables and circulating levels of 
pro-inflammatory cytokines. In a population of over 1000 middle-aged Chinese women, 
significant inverse correlations were found with increasing levels of cruciferous 
vegetable consumption and the circulating levels of IL-6, IL-1β and TNFα with between 
a 12-25% reduction in levels [120].  
 
 
1.3. Cruciferous vegetables 
Cruciferous or Brassica vegetables belong to the Cruciferae or Brassicaceae family 
which consists of some of the most highly consumed vegetables throughout Europe and 
Asia, including broccoli, cabbage, Brussels sprouts, cauliflower, kale, bok choy and 
Chinese cabbage [112]. These vegetables are a major source of GSLs, the 
phytochemicals that are thought to be responsible for the beneficial health effects seen in 
response to diets rich in cruciferous vegetables [113-115, 118-120]. 
 
 
1.3.1. Glucosinolates 
Different Brassica vegetables have different GSL compositions. While for broccoli the 
predominant GSL is glucoraphanin, for cabbage, sinigrin is found at high levels. In 
rocket high levels of glucoerucin can be found and in kale, high levels of glucoiberin are 
present. GSLs share a structure consisting of a sulphur-linked β-D-glucosepyranose 
moiety in addition to a variable side chain (Figure 1.4). The sulphate group is strongly 
acidic and as a result, GSLs accumulate within cells commonly as a potassium salt 
[121]. It is the variable side chain that is able to determine whether the GSL is 
characterised as aliphatic (methionine), aryl (phenylalanine) or indole (tryptophan) 
[122]. Thus far, 120 members of the GSL family have been identified [123]. 
 
 
 
 
 
Figure 1.4. Glucosinolate structure. Each GSL contains a sulphur-linked β-D-
glucosepyranose group, a sulphonated oxime group and a variable side chain that 
determines its aliphatic, aryl and indole characteristics [121]. 
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When cruciferous vegetables are consumed, it is not the GSLs that are biologically 
active. Due to the chemical stability of GSLs within the plant, the hydrolysis process is 
controlled enzymatically by the only thioglucosidase enzyme known to be able to 
catalyse this reaction, namely myrosinase [122, 124]. The enzyme is physically 
separated from the GSLs within the plant but when the plant cells are damaged by 
chewing or mild cooking, the enzyme and GSLs can come into contact to allow the 
hydrolysis reaction to occur, however, the myrosinase enzyme may become denatured 
following long and high temperature cooking [114]. Tests investigating the stability of 
GSLs within the stomach have demonstrated that even in the highly acidic environment 
(pH 2) most are fairly stable and due to the potential denaturation of myrosinase during 
cooking practices, it is thought around 60% of GSLs reach the colon intact. Within the 
colon, it is possible for these GSLs to be hydrolysed by the gut microbiota 
demonstrating myrosinase-like behaviour, however the details are unclear [122].  
 
Broccoli is now commonly available both fresh and frozen and evidence suggests that 
consumption of frozen broccoli, produced following blanching at 91°C for around 2.5 
minutes, compared to lightly cooked fresh broccoli, can result in significantly less ITCs 
in the plasma. This is likely due to the degradation of the myrosinase enzyme, 
demonstrating that the source of the broccoli significantly affects the potential ITC 
concentration achieved [125]. A later study by Dosz and colleagues demonstrated that if 
the blanching process was carried out at a temperature of 86°C or higher, myrosinase 
was inactivated. However, if the blanching step was carried out at a temperature of 
76°C, there was only an 18% loss observed in myrosinase converstion of glucoraphanin 
to SF [126]. These studies demonstrate the importance for using specific cooking 
practices to ensure the potential concentration of SF that can be reached in the plasma is 
achieved.  
 
The enzymatic breakdown of GSLs can lead to the production of a number of different 
compounds depending on the reaction conditions such as ITCs, thiocyanates and nitriles 
[122]. At a neutral pH, the most common products are stable ITCs and while under 
acidic or alkaline conditions, nitriles are most commonly produced (Figure 1.5) [122].  
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1.4. Sulforaphane 
SF is the most commonly studied ITC both in vitro and in vivo. It is derived from the 
GSL glucoraphanin, which is the predominant GSL found in broccoli [122] (Figure 
1.5). Over the next few sections, its bioavailability and subsequent modes of actions will 
be introduced. 
Figure 1.5. Enzymatic breakdown of glucoraphanin. Myrosinase behaves to cleave 
the thioglucose bond which results in the formation of an unstable aglycone. Depending 
on the pH of the environment, the ITC SF can be formed or following the loss of a 
sulphur, SF nitrile (Adapted from [121]).  
  
 
1.4.1. Bioavailability 
Once converted to SF, the ITC is readily conjugated to increase stability and allow 
distribution around the body. ITCs are known to accumulate intracellularly with the 
concentration reaching mM levels [127], much higher than that achieved in circulation 
following the consumption of broccoli. A study in rats found that except for the liver, GI 
tract and kidneys, the only other relatively high concentrations of ITCs and their 
metabolites were found within the blood [122]. In order to study the presence of ITCs 
within the plasma and urine, a cyclocondensation method was developed allowing 
quantification via HPLC. Within the plasma, different studies have reported varying 
levels of ITCs. In a study by Ye and colleagues, when individuals consumed a broccoli 
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sprout preparation supplying around 200µmoles of ITCs, predominantly SF, a peak 
concentration of 1µM SF was recorded after 1 hour indicating rapid absorption [128]. In 
a study by Gasper and colleagues, a higher level of SF was recorded with a peak 
concentration of 2µM at 2 hours following standard broccoli consumption and 7.4µM 
after consuming high-GSL broccoli [129].  
 
The bioavailability of ITCs is limited due to the fact that after ITCs enter the cells, there 
is rapid conjugation to glutathione (GSH) to form dithiocarbamates, a reaction catalysed 
by glutathione-S-transferase enzymes (GSTs). The liver is the organ known to 
demonstrate the highest level of GST activity and also contains a high concentration of 
GSH [122]. These GSH conjugates are subsequently metabolised via the mercapturic 
acid pathway [130-132]. This pathway involves a number of sequential enzymatically 
controlled steps in which the ITC-GSH conjugate has the glutamine and glycine residues 
removed, before the remaining cysteine residue undergoes N-acetylation to ultimately 
form the N-acetylcysteine (NAC) conjugate [133]. The kidney is the principle organ 
involved in this conversion of ITC-GSH conjugates to NAC conjugates [122]. In terms 
of the ITC conjugates identified in urine, the NAC conjugate can account for up to 60% 
of the initial dose consumed [132]. However, the result of this conjugation means that 
the ITCs are modified at their electrophilic sulphur and consequently, the metabolites 
will have very low biological activity levels as many of the functions are reliant on a 
thiol modification.  
 
The GST enzymes are categorised into cytosolic, mitochondrial and microsomal 
families. The cytosolic GSTs all exist as dimers and consist of at least 17 subunits which 
themselves are divided into 7 classes [134]. Of all the GSTs available, only a small 
subgroup have been investigated in terms of their effects on the conjugation of ITCs, 
namely GSTA1, M1, M4 and P1 [135]. Of these, the GSTM1 enzyme was most efficient 
at catalysing the conjugation reaction, followed by GSTP1. While aromatic ITCs were 
the favoured substrates, SF was the poorest [131, 135]. Based on their essential function 
in ITC conjugation, it is unsurprising that common polymorphisms within these 
enzymes have demonstrated variable rates in the response to SF. A null mutation in 
GSTM1 that results in the absence of a functional protein was thought to be as common 
as approximately 50% of the population potentially carrying the mutation [136]. When 
considering the presence of common mutations within the GST genes, epidemiological 
data found that GSTM1 positive individuals demonstrated greater reductions in the risk 
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of developing certain cancers, for example lung and prostate cancer [137-139]. 
However, these findings have been largely contradictory.  
 
In a study by Gasper and colleagues, it was identified that individuals with the GSTM1 
null genotype excreted a significantly higher proportion of SF from the broccoli 
consumed over a more rapid time course [129]. While these results are controversial 
compared to other studies, it may be an important factor to consider in terms of the 
effect of varying conjugation and excretion levels of SF, which may in turn impact on 
the level available to exert its beneficial actions.  
 
 
1.4.2. Targets of SF 
Within the last 20 years a great deal of research has been carried out into the effects of 
SF and several modes of actions have been consistently demonstrated. While much of 
the research has been carried out in vitro with the pure compound, its effects in vivo 
using both mouse models and humans has also been studied, principally in relation to the 
effects on carcinogenesis but more recently, in terms of its anti-inflammatory effects. 
Over the next few sections, the common functions of SF are discussed including the 
ability of SF to induce phase 2 enzymes, reduce oxidative stress, effect cell metabolism, 
induce cell cycle arrest and apoptosis and also the reduction of inflammatory signalling.  
 
 
1.4.2.1. Phase 2 enzymes and oxidative stress 
Phase 2 enzymes detoxify xenobiotics and oxidants that may be encountered by the body 
allowing them to be rapidly excreted, preventing damaging effects to DNA and other 
molecules. Examples of phase 2 enzymes include the GSTs previously mentioned, 
NAD(P)H-quinone oxidoreductase (NQO1), superoxide dismutase 1 (SOD1) and 
hemoxygenase 1 (HO-1). These genes share a common mechanism for transcriptional 
regulation with each of the genes containing an antioxidant response element (ARE) 
within their promoters which are recognised by the transcription factor, nuclear factor 
(erythroid-derived)-like 2 (Nrf2). SF, along with several other agents with an 
electrophilic nature, is able to induce the activity of the Nrf2 transcription factor as 
demonstrated consistently by many groups in vitro and in vivo [140-153]. 
 
The mechanism, by which SF is able to induce Nrf2 activity, is via the targeting of its 
associated inhibitor Kelch-like ECH-associated protein 1 (Keap1). Keap1 behaves to 
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sequester the Nrf2 transcription factor to the cytoplasm where it is inactive and targeted 
for degradation. In response to SF, Nrf2 dissociates from Keap1, allowing translocation 
of the transcription factor to the nucleus where it is able to recognise and bind to AREs 
and activate the expression of its target genes [154, 155]. 
  
The structure of SF results in an electrophilic nature and SF is thus able to directly bind 
to the free thiol groups of the available cysteine residues within Keap1 to form thioacyl 
adducts [156, 157]. It is predicted that this mechanism results in Nrf2 being able to 
accumulate within the nucleus and subsequent induction of the transcription of its target 
genes however, due to the reversible nature of SF binding this is yet to be confirmed 
[157-159]. 
 
 
1.4.2.2. Cell metabolism 
Recently, several papers have described evidence for a function of SF in cell 
metabolism. Following global gene expression analysis, a study in a non-cancerous 
breast cell line identified the up-regulation of a selection of enzymes involved in 
glycolysis and the pentose phosphate pathway [160]. Furthermore, SF has been shown to 
prevent adipogenesis which is reliant on the accumulation of lipids within adipocytes 
and moreover, in murine adipocyte-like cells, lipolysis was induced [161-164]. Thus far, 
the main pathway thought to be responsible for this function was the AMP-activated 
protein kinase (AMPK) pathway, which behaves to monitor the energy status of cells 
[165]. 
 
In a recent human intervention study, consumption of high-GSL broccoli for 12 weeks 
resulted in a significant alteration in the plasma metabolite profile, indicative of an 
improvement in the integration of fatty acid β-oxidation and TCA cycle activity [166]. 
The dysfunction of β-oxidation and TCA cycle activity is linked to the increased levels 
of FFAs in systemic circulation as well as cholesterol synthesis as a result of increased 
citrate. This link is supported by the findings that SF was able to induce a reduction in 
the levels of hepatic cholesterol in hamsters with dietary-induced hypercholesterolemia, 
hypothesised as a result of the down-regulation of the levels of enzyme fatty acid 
synthase (FAS) and sterol regulatory element-binding proteins (SREBP-1 and 2) [167]. 
While there are hypothetical links evident, more research should be carried out to further 
investigate the details of how SF can exert such profound effects on cellular metabolism.  
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1.4.2.3. Cell cycle and apoptosis 
Another mechanism that has been explored in a number of different models e.g. prostate, 
colon and breast cells is the ability of SF to arrest the cell cycle. The cell cycle is made 
up of five phases: G0 where the cells are senescent; G1 where the cell increases in size; S 
which is responsible for DNA replication; G2 where the cells prepare to divide; and M 
where the cells undergo mitosis. Each phase is regulated by a number of different 
molecules; the cyclin-dependent kinases (CDKs), cyclin proteins, and CDK inhibitors. 
SF has demonstrated the ability to inhibit the cell cycle at a number of phases with 
G2/M being commonly described in prostate cell lines [168-170]. This is thought to be 
as a result of altering the expression levels of cyclin B1 in addition to the cell cycle 
inhibitors including p21 and p27 [168, 171-176].  
 
Furthermore, in some cases SF has been shown to induce apoptosis in a number of cell 
lines and in mouse models where an increase in transcription factors or proteins e.g. 
caspases involved in apoptosis are up-regulated [170, 172, 177, 178]. It is however, 
important to note that these results were achieved in studies with concentrations of SF in 
excess of 15µM which would require high levels of broccoli consumption or 
supplementation. 
 
 
1.4.2.4. Inflammation 
With most relevance to the research aims of this thesis, SF has been shown to exert anti-
inflammatory effects through several mechanisms. In response to pro-inflammatory 
stimuli such as TNFα, IL-1 and more commonly LPS, SF was able to significantly 
suppress the expression of pro-inflammatory mediators: cytokines including IL-6, IL-1β 
and TNFα; inflammatory enzymes such as cyclooxygenase-2 (COX-2) and inducible 
nitric oxide synthase (iNOS) and proteins involved in vascular cells e.g. vascular cell 
adhesion molecule 1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) in a 
number of different cell models from both murine and human origin [179-189].  
 
A number of different mechanisms have been suggested to explain these observations: 
induction of Nrf2, inhibition of NF-κB and targeting of the TLR4 molecule. In terms of 
Nrf2 induction, Lin and colleagues demonstrated a significant reduction in the levels of 
pro-inflammatory mediators induced in response to LPS when murine macrophages 
were treated with SF. However, the effect was seen to a much greater extent with 
macrophages derived from Nrf2 (+/+) mice as compared to Nrf2 (-/-) mice [185]. A 
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similar dependence was seen in endothelial cells where SF was able to significantly 
reduce VCAM-1 expression only in the Nrf2 wildtype animals and not in those without 
Nrf2 expression [190]. 
 
More commonly described is the finding that SF is able to significantly suppress the 
levels of the active subunit of NF-κB p65 observed in the nucleus, as well as its 
transcriptional activity and the reduction in the levels of its inhibitor IκB [184, 189, 191-
194]. This is likely of fundamental importance in the anti-inflammatory effects of SF in 
response to LPS in particular, due to the downstream activation of the transcription 
factor in response to TLR4 activation (Figure 1.1). More recently, however, Youn and 
colleagues described the potential for SF to interact with the TLR4 receptor directly via 
free thiol groups of cysteine residues within the extracellular domain of the receptor, 
which resulted in the suppression of oligomerisation, a step required for downstream 
production of inflammatory mediators [195]. Further support for the targeting of SF at 
the ligand-receptor interaction, came from the same research group, which demonstrated 
an additional interaction between SF and a cysteine residue within the MD2 molecule, 
the co-receptor for TLR4 [196]. 
 
It is however, important to note that there is a requirement for the development of an in 
vitro experimental design which mimics a state of low-grade inflammation. As 
previously mentioned, endotoxin levels circulating in individuals suffering from a 
chronic inflammatory disorder is in the range of 1ng/ml, whereas the concentrations 
used in the experiments above are much higher, often surpassing those seen following 
acute inflammation [37, 45, 46, 197].  
 
 
1.5. Thesis Aims 
Previously the majority of studies investigating inflammation in vitro use concentrations 
of LPS that are far in excess of that found in circulation of patients suffering from 
chronic disease. In addition, investigations of the anti-inflammatory effects of SF have 
principally been carried out in murine cell models with a reductionist approach of 
selecting only several biomarkers for measurement. The overall hypothesis of this thesis 
was that SF would suppress chronic inflammatory signalling via a multi-targeted 
approach at physiologically relevant concentrations. In order to test this overall aim, a 
number of different research questions were tested to progress the research from the 
present literature.  
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Within this thesis the following objectives were addressed: 
 
1. The development of an in vitro model of chronic inflammation with human 
monocytes and physiologically relevant concentrations of both LPS and SF. 
Much of the previous literature investigating pro-inflammatory biomarker 
production has been carried out in cell lines of murine origin and with a 
concentration of inflammatory stimulus that is out of range of even acute 
inflammatory attack. With one of the main limitations of in vitro investigations 
being that it is difficult to translate the findings to an in vivo situation, this 
objective was fundamental in going some way to bridge this problem.  
 
2. To investigate whether SF was able to target global gene expression in response 
to LPS and whether the mechanism was directly via TLR4 in vitro. While 
several pro-inflammatory biomarkers have been reported to be suppressed by SF 
in the presence of an inflammatory stimulus, little research has been carried out 
into the scope of this effect. SF alone has been studied on a global scale in a 
number of different cell models however, there have been no previous studies 
that investigated the effect of SF on inflammation on a global scale. 
Additionally, while the investigations into the global effect of SF can be 
potentially highly informative in terms of the capability of SF, it is important to 
try and elucidate the mechanism by which SF is able to have an effect on 
inflammation, by progressing previous research into the thiol modification of the 
TLR4. 
 
3. To establish whether the anti-inflammatory effects of SF were restricted to 
TLR4 alone or if it was also able to target additional signalling pathways. The 
initial experiments all utilised LPS as the artificial inducer of pro-inflammatory 
biomarkers due to its relevance with chronic disease. However, a more 
informative approach would be to investigate whether effects of SF on LPS-
signalling are able to be replicated in response to the activation of additional 
signalling pathways including the TLR2 which is important in the response to 
lipopeptides and the NOD2 pathway, which has been highly implicated in the 
IBD Crohn’s disease. 
 
4. To progress the methods used initially into a more complex model of chronic 
inflammation using human SGBS adipocytes and MaCM from human THP-1 
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macrophages to determine the effect of SF on adipogenesis and cytokine 
production as a result of adipose tissue inflammation. By using this more 
complex in vitro model of adipose tissue inflammation, different endpoints are 
able to be tested with disease relevance e.g. lipid accumulation in adipocytes 
and the inflammatory response to MaCM, mimicking the infiltration of 
macrophages within adipose tissue of obese individuals. This objective behaves 
to investigate the potential multi-targeting ability of SF in a disease-related 
context.  
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2.1. General reagents 
SF was supplied from LKT laboratories (L-SF; Cat. # S8046 and DL-SF; S8044, 
respectively). DL-SF was used in all chapters, while L-SF was only used in Chapter 6. A 
stock solution of each was prepared in dimethyl sulfoxide (DMSO). As the vehicle 
control for SF, it was ensured that the final concentration of DMSO added to the cell 
culture medium was below 0.1% (v/v). LPS from Escherichia Coli strain 055:B5 (Cat. # 
L6529, Sigma-Aldrich) and 0111:B4 (for experiments with PRR cell lines, Cat. # tlrl-
eblps, InvivoGen) were used in experiments to induce inflammation. LPS was prepared 
in phosphate buffered saline (PBS) to produce stock solutions. Pam3CSK4 (Cat. # tlrl-
pms), FSL-1 (Cat. # tlrl-fsl) and MDP (Cat. # tlrl-mdp) were also supplied from 
InvivoGen. All stock solutions were prepared in sterile endotoxin-free water at 
concentrations of 1mg/ml, 100µg/ml and 5mg/ml, respectively. TNFα was supplied from 
R&D systems (Cat. # 210-TA-005). A stock solution was prepared in PBS at a 
concentration of 100µg/ml.  
 
 
2.2. Cell culture  
2.2.1. Human monocytes 
Human peripheral blood mononuclear cells (PBMCs) were isolated from 10ml of whole 
blood provided by healthy, volunteer assay blood donors (male and female) from the 
Human Nutrition Unit of the Institute of Food Research. Ethical approval was obtained 
from the Human Research Governance Committee at the Institute of Food Research for 
optimisation of techniques and experimental design. Whole blood was anti-coagulated 
using EDTA-containing tubes and diluted 1:1 with PBS to improve the separation 
process. PBMCs were isolated from the whole blood using sterile, endotoxin-free 
Accuspin
TM
 System-Histopaque® 1077 (Cat. # A7054, Sigma-Aldrich) according to 
manufacturer’s instructions. From 10ml of whole blood, approximately 10-20 x 106 
PBMCs were isolated. Cryopreserved PBMCs were also supplied from ZenBio (Cat. # 
SER-PBMC-F, Cambridge Biosciences). They were a pooled sample from 5 different 
donors, both male and female, ranging in age and ethnicity.  
 
PBMCs were routinely cultured in RPMI-1640 medium with stable glutamine (Cat. # 
E15-840, PAA Laboratories) supplemented with 10% (v/v) foetal bovine serum (FBS; 
Cat. # 10270, Life Technologies) and 1% (v/v) penicillin/streptomycin (Cat. # 15140, 
Life Technologies). 
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Human monocytic THP-1 cells were obtained from the European Collection of Cell 
Culture (ECACC; Cat. # 88081201). THP-1 cells were originally isolated from the 
peripheral blood of a one year old male suffering from acute monocytic leukaemia 
[198]. THP-1 cells were routinely cultured in RPMI-1640 medium with stable glutamine 
supplemented with 10% (v/v) FBS and 1% (v/v) penicillin/streptomycin. THP-1 
monocytes have the capability to be chemically differentiated into macrophages as a 
result of culturing the monocytes in serum-free RPMI-1640 medium in the presence of 
125ng/ml phorbol 12-myristate 13-acetate (PMA; Cat. # P1585, Sigma-Aldrich) for 48 
hours [199]. This differentiation process was monitored simply by following the 
morphological transition of the monocytes, which grow in suspension, becoming 
adherent as they differentiate in to macrophages.  
 
 
2.2.2. PRR-transfected cell lines 
Human embryonic kidney (HEK)-Blue
TM
 cells were obtained from InvivoGen (Cat. # 
hkb-htlr4, hkb-htlr2 and hkb-hnod2). All HEK-Blue
TM
 cells were developed by stable 
transfection with the necessary receptors, TLR4, the MD2/CD14 co-receptors, TLR2 or 
NOD2, along with a secreted embryonic alkaline phosphatase (SEAP) reporter gene. 
The SEAP reporter gene is under the control of an IL-12 p40 minimal promoter fused to 
five NF-κB and AP-1 binding sites. Stimulation with the appropriate ligands activates 
NF-κB and AP-1 which induces the production of SEAP.  
 
To generate the mutant G908R NOD2-expressing lines, HEK cells (Cat. # 293-null, 
InvivoGen) were co-transfected with a pSV-β-Galactosidase control vector, pNifty2-
SEAP (Cat. # pnifty2-seap, InvivoGen) and the mutant form of the receptor, pUNO-
hNOD2a G908R, generated as a result of the substitution of the glycine residue at 
position 908 in the amino acid sequence for an arginine. For transient transfection 
experiments, 293-hMD2-CD14 cells (Cat. # hek-hmdcd, InvivoGen), prepared by the 
co-transfection of HEK cells with the MD2 and CD14 genes, were used and transiently 
transfected with TLR4 wildype (pUNO-hTLR4-A) and mutant receptors D299G where 
an aspartate at position 299 has been exchanged for a glycine (pUNO-hTLR4-A, 
rs4986790) and T399I where a threonine at position 399 has been exchanged for an 
isoleucine (pUNO-hTLR4-A, rs4986791).  
 
All PRR-expressing cell lines were maintained in DMEM medium with stable glutamine 
(Cat. # 41965, Gibco) supplemented with 10% (v/v) FBS and 1% (v/v) 
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penicillin/streptomycin, with variations in the necessary antibiotic combinations. The 
growth media for HEK-Blue
TM
 TLR4 and TLR2 cell lines required the addition of 1% 
(v/v) penicillin, streptomycin, gentamicin cocktail, 0.18% (v/v) Normocin
TM 
(Cat. # ant-
nr, InvivoGen) and 1X HEK-Blue
TM
 selection antibiotics (Cat. # hb-sel, InvivoGen). The 
NOD2 cell lines required 1% (v/v) penicillin, streptomycin, 0.06% (v/v) blasticidin (Cat. 
# ant-bl-5b, InvivoGen) and 0.1% (v/v) Zeocin
TM 
(Cat # ant-zn, InvivoGen). The 
transiently transfected 293-hMD2-CD14 cells required 1% (v/v) penicillin, 
streptomycin, gentamicin cocktail and 0.05% (v/v) Hygrogold
TM
 (Cat. # ant-hg-1, 
InvivoGen). 
 
To produce HEK cells transiently transfected with either the wildtype or mutant TLR4 
receptors, 293-MD2-CD14 cells were grown to a confluency of 60-80% before being 
transfected using Lipofectamine 2000 (Cat. # 11668027, Invitrogen) according to the 
manufacturer’s instructions. The cells were co-transfected with the wildtype or mutant 
plasmids and the reporter SEAP plasmid (pNifty2-SEAP) with optimised conditions 
(1µg TLR4 plasmids and 8µg pNifty2-SEAP).  
 
 
2.2.3. HT-29 colon adenocarcinoma cells 
The human colon adenocarcinoma HT-29 cells were supplied by ECACC (Cat. # 
91072201). They were isolated from a primary tumour in a 44 year old Caucasian 
female. These cells can form a well differentiated adenocarcinoma consistent with 
colonic primary grade I. The cells were routinely cultured in McCoys’s 5A modified 
medium with stable glutamine (Cat. # M9309, Sigma-Aldrich) supplemented with 10% 
(v/v) FBS and 1% (v/v) penicillin/streptomycin. 
 
 
2.2.4. SGBS preadipocyte cells 
The human preadipocyte SGBS cell line was kindly gifted by Prof. M. Wabitsch 
(University of Ulm, Germany). This cell line was isolated from an infant suffering from 
Simpson-Golabi-Behmel Syndrome (SGBS) which is characterised by enhanced 
prenatal and postnatal growth associated with large adipose tissue depots [200]. This cell 
line is characterised by the high capacity to be differentiated into mature adipocytes up 
to generation 60. SGBS preadipocyte cells were routinely cultured in DMEM/F12 (1:1) 
medium with stable glutamine and Hank’s Balanced Salt Solution (HBSS; Cat. # 11330, 
Life Technologies) supplemented with 33µM biotin (Cat. # B4639, Sigma-Aldrich), 
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17µM pantothenate (Cat. # P5155, Sigma-Aldrich), 10% (v/v) FBS (not heat-
inactivated) and 1% (v/v) penicillin/streptomycin. 
 
In order to differentiate SGBS preadipocytes into mature adipocyte cells, the cells were 
cultured to reach 70-80% confluency before replacing the medium with basal growth 
medium (serum-free) supplemented with 0.01mg/ml transferrin (Cat. # T2252, Sigma-
Aldrich), 20nM insulin (Cat. # I1507, Sigma-Aldrich), 0.1µM cortisol (Cat. # H0888, 
Sigma-Aldrich), 0.2nM triiodothyronine (T3; Cat. # T6397, Sigma-Aldrich), 25nM 
dexamethasone (Cat. # D1756, Sigma-Aldrich), 0.25mM isobutylmethylxanthine 
(IBMX; Cat. # I5879, Sigma-Aldrich) and 2µM rosiglitazone (Cat. # CAY71740, 
Caymen Chemicals) on day 0. On days 4, 8 and 12, the medium was replaced with basal 
growth medium (serum-free) supplemented with only 0.01mg/ml transferrin, 20nM 
insulin, 0.1µM cortisol and 0.2nM T3 to continue differentiation. By day 14, the 
differentiation process was complete and the cells were treated as mature adipocytes. 
This process was monitored by following the increased accumulation of lipid droplets 
within the cells, giving clear morphological changes. 
 
All cell lines used were maintained in a humidified atmosphere containing 5% CO2 at 
37°C and were routinely passaged to continue growth.  
 
 
2.3. Cell viability assay 
2.3.1. Background 
The viability of all the cell lines described in the previous section was estimated in 
response to a number of different treatments using the WST-1 assay. This assay is based 
on the conversion of the tetrazolium salt WST-1 (4-[3-(4-iodophenyl)-2-(nitrophenyl)-
2H-5-tetrazolio]-1,3-benzene disulfonate) into formazan by mitochondrial 
dehydrogenase enzymes (Figure 2.1). If a reduction of viability is observed as a result 
of the cell treatment, fewer cells will be metabolically active and therefore will be 
unable to carry out the conversion due to a reduction in the activity of mitochondrial 
dehydrogenases. The product of the enzymatic reaction, formazan is a deep red colour 
and this colour change enables a spectrophotometric assay to be used to allow 
quantitative determination of the number of viable cells.  
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Figure 2.1. Conversion of WST-1 to formazan.  
WST-1 can be reduced to formazan resulting in a colour change that is proportional to 
cell viability. (EC = electron coupling reagent; MSTR = mitochondrial succinate-
tetrazolium reductase system). Figure adapted from product data sheet. 
 
 
2.3.2. Measurement of cell viability 
Cells were seeded into 96 well plates for this assay. For the adherent cell lines, (THP-1 
macrophages, HEK-Blue
TM
, HT-29 and SGBS) cells are grown to around 70-80% 
confluence. For THP-1 monocytes and PBMCs, 1 x 10
5
 cells and 2.5 x 10
5
 cells 
respectively, were seeded into 96 well plates and treated immediately. SGBS 
preadipocytes were seeded into 96 well plates and allowed to reach 70-80% confluence. 
For adipocytes, the preadipocytes at this point followed the differentiation process as 
described in section 2.2.4. THP-1 monocytes were differentiated into macrophages 
following the protocol explained in section 2.2.1. Cells were treated with concentrations 
of SF ranging from 1-200µM (vehicle control for SF = < 0.1% (v/v) DMSO) in six 
replicate wells. 
 
For treatment with MaCM, THP-1 monocytes were differentiated by treating cells with 
125ng/ml PMA for 48 hours in serum-free conditions. Once the differentiation of the 
macrophages was complete, the medium was replaced with serum-free RPMI-1640 
containing 0.5% (w/v) bovine serum albumin (BSA; Cat. # A9418, Sigma-Aldrich) to 
stabilise the macrophage-secreted factors for a further 48 hours to produce the MaCM. 
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The MaCM was collected and cleared of cell debris by centrifugation. SGBS adipocytes 
were treated with doses of MaCM (10, 20 and 50%; v/v) in six replicate wells.  
 
After 24 hours of cell treatments, 10µl (per 100µl media) of WST-1 reagent (Cat. # 
05015944001, Roche) was added to each well. Cells were incubated in a humidified 
atmosphere containing 5% CO2 at 37°C for up to 3 hours. The metabolic conversion of 
the WST-1 reagent to formazan was quantified by measuring the absorbance using a 
spectrophotometer at 450nm with a reference wavelength of 610nm. Medium only was 
used for the blank correction to compensate for any absorbance contribution of the basal 
colour from the phenol red present within the medium.  
 
 
2.3.3. Data analysis and statistics 
Optical density (OD) values from 450nm reading (corrected with data from 610nm) 
were used to determine the percentage cell viability. For all treatments the percentage 
viability was calculated against the untreated control cells. The IC50 (half maximal 
inhibitory concentration) was calculated using GraphPad Prism software including a 
logarithm transformation of the data and a non-linear analysis to determine the 
concentration at which 50% cell viability remained. The effect of the treatment was 
analysed using one-way analysis of variance (ANOVA) followed by Bonferroni multiple 
comparison tests.  
 
 
2.4. Measuring cytokine secretion using enzyme-linked 
immunosorbant assay (ELISA) 
2.4.1. Background 
To determine the concentration of cytokines secreted in to the cell culture supernatant 
following cell treatments, Quantikine ELISA kits were used: IL-6 (Cat. # D6050); IL-1β 
(Cat. # DLB50) and TNFα (Cat. # DTA00C) kits were all purchased from R&D systems 
and carried out according to manufacturer’s instructions (Figure 2.2). These kits all 
provide a standard of each compound in order to produce a calibration curve enabling 
quantification.  
 
 
General materials and methods 
 
36 
 
Prepare all reagents, standards and samples as described 
Add 100-200µl** standard, control and samples to each well 
Aspirate and wash four times to remove unbound cytokine  
Add 200µl Conjugate (enzyme-linked secondary antibody) to 
each well 
Cover and incubate for 1-2 hours*** 
Aspirate and wash four times to remove unbound conjugate  
Add 200µl Substrate Solution to each well 
Cover and incubate for 30 minutes shielded from direct light 
Add 50µl Stop Solution to each well 
Read at 450nm within 30 minutes. Wavelength correction at 
540nm 
Add 0-100µl* Assay diluent to each well  
Cover and incubate for 2 hours 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2. Quantikine ELISA protocol. Information taken from the protocol provided 
within the kits. Same protocol for all ELISA kits with the following variations. *0µl 
Assay diluent added for IL-1β, 50µl for TNFα and 100µl for IL-6. **100µl of standards, 
samples and controls for IL-6, 200µl for IL-1β and TNFα. ***Incubation for 1 hour for 
IL-1β and TNFα, 2 hours for IL-6. 
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2.4.2. Measurement of cytokine secretion 
Cells were seeded into 6, 12, 24 or 48 well plates depending on the cell type used and 
grown to 70-80% confluency. Cells were exposed to the treatments for varying times 
depending on the experimental design. Cell culture supernatant was collected and 
centrifuged at 13000rpm for 20 minutes at 4°C to remove any cell debris. Supernatants 
were stored at -20°C until required. On the day of use, the samples were thawed and 
inspected for the presence of precipitates. If visible, samples were centrifuged at 
13000rpm for 10 minutes at 4°C and the supernatant was transferred to a fresh tube. 
Depending on the levels of cytokines expected to be present within the samples, 
necessary dilutions were carried out with the appropriate calibrator diluent provided in 
the kit to ensure the measurements remained within the calibration curve. After 
following the manufacturer’s instructions, the levels of cytokines in the samples were 
quantified (Figure 2.2).  
 
 
2.4.3. Statistics 
In experiments carried out with ranging doses of treatments, one-way ANOVA was 
performed followed by Bonferroni multiple comparison tests. In experiments with two 
variables (dose of treatment and time of exposure) two-way ANOVA was performed 
with Bonferroni multiple comparison tests. In experiments that were carried out over a 
period of time with single dose treatments, the area under the curve (AUC) was 
measured and Student t-tests carried out to statistically compare each time point.  
 
 
2.5. Gene expression using real-time reverse transcriptase – 
polymerase chain reaction  
2.5.1. Background 
Real-time RT-PCR is a common technique used to quantify gene expression. A number 
of different companies provide products that allow detection of amplified target gene 
expression levels and for the present study, Taqman® was used (Applied Biosystems) 
which relies on the detection of the products via the generation of a fluorescent signal. 
 
  
General materials and methods 
 
38 
 
2.5.2. RNA extraction and quantification 
Total RNA was extracted from treated cells using the QIAGEN® RNeasy Mini Kit (Cat. 
# 74104, QIAGEN) according to manufacturer’s instructions. Cells were initially lysed 
using the provided Buffer RLT and further homogenised using a QIAshredder (Cat. # 
79654, QIAGEN). The differentiated SGBS adipocyte cells were the only exception in 
which total RNA was extracted from the cells using the QIAGEN® RNeasy Lipid 
Tissue Mini Kit (Cat. # 74804, QIAGEN) due to the high levels of intracellular lipid 
accumulation. Lysis of the SGBS adipocytes required the QIAzol Lysis Reagent 
provided with the kit. Additional steps were necessary to remove the lipid content from 
the homogenate. Chloroform was added to the homogenate to promote precipitation of 
the lipids and a centrifugation step was used to separate the aqueous layer containing the 
RNA for the subsequent steps.  
 
RNA samples were quantified after extraction using the NanoDrop ND-1000 
spectrophotometer. Triplicate readings for RNA quantification were performed per 
sample and the average was calculated. This technique also gives an indication of the 
purity of the RNA. Each sample receives a 260/280 absorbance ratio, where the 260nm 
reading is the wavelength absorbed by nucleic acids and the 280nm reading is indicative 
of protein absorbance. When the RNA is pure, you would expect a ratio of 2.0, however 
this does not necessarily mean that the RNA is of high quality due to the 280nm reading 
being susceptible to errors.  
 
 
2.5.3. Real-time RT-PCR 
For the quantification of gene expression, the Taqman® RNA to CT 1-step kit was used 
(Cat. # 4392938, Life Technologies). This uses RNA extracted from the cells as its 
starting material and in one step produces the complimentary DNA strand based on the 
RNA sequence and amplifies the target genes. The fluorescent signal is generated 
through the use of dual-labelled probes. The probes are labelled with a reporter dye 
attached at the 5’ end e.g. FAM (6-carboxyfluorescein) and a quencher dye at the 3’ end 
e.g. TAMRA (6-carboxytetramethylrhodamine). When the probe is intact, the close 
proximity of the two dyes means that no fluorescent signal is generated. However, when 
the Taq polymerase extends the complementary DNA strand where the probe is bound, 
the 5’ nuclease activity of the polymerase is able to cleave the probe resulting in the 
reporter and quencher dyes being decoupled and a fluorescent signal can occur. As each 
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cycle takes place, the fluorescent signal increases and this signal can be used to 
determine relative expression level of the target gene.  
 
To prepare the samples for real-time RT-PCR, the CAS-1200 robot and Robotics 4 
software was used (Corbett Life Sciences). MicroAmp Optical 96 well reaction plates 
(Cat. # N8010560, Life Technologies) were used for the ABI Prism 7500 Detection 
System (Applied Biosystems) and 96 well Semi-Skirted fast plates (Cat. # LW2214, 
Alpha Laboratories) were used for the ABI StepOne Plus machine (Applied 
Biosystems). A No Template Control (NTC) was loaded (double-autoclaved RNase-free 
water) to ensure there is no RNA contamination, followed by each of the samples of 
which there were three biological replicates and three technical replicates.  
 
The ABI Prism 7500 Detection System or the ABI StepOne Plus instruments were used 
to quantify target mRNA expression levels under the following conditions: 48°C for 30 
minutes to allow reverse transcription, 95°C for 10 minutes to activate the AmpliTaq
TM
 
Gold polymerase, followed by 40 cycles of 95°C for 15 seconds for denaturation and 
60°C for 1 minute to anneal and extend the target gene DNA. Each of the reactions were 
performed in a volume of 20µl containing RNA, primers and probes either individually 
or as part of a prepared assay kit (IDT technologies), Taqman® Master Mix and the 
reverse transcriptase enzymes. Table 2.1 gives the sequences of the primers and probes 
used for the assays. 
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Table 2.1. Primer and probe sequences of genes analysed 
Gene Name IDT kit I.D.  Sequence 
IL-6  Forward: 
Reverse: 
Probe: 
5’-CTCTTCAGAACGAATTGACAAACAAAT-3’a 
5’-ATGTTACTCTTGTTACATGTCTTCTTTCTC-3’a 
5’-FAM-TACATCCTCGACGGCATCTCAGCCC-TAMRA-3’b  
IL-1β Hs.PT.51.20299051 Forward: 
Reverse: 
Probe: 
5’-AGGAGCACTTCATCTGTTTAGG-3’c 
5’-GCCAATCTTCATTGCTCAAGTG-3’c 
5’-FAM-TTCACTGGCGAGCTCAGGTACTTC-TAMRA-3’b 
TNFα Hs.PT.51.22572112.gs Forward: 
Reverse: 
Probe: 
5’-CTCAGCTTGAGGTTTGC-3’c 
5’-CCTCTCTCTAATCAGCCCTCT-3’c 
5’-FAM-CAGGCAGTCAGATCATCTTCTCGAACC-TAMRA-3’c 
18S  Forward: 
Reverse: 
Probe: 
5’-GGCTCATTAAATCAGTTATGGTTCCT-3’b 
5’-GTATTAGCTCTAGAATTACCACAGTTATCCA-3’b 
5’-FAM-TGGTCGCTCGCTCCTCTCCCAC-TAMRA-3’b 
CPT1A Hs.PT.56a.28218391 Forward: 
Reverse: 
Probe: 
5’-TGAAGACAACAAACGTGAACG-3’c 
5’-CAGAAGTGAAGACCCGGATAC-3’c 
5’-FAM-CAAACCACCTGTCGTAACATCGGCC-TAMRA-3’c 
a
Primers were designed and purchased from Eurofins. 
b
Primers and probes were designed and purchased from Sigma-Aldrich. 
c
Pre-designed assay kits were purchased from IDT technologies. 
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The Applied Biosystems software calculated the threshold cycle (CT) values for each 
reaction and with the use of a standard curve of known total RNA quantities, the 
quantity of the target RNA was calculated. In order to normalise the expression of the 
specific target genes, an endogenous control, also known as a housekeeping gene, was 
used to account for potential differences in the total amount of RNA in each sample. For 
normalisation of the target genes used in the present study, 18S ribosomal RNA was 
used as the chosen housekeeping gene. The expression level of this gene should not vary 
with experimental treatment as it is very highly expressed and therefore the normalised 
data will allow demonstration of changes in target gene expression that are only as a 
result of experimental treatments.  
 
The amplification efficiency is calculated using the standard curve and for all the genes 
considered, efficiencies were > 96%. A reaction that has been 100% efficient will result 
in the gradient of the standard curve being -3.32, meaning the CT difference between two 
sequential 2-fold dilutions will equal 1. The final essential parameter to take note of is 
the R
2
 value of the standard curve line of best fit. With an R
2
 value of 1, the value of Y 
(the CT) can be accurately from the X value. Values > 0.99 are considered to be highly 
accurate.  
 
 
2.5.4. Statistics 
In experiments carried out with ranging doses of treatments, one-way ANOVA was 
performed followed by Bonferroni multiple comparison tests. In experiments with two 
variables (dose of treatment and time of exposure) two-way ANOVA was performed 
with Bonferroni multiple comparison tests. In the experiments that were carried out over 
a period of time with single dose treatments the AUC was measured and Student t-tests 
carried out to statistically compare each time point. 
 
 
2.6. Whole genome expression analysis using microarray 
techniques 
2.6.1. Background 
In the present study, commercially available Affymetrix GeneChip® Human Exon 
1.0ST arrays were used to analyse whole genome expression and has the capability to 
monitor expression at the exon level. Compared to the traditional 3’ expression arrays 
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that have been commonly used, the Affymetrix GeneChip® Human Exon 1.0ST array 
contains probes that span the entire length of the gene and is not restricted to only the 3’ 
end. In addition, with probes assigned to each individual exon, the expression of each 
exon within the gene can be measured allowing information on potential alternative 
splicing events.  
 
The Affymetrix GeneChip® Human Exon 1.0ST array is made up of approximately 1.4 
million probe sets and more than 5.5 million individual probes. Four individual probes 
comprise one probe set, with each probe set corresponding to individual exons. 
Depending on the length of the exon, more than one probe set may be assigned. While 
the 3’ expression arrays contains ‘mismatch probes’, the Affymetrix GeneChip® Human 
Exon 1.0ST array contains only perfectly matched probes and the non-specific 
hybridisation is accounted for using background correction based on the GC content of 
the probes. Each of the probe sets specific for individual exons are grouped into 
transcript clusters. Gene level analysis is measured by considering all probes within a 
single transcript cluster. By focusing on the individual exons and not the gene as a 
whole, novel transcripts can be identified which may be present as a result of alternative 
splicing in response to factors within the experimental design. Many genes have a 
number of transcripts associated where the exons are spliced together in various 
combinations for example, certain exons may be missing from the final transcript. Each 
of the probe sets are categorised based on the level of characterisation of each exon. 
‘Core’ probe sets are those which are annotated by RefSeq; ‘extended’ probe sets have 
mRNA evidence available and ‘full’ probes sets are those where there is a prediction 
based on bioinformatics for a particular exon. In the present study, the analysis was 
carried out using the ‘core’ probe sets (18708 transcripts, 284258 probe sets). 
  
THP-1 monocytes (6 x 10
6
 cells per 10cm dish) were treated with 1ng/ml LPS (vehicle 
control for LPS = PBS) in the presence or absence of 5µM SF (vehicle control for SF = 
< 0.1% (v/v) DMSO) for 12 hours with three biological replicates for each condition. 
RNA was extracted using the QIAGEN® RNeasy Mini Kit according to manufacturer’s 
instructions and quantified as in section 2.5.2.  
 
 
2.6.2. Assessment of RNA quality 
As explained in section 2.5.2, RNA quantity and purity was determined using the 
NanoDrop ND-1000 spectrophotometer. An absorbance ratio between 260nm and 
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280nm of 2 is indicative of highly pure RNA but this does not necessarily mean the 
RNA is of high quality. To measure the quality of RNA, the Agilent 2100 Bioanalyzer 
was used. The system uses an electrophoretic principle with quick separation on a chip 
system. The microchannels within the chip are filled with a sieving polymer and 
fluorescence dye. Once the wells are filled, the chip becomes part of an electrical circuit. 
When the dye molecules intercalate with the RNA, fluorescence occurs and this is 
measured and plotted graphically over time, in addition to a densitometry plot to show 
the two markers of ribosomal RNA, 28S and 18S. In order to quantitate the RNA quality 
a ladder was used and the ratio of the 28S and 18S ribosomal RNA markers was 
calculated to assess the integrity of the RNA. The 28S peak should have a larger area 
than 18S in samples of high quality. In addition, an RNA integrity number (RIN) can be 
used to estimate the quality and is based on the electrophoretic trace of the RNA sample. 
The RIN number ranges from 1-10 where 1 is a completely degraded sample and 10 is a 
perfect quality sample. All samples used for microarray analysis had a RIN value of ≥ 
9.6.  
 
The RNA samples were sent to Nottingham Arabidopsis Stock centre and the 
Affymetrix GeneChip® Human Exon 1.0ST array was carried out according to 
manufacturer’s protocols.  
 
 
2.6.3. Data analysis and statistics 
For the analysis of the data from the microarray, the R/Bioconductor package was used. 
The raw signal intensity data was provided in .CEL files. The data was RMA (robust 
multi-array analysis)-background corrected and quantile normalised to determine if any 
outliers are present. Once complete, linear probe level models were fit to the data to 
analyse gene level summaries. For annotation of the data, the current file available at the 
aroma.affymetrix website (HuEx-1_0-st-v2.na32.hg19.transcript.csv) was downloaded, 
which contains the information available for all transcripts and the core CDF probe set 
was selected. Subsequent statistical data analysis to identify differentially expressed 
genes was performed using limma [201]. Identification of genes that were differentially 
expressed were analysed for the level of statistical significance at different Benjamini 
and Hochberg adjusted p-values, to account for the potential false discovery rate.  
To highlight pathways that were largely represented by the differentially expressed 
genes, functional analyses using the Database for Annotation, Visualisation and 
Integrated Discovery v6.7 (DAVID; http://david.abcc.ncifcrf.gov) was used [202, 203].   
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Microarray data generated in this study were compliant to MIAME (Minimum 
information about a microarray experiment) criteria and were made publicly available 
through ArrayExpress (Accession E-MEXP-3931, Date of Release: December 2014). 
 
 
2.7. Western blotting 
2.7.1. Background 
Western blotting is a fundamental technique used in cell and molecular biology to 
identify specific proteins from a crude protein extract. The extracted proteins are 
separated based on their molecular weight via gel electrophoresis and transferred to a 
membrane producing a band for each protein. The membrane is incubated for the 
relevant times with antibodies specific to the protein of interest. The next step involves 
incubation of the membrane with an enzyme-linked secondary antibody which allows 
visualisation of the blot following the addition of a chemiluminescent substrate.  
 
 
2.7.2. Sample preparation 
HT-29 cells were treated with SF (5, 10 and 25µM, vehicle control for SF = < 0.1% 
(v/v) DMSO) in the presence or absence of 1ng/ml LPS (vehicle control for LPS = PBS) 
for 1 hour. Following treatment, the proteins were extracted from the cells using the 
Novagen ProteoExtract® Transmembrane Extraction kit (Cat. # 71772, Millipore) which 
enables the separation of the insoluble membrane fraction from the soluble cytoplasmic 
fraction to allow determination of the target protein level in both locations of the cell.  
 
Briefly, HT-29 cells were washed with PBS and scraped into solution. Cells were 
centrifuged at 1000 x g for 5 minutes at 4°C before being resuspended in 1ml of 
extraction buffer 1 supplied in the kit. The solution was incubated for 10 minutes at 4°C 
and after repeating the centrifugation step, the soluble cytoplasmic fraction was 
collected. The remaining cell pellet was resuspended in 0.2ml of extraction buffer 2A 
(1:1 extraction buffer 2: reagent A supplied in the kit). The suspension was incubated at 
room temperature for 45 minutes with gentle agitation before centrifugation at 16000 x g 
for 15 minutes at 4°C yielding the membrane fraction.  
 
The bicinchoninic acid (BCA) assay was used to determine the quantity of total protein 
within each sample (Cat. # BCA1-1KT, Sigma-Aldrich). The principle of the assay 
relies on the formation of a Cu
2+
 protein complex under alkaline conditions followed by 
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the reduction of Cu
2+
 to Cu
1+
. The extent of the reduction is proportional to the amount 
of protein present and can be analysed by measuring absorbance of the purple-blue 
complex formed between BCA and Cu
1+ 
[204]. Each of the protein samples were diluted 
1:5 with NaPi buffer (50mM NaPi, pH 6, containing 5mM EDTA) prior to quantification 
and a standard curve using BSA was produced ranging from 0-1000µg/ml by diluting 
the standards in NaPi buffer. The assay was performed in a 96 well plate in which 25µl 
of the standards and samples were added to each well in addition to 200µl of BCA 
working reagent (50:1 dilution between BCA and copper (II) sulphate solution) in 
duplicate. The plate was incubated at 37°C for 30 minutes and shielded from the light to 
allow the reduction to occur. The absorbance was measured at 550nm on the FLUOstar 
OPTIMA microplate reader (BMG Labtech) and the concentration of protein was 
calculated using the standard curve. 
 
For gel electrophoresis, 35µg of protein was used for each sample. Protein samples were 
diluted appropriately with ultra-pure water to produce the final concentrations in a total 
volume of 18µl. 4.5µl of NuPAGE® LDS sample buffer (4X; Cat. # NP0008, Life 
Technologies) was added to each sample and samples were heated at 70°C for 10 
minutes to denature tertiary and secondary protein structures. No dithiothreitol (DTT) 
was added as the samples required non-reducing conditions. The samples were 
centrifuged briefly to remove any air bubbles present before loading on to the gel. 
 
 
2.7.3. Gel electrophoresis 
2µl of MagicMark
TM
 XP Western Standard (Cat. # LC5602, Life Technologies) was 
used as the protein ladder to determine the size of the proteins. A total volume of 22.5µl 
of each protein sample was loaded in to the wells of a NuPAGE® 10 well 10% Bis-Tris 
SDS-PAGE gel (Cat. # NP0306, Life Technologies) for electrophoresis. Appropriately 
diluted NuPAGE® MOPS SDS running buffer (20X, Cat. # NP0001, Life Technologies) 
was used and the gel was run at 200V for 50 minutes at room temperature using the 
XCell SureLock
TM
 Mini-Cell Electrophoresis system (Life Technologies).  
 
 
2.7.4. Immunoblotting 
Once the gel electrophoresis was complete, the gel was separated from the plates and 
together with blotting paper, sponges and nitrocellulose membrane (Cat. # 162-0112, 
BioRad) that had been soaked in dilute NuPAGE® transfer buffer (20X, Cat. # NP006, 
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Life Technologies) containing 10% (v/v) methanol, were loaded into the XCell II
TM
 Blot 
Module (Life Technologies). The blot module was then placed in the XCell SureLock
TM
 
Mini-Cell Electrophoresis system and the running chamber saturated with NuPAGE® 
transfer buffer while the outer chamber was filled with distilled water. The transfer was 
run at 30V for 1 hour to allow the proteins to transfer from the gel to the membrane.  
 
Ponceau S staining (Sigma-Aldrich, Cat. # P7170) was used to determine successful 
transfer of the proteins from the gel to the membrane. The membrane was washed with 
Tris-buffered saline Tween-20 (TBST; 50mM Tris, pH 7.4; 200mM NaCl and 0.1% 
(v/v) Tween-20) three times for 5 minutes to ensure the Ponceau S stain was removed 
before the membrane was blocked with 5% (w/v) skimmed milk powder solution in 
TBST at room temperature for 1 hour with gentle agitation. Three washes with TBST 
were carried out after blocking to remove any residual milk powder solution before the 
membrane was probed with the primary antibodies. Anti-TLR4 (Cat. # ab22048, 
Abcam) at a concentration of 2µg/ml in 5% (w/v) BSA/TBST solution and the anti-
Sodium-Potassium ATPase transporter used as the housekeeping protein for the 
membrane fractions (Cat. # ab76020, Abcam) at a 1:20000 dilution in 2% (w/v) 
BSA/TBST were incubated overnight at 4°C with gentle agitation. Anti-GAPDH (Cat. # 
AM4300, Life Technologies) was diluted 1:4000 in 5% (w/v) skimmed milk powder in 
TBST and incubated for 1 hour. Following incubation, the primary antibody was 
removed and the three washes with TBST were repeated to remove any unbound 
primary antibody. The enzyme-linked secondary antibody, either anti-Mouse (Cat. # 
A3682, Sigma-Aldrich) or anti-Rabbit HRP-linked IgG antibodies (Cat. # 70745, New 
England Biolabs) as appropriate were diluted 1:1000 with a 5% (w/v) skimmed milk 
powder solution in TBST and the blot was incubated at room temperature for 1 hour 
with gentle agitation. Three TBST washes were completed after the incubation to 
remove any unbound secondary antibody before adding the working reagent of 
SuperSignal West Pico Chemiluminescent Substrate (1:1 Luminol/Enhancer: Stable 
Peroxide buffer; Cat. # 34080, Thermo Scientific) according to manufacturer’s 
instructions. The blot was protected from the light and incubated for 5 minutes to allow 
the enzyme linked to the secondary antibody to convert the substrate to a 
chemiluminescent product. The intensity of the chemiluminescence was measured using 
the BioRad Fluor-S MultiImager. To re-probe the membrane, the previous antibodies 
were stripped for 15 minutes at room temperature using Restore
TM
 Western blot 
Stripping buffer (Cat. # 21059, Thermo Scientific) before re-blocking the membrane and 
repeating the process.  
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2.7.5. Data analysis and statistics 
In experiments carried out with ranging doses of treatments, one-way ANOVA was 
performed followed by Bonferroni multiple comparison tests.  
 
 
2.8. Analysis of SF modifications on TLR4 using liquid 
chromatography-tandem mass spectroscopy (LC-MS/MS) 
2.8.1. Sample preparation 
2.8.1.1. Recombinant TLR4 protein 
Purified extracellular domain of TLR4 (sourced from a mouse myeloma cell line, NS0-
derived, Glu24-Lys631, with a C-terminal Ser and 10-His tag) was obtained from R&D 
systems (Cat. # 1478-TR-050). TLR4 (1μg) was incubated with SF (5-50µM; vehicle 
control for SF = < 0.1% (v/v) DMSO) for 1 hour at 37°C in a 100mM Tris-HCl (pH 7.8) 
and 10mM CaCl2 digestion buffer. For reducing conditions, 1mM DTT was added for 15 
minutes following SF treatment. Sequencing grade chymotrypsin (Cat. # 11418467001, 
Roche) was added for 7 hours, followed by trypsin digestion overnight after thermal 
denaturation of the chymotrypsin for 5 minutes at 95°C (both at 1:50 enzyme to 
substrate ratio). Protein digestion was quenched using formic acid at a final 
concentration of 5%. OMIX C18 pipette tips (Cat. # A57003100, Agilent Technologies) 
were used to concentrate the peptide fragments and remove undigested protein.  
 
 
2.8.1.2. Cytoplasmic and membrane protein extracts 
Duplicate membrane and cytoplasmic protein fractions were subjected to gel 
electrophoresis as explained in section 2.7.3. 
 
 
2.8.1.3. Immunoprecipitation of TLR4 protein 
In order to enrich the samples with TLR4, an immunoprecipitation (IP) method was 
used. The Pierce Classic IP Kit (Cat. # 26416, Thermo Scientific) was used according to 
manufacturer’s instructions (Figure 2.3).  
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Figure 2.3. Protocol for immunoprecipitation of TLR4. 
 
 
  
HT-29 cells treated with SF (5, 10 and 25µM) +/- 1ng/ml LPS for 1 
hour 
Cell lysate vortexed twice and centrifuged for 10 minutes at 13000 x g 
Supernatant transferred to fresh tube and protein quantified using 
the BCA assay (section 2.7.2.)  
1mg protein added to control agarose resin to pre-clear. Incubate for 
1 hour and centrifuge 1000 x g 30 seconds 
10µg anti-TLR4 added to lysate and left overnight at 4°C 
Antibody-lysate solution incubated with protein A/G agarose for 1 
hour at 4°C 
Wash twice with wash buffer and once with conditioning buffer 
Elute complex with sample buffer with added DTT to dissociate 
antibody-protein complex 
10µl for western blot analysis and the rest was subjected to gel 
electrophoresis for gel digest 
Proteins extracted using IP lysis buffer. Incubate on ice 5-10 minutes 
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2.8.2. Gel digestion of protein bands 
Following gel electrophoresis, gels were fixed with a solution of 50% (v/v) methanol 
and 7% (v/v) acetic acid for 15 minutes to improve staining. The fixed gels were washed 
with distilled water three times to remove any remaining fixing agent. The gels were 
stained with GelCode Blue Stain Reagent, a coomassie blue protein stain (Cat. # 24590, 
Thermo Scientific) for 1 hour, followed by destaining with three washes of distilled 
water in order to reduce the background, resulting in only the proteins being stained. The 
gels were visualised using the GS800 Calibrated Densitometer (BioRad) using the 
Quantity One 4.6.1 software with Gel Coomassie setting and selected at 36.3µm.  
 
The approximate band size of the expected TLR4 band is at 93kDa therefore from the 
gels where the cytoplasmic and membrane fractions were used, the area of gel excised 
was between the 80 and 100kDa markers. For the IP product, several bands were excised 
as described in further detail in Chapter 5, section 5.2.4. Once excised from the gel, as 
much unstained gel as possible was removed and the stained portion was cut finely into 
1mm
3
 with a razor blade. The samples were transferred in to 1.5ml eppendorfs and 
400µl distilled water was added. The gel pieces were washed with 1ml of 0.2M 
ammonium bicarbonate (ABC) in 50% acetonitrile via vortexing briefly and leaving for 
15 minutes to remove the GelCode Blue Stain Reagent. This step was repeated two-three 
times until the gel pieces were clear in colour. Once the stain was completely removed, 
the solution was aspirated. 1ml of acetonitrile was added for 10 minutes to remove 
aqueous solutions resulting in the gel pieces become white in colour and dry. The 
solution was aspirated and the tubes were left open to allow the remaining acetonitrile to 
evaporate. 
 
For the enzyme digestion step, chymotrypsin was prepared in a solution of 20mM 
ABC/10mM CaCl2. A 25µg aliquot of chymotrypsin was dissolved in 500µl 20mM 
ABC/10mM CaCl2 and 100µl of this solution was added to 150µl solvent to give a 
20ng/µl working concentration and was kept on ice. A 5µg aliquot of trypsin was 
solubilised in 245µl 20mM ABC/10mM CaCl2 to give a 20ng/µl working concentration 
and was left on ice. 10-20µl of each enzyme was added which was absorbed by the gel 
pieces, allowing the proteins within the gel pieces to be enzymatically digested. An 
appropriate volume of 20mM ABC/10mM CaCl2 was subsequently added to each 
sample to ensure all gel pieces were in solution and samples were left overnight in a 
water bath at 37°C. To quench the enzyme reaction, the total volume of liquid added to 
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the gel pieces was calculated and this amount of 1% formic acid was added to each 
sample before they were left on dry ice for 10 minutes.  
 
Samples were thawed and the digest solution was aspirated and transferred into fresh 
1.5ml eppendorfs. The gel pieces were washed with 50% acetonitrile for 10 minutes 
before the solution was collected to increase the recovery of the digested proteins. The 
extracted digest samples were then dried down on the medium drying setting using the 
Speed Vac SC110 (Savant) fitted with a refrigerated condensation trap and a Vac V-500 
(Buchi). The samples were then frozen at -80°C until ready for Orbitrap analysis.      
 
 
2.8.3. LC-MS/MS analysis 
Samples were prepared in 50% acetonitrile and subjected to micro-LC-MS/MS analysis 
using the LTQ Orbitrap mass spectrometer (Thermo Electron) and a nanoflow-HPLC 
system (nanoACQUITY; Waters). Peptides were trapped on line to a Symmetry C18 
Trap (5µm, 180µm x 20µm) held at 45°C. Peptides were eluted by a gradient of 0-80% 
acetonitrile in 0.1% formic acid over 50 minutes at a flow rate of 250nl/min. The mass 
spectrometer was operated in positive ion mode with a nano-spray source at a capillary 
temperature of 200°C.  
 
The Orbitrap was run with a resolution of 60,000 over the mass range m/z 300-2000 and 
an MS target of 10
6
 and 1 second maximum scan time. The MS/MS was triggered by a 
minimal signal of 2000 with an Automatic Gain Control target of 30000 ions and a 
maximum scan time of 150 milliseconds. For MS/MS events selection of 2+ and 3+ 
charge states selection were used. Dynamic exclusion was set to 1 count and 30 second 
exclusion time with an exclusion mass window of ± 20ppm. 
 
 
2.8.4. Data analysis and statistics 
The protein levels of the bands from the IP product gel stained with coomassie blue were 
quantified using the Quantity One software. Adjusted % band volumes were used and 
for normalisation, the antibody band was used (Chapter 5, section 5.2.4). 
 
For the LC-MS/MS data, the spectra were analysed using Mascot against the Uniprot 
protein database, restricted to taxonomy Homo sapiens of the SPtrEMBL database, 
chymotrypsin/trypsin digest which was permitted to have four missed cleavages and 
General materials and methods 
 
51 
 
oxidised methionine and cysteine-bound SF were selected as variable modifications. The 
peptide masses were monoisotopic and either 2+ or 3+ charged and the peptide error 
tolerance was ± 1.5Da and MS/MS error tolerance was ± 0.5Da. Data was also analysed 
using Peaks software to investigate the significance of the fragmentation pattern and 
Progenesis software to evaluate the dose-response relationship. 
 
For investigating the relationship between SF treatment and the abundance of the 
modified cysteine-containing peptides, the abundance values were extracted from the 
Progenesis software and a one-way ANOVA was carried out followed by Bonferroni 
multiple comparison tests.  
 
 
2.9. Measure of NF-κB activity using QUANTI-BlueTM assay 
2.9.1. Background 
QUANTI-Blue
TM 
is a colorimetric enzyme assay which is able to determine the amount 
of alkaline phosphatase (AP) activity in cell culture supernatants via an enzymatic 
reaction resulting in the change of the QUANTI-Blue
TM
 solution from a pink colour to a 
purple-blue colour in the presence of AP. SEAP, a truncated form of the GPI-anchored 
protein placental AP, is a commonly used reporter gene. It is secreted into the cell 
culture medium making this a quick assay that does not require disruption of the cells. 
 
 
2.9.2. QUANTI-Blue
TM
 assay 
HEK-Blue
TM
 cells (described in section 2.2.2) were grown to 70% confluence in 384 
well plates. Once treated for 24 hours with appropriate ligands in the presence or 
absence of SF (L-SF or DL-SF; 2, 5 and 10µM; vehicle control for SF = < 0.1% (v/v) 
DMSO), the level of SEAP was measured. QUANTI-Blue
TM 
powder (Cat. # rep-qb1, 
InvivoGen) was dissolved in distilled water and warmed to 37°C before use. 50µl of 
QUANTI-Blue
TM
 was added to each well of a new 384 well plate before the addition of 
5µl cell culture supernatant from each replicate. The plate was then incubated at room 
temperature (required between 10-60 minutes depending on which cells were used) and 
was shielded from the light to allow a colour change to occur from pink to purple-blue 
after which the absorbance was measured at 650nm using the MultiSkan Spectrum 
spectrophotometer (Thermo Scientific). 
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2.9.3. Statistics 
With ranging doses of treatments, one-way ANOVA was performed followed by 
Bonferroni multiple comparison tests. 
 
  
2.10. Analysis of lipid accumulation and lipolysis in SGBS cells 
2.10.1. Background 
During adipogenesis, preadipocyte cells can be differentiated into mature adipocytes in 
response to a number of signals which results in the increased accumulation of lipids 
within the cells. This lipid accumulation can be used to quantify the level and 
progression of differentiation over time. In the present study, Oil Red O staining was 
performed. 
  
Oil Red O is otherwise known as Sudan Red 5B and is a fat soluble diazo dye used for 
staining lipids. By using isopropanol as a solvent, the dye is able to enter the cells and 
stain the lipids bright red while the excess can be removed via washing with water. An 
advantage of this protocol is that the Oil Red O stain can be eluted from the cells using 
isopropanol without dissolving the lipids themselves and the level of staining can be 
quantified spectrophotometrically. 
 
In terms of measuring lipolysis within the cells, a commonly used technique is 
measuring the glycerol release into the cell culture supernatant. Glycerol is the backbone 
of triglycerides and under a number of physiological conditions triglycerides can be 
hydrolysed, resulting in the release of glycerol and FFAs. Unlike the FFAs, glycerol is 
not reutilised by the adipocytes and is released by the cells. By measuring the levels of 
glycerol in the cell culture supernatant we can consider this to reflect the level of 
lipolysis. Kits are commercially available and involve an enzymatic reaction in which a 
coloured product is formed. The absorbance is proportional to the amount of glycerol 
released. Figure 2.4 presents the reactions involved in measuring glycerol levels. 
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Figure 2.4. Glycerol assay principle.  
Glycerol is phosphorylated by glycerol kinase to produce glycerol-3-phosphate and 
adenosine diphosphate (ADP). The glycerol-3-phosphate is oxidised by glycerol 
phosphate oxidase producing dihydroacetone phosphate and hydrogen peroxide (H2O2). 
Peroxidase catalyses the redox-coupled reaction of H2O2 with 4-aminoantipyrine (4-
AAP) and N-ethyl-N-(3-sulfopropyl)-m-anisidine (ESPA), producing a brilliant purple 
product with an absorbance maximum at 540nm. Figure adapted from the kit protocol. 
 
 
2.10.2. Oil Red O staining 
Oil Red O was obtained from Sigma-Aldrich (Cat. # O0625) and a stock solution of 
3.4mM in isopropanol was produced. This was left on a stirrer plate overnight, filtered 
using a sterile 0.2µm pore size syringe filter and stored at 4°C. The working solution 
was produced using a 1.6-fold dilution in water to yield a working concentration of 
2.1mM. The solution was mixed and left at room temperature for 20 minutes before 
being filtered again using a sterile 0.2µm pore size syringe filter. Details of the protocol 
are given in Figure 2.5. 
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Medium was removed from cells and stored for additional 
analyses 
Aspirated and replaced with fresh 10% formalin and left 
overnight 
Aspirate and wash with 60% isopropanol  
Add Oil Red O Stain for 10 minutes 
Aspirate stain and wash immediately with distilled water four 
times 
Pictures can be taken of stained intracellular lipids 
Elute intracellular Oil Red O with 100% isopropanol 
Solution transferred into a 96 well plate with 6 replicates 
Read absorbance at 500nm with 100% isopropanol as a blank 
measurement  
Cells were fixed: 10% formalin for 5 minutes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.5. Oil Red O staining protocol. 
 
 
2.10.3. Glycerol release analysis 
Prior to the Oil Red O staining, the cell culture supernatant was collected and cleared by 
centrifugation at 13000rpm for 20 minutes at 4°C before being stored at -20°C. For 
glycerol analysis, the Glycerol Colorimetric Assay Kit (Cat. # 10010755, Cambridge 
Biosciences) was used.  
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20µl of the Glycerol Standard was diluted with 980µl of the diluted Standard Diluent 
(all reagents were provided in the kit) to produce a stock solution of 20mg/l. From the 
stock solution, a standard curve was produced over the range of 0-20mg/l in order to 
allow the quantification of glycerol present in the samples. 10µl of standards and 
samples were added to the 96 well plate provided in the kit before the reaction was 
initiated via the addition of the diluted Enzyme Buffer solution to each well. The plate 
was shaken for a few seconds to mix before being covered and incubated for 15 minutes 
at room temperature. The absorbance was then measured at 550nm using the FLUOstar 
OPTIMA microplate reader. The concentration in each sample was determined by the 
use of the standard curve algorithm.  
 
 
2.10.4. Data analysis and statistics 
For the Oil Red O data, the OD values were corrected by subtracting the value found 
with isopropanol alone and these raw data values were used for analysis. For the 
glycerol release data, OD values were blank-corrected by subtracting the value found 
with 0mg/l of the glycerol standard curve and applying the standard curve equation to 
calculate the concentration of glycerol in each sample.  
 
In experiments carried out with ranging doses of treatments, one-way ANOVA was 
performed followed by Bonferroni multiple comparison tests. In experiments with two 
variables (dose of treatment and time of exposure) two-way ANOVA was performed 
with Bonferroni multiple comparison tests. 
 
 
2.11. Analysis of TCA intermediates in MaCM using LC-MS/MS 
analysis 
2.11.1. Sample preparation 
MaCM was produced following the differentiation of monocytes into macrophages as 
described in section 2.3.2. 
 
Both the DMEM/F12 + 10% (v/v) non-heat inactivated FCS (normal growth medium for 
the SGBS cells) and RPMI-1640 serum-free with and without 0.5% (w/v) BSA 
(differentiation medium for the monocytes to macrophages) were measured in 
combination with a number of doses (10, 20 and 50% MaCM). All were carried out in 
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two biological replicates and two technical replicates. Once prepared, all solutions were 
centrifuged at 1200 x g for 10 minutes at room temperature and the supernatant 
transferred to a fresh eppendorf. 100µl 3mM perchloric acid was added to all media 
samples to acidify the solution and samples were immediately placed on ice for 10 
minutes. Samples were centrifuged at 12000 x g for 10 minutes at 4°C and the 
supernatant was collected. 100µl of each sample was added to amber 2ml HPLC vials 
with inserts.  
 
A standard curve was produced with 1mg/ml concentration of a number of TCA 
intermediates, all purchased from Sigma-Aldrich; glutamic acid (Cat. # G1251), citric 
acid (Cat. # C0759), malic acid (Cat. # M0875), oxaloacetic acid (Cat. # O4216), 
succinic acid (Cat. # S3674), fumaric acid (Cat. # 47910), malonic acid (Cat. # M1296) 
and lactic acid (Cat. # L0625) were all solubilised in acidified medium (RPMI-1640 + 
10% 3mM perchloric acid). 100µl of each of the standards were added together and 
made up to 1ml to give a solution of 100µg/ml of each standard. A separate standard 
curve was made up for isocitric acid (Cat. # I1252) and 100µl was taken and made up to 
1ml in the same way as with the other intermediates. A five point standard curve is 
produced with a 10-fold serial dilution over the range of 10000ng/ml to 0ng/ml. 10µl of 
deuterated citrate is added to all samples as an internal standard (final concentration of 
10µg/ml) to allow quantification based on the ratio of the internal standard to each 
intermediate peak. 
 
 
2.11.2. LC-MS/MS analysis 
For LC-MS/MS analysis, the Agilent 1200 Series LC 6490 Triple Quad LC-MS mass 
spectrometer was used (Agilent). The HPLC column was a Kinetex C18 1.7µm (100 x 
2.1mm) from Phenomenex. The flow rate was 0.4ml/min with a mobile phase of 0.2% 
formic acid. Electrospray ionisation (ESI) was used in the positive mode for glutamic 
acid and in the negative mode for the remaining intermediates investigated. 2µl was used 
for the injection volume and the autosampler was maintained at 4°C. Table 2.2 
summarises the monitored ions and the optimised MS operating parameters of the 
analytes.  
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Table 2.2. LC-MS/MS parameters for analytes measured  
Analyte Retention time 
(minutes) 
Precursor Ion 
(m/z) 
Product Ion 
(m/z) 
Polarity 
Glutamic Acid 0.6 148.1 129.9 Positive 
Citric Acid 0.9 191.0 110.9 Negative 
Iso-Citric Acid 0.7 191.0 154.9 Negative 
α-Ketoglutaric acid * 145.1 100.9 Negative 
Malic Acid 0.7 133.1 114.8 Negative 
Oxaloacetic Acid * 131.0 87.1 Negative 
Succinic Acid 1.2 117.0 98.9 Negative 
Fumaric Acid 1.1 115.0 70.9 Negative 
Malonic Acid * 103.0 58.9 Negative 
Lactic Acid 0.8 89.0 42.9 Negative 
* The retention time was unavailable as compounds were not found in samples 
 
 
2.11.3. Data analysis and statistics 
Data files were explored and analysed using MassHunter Workstation software 
(Agilent). The peak areas of the analytes were determined and using the peak area ratio 
(peak area of analyte/peak area of the internal standard) the concentration of the analyte 
was determined. In the present study, the treatment consisted of a number of doses thus 
requiring one-way ANOVA followed by Bonferroni multiple comparison tests. 
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Chapter Three 
Effect of SF on LPS-induced cytokine 
production in human monocytes 
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3.0. Introduction 
Chronic inflammation is a complex condition that has been described as the ‘common 
soil’ in the aetiology of a number of multifactorial diseases such as cancer, CVD and 
T2DM [205]. It is often characterised by the modulation of inflammatory mediators, e.g. 
cytokines, following a sustained response to an inflammatory stimulus. Cytokines are a 
large group of signalling molecules involved in cell communication and are often 
described as either pro- or anti-inflammatory [206]. However, many cytokines have a 
pleiotropic nature and can function as both pro- and anti-inflammatory, depending on the 
circumstances, which makes classification difficult. Of the cytokines found to be altered 
in chronic diseases, IL-6, IL-1β and TNFα are commonly investigated in vitro and in 
vivo, and most research classifies these as pro-inflammatory [33, 42, 43, 45, 206-213].  
 
Chronic inflammation occurs when an acute inflammatory attack becomes dissociated 
from a specific stimulus. This stimulus may be a bacterial infection in which structural 
components of the bacteria elicit an inflammatory response. An example is LPS, a 
bacterial endotoxin found in the cell walls of Gram-negative bacteria. Endotoxin can be 
measured at detectable levels in circulation. In healthy individuals, it is present at a level 
in the low pg/ml range, however, in individuals suffering from chronic disease levels 
may be elevated at levels up to 0.9ng/ml [37, 45, 46]. LPS is a specific agonist for 
TLR4, a PRR which when activated by ligand binding, results in the stimulation of 
transcription factors including NF-κB and AP-1, which in turn control the expression of 
pro-inflammatory mediators [13]. Thus, elevation of LPS in circulation may be 
responsible for increased serum levels of cytokines seen in sufferers of chronic disease.  
 
Monocytes are a fundamental cell type involved in both acute and chronic inflammation. 
They are found in circulation and are primed with the ability to rapidly invade tissues in 
response to an inflammatory stimulus [214]. In a low-grade inflammatory state, for 
example during atherosclerosis, monocytes are recruited as a result of increased LDL 
levels within the plasma. A positive correlation is seen between the number of 
monocytes in circulation and atherosclerotic plaque size in animal models and in 
humans, resulting in the level of circulating monocytes being described as an 
independent risk factor for CVD [215]. As a result, monocytes are commonly chosen as 
a model to study chronic inflammatory signalling pathways. 
 
When investigating the role of dietary agents in human health, biological relevance is of 
critical importance. The fact that a state of low-grade systemic inflammation is common 
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to a number of chronic diseases makes the process a crucial target for dietary 
interventions. Diets rich in cruciferous vegetables have been associated with a decreased 
risk of developing cancer at a number of different sites and also with a lower risk of 
CVD mortality [115, 216-222]. ITCs, derived from GSLs present in cruciferous 
vegetables such as broccoli, are bioactive components that may mediate the observed 
beneficial health effects with increased cruciferous vegetable consumption. SF is the 
predominant ITC obtained from broccoli. Based on research by Gasper and colleagues, a 
peak concentration of 2.4 ± 0.4µM of total SF metabolites were found in the plasma of 
individuals 2 hours after consumption of standard broccoli, while consumption of high-
GSL broccoli achieved a concentration of 7.4 ± 3.1µM [129]. This provides direct 
experimental evidence that consumption of broccoli results in the presence of 
biologically active SF in circulation.  
 
SF has been previously shown to exert anti-inflammatory effects both in vitro and in 
vivo [181-187, 190-192, 195, 223, 224]. Taking into consideration the elevation of pro-
inflammatory cytokines in sufferers of chronic disease, with the evidence that SF is able 
to exert anti-inflammatory effects, the hypothesis that SF was able to significantly 
suppress IL-6, IL-1β and TNFα expression and secretion in human monocytic cells in 
response to LPS was tested within this chapter. 
 
 
3.1. Materials and Methods 
The cell models used were human PBMCs from healthy blood donors in order to 
optimise experimental design or from a commercial source, in addition to THP-1 
monocytes. Details of these cell types are described in section 2.2.1. In order to measure 
the levels of cytokines secreted in response to LPS in the presence or absence of SF, an 
ELISA specific to each of the cytokines measured (IL-6, IL-1β and TNFα) was 
performed and the technique is described in further detail in section 2.4. To determine 
the viability of the cells in response to SF a WST-1 cell viability assay was used (section 
2.3). For investigations into the level of expression of each cytokine in the THP-1 
monocytes, real-time RT-PCR was used (section 2.5). 
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3.2. Results 
3.2.1. PBMCs  
3.2.1.1. Effect of SF on LPS-induced cytokine secretion 
Human PBMCs were the chosen cell model in this experimental design due to their 
principle involvement in responding to pro-inflammatory signals. LPS is commonly 
used as an artificial inducer of inflammation but often at very high concentrations. The 
reason LPS was favoured in this experimental design as opposed to other inflammatory 
stimuli such as IL-1β and TNFα, was due to the presence of endotoxin circulating in 
different chronic conditions e.g. CVD and T2DM. Also, with choosing to measure IL-1β 
and TNFα as my endpoint biomarkers, using them as the inflammatory stimulus would 
have been inappropriate for the secretion studies and expression would have been 
potentially induced as a result of positive feedback. In the present study, concentrations 
of LPS were used in the range of 1-500ng/ml, with a level of 1ng/ml being relevant to 
the levels found circulating in sufferers of chronic disease [37, 45, 46]. When human 
PBMCs were treated with 1ng/ml LPS for 4 hours, a significant increase in the levels of 
IL-6 secretion was observed (Figure 3.1). Thus demonstrating that this physiologically 
relevant concentration was sufficient for induction of an inflammatory response and it 
was not necessary to further increase the concentration of LPS used.  
 
 
 
  
 
 
 
 
 
 
 
Figure 3.1. Induction of IL-6 secretion with different LPS concentrations in human 
PBMCs. Human PBMCs were treated with LPS at different concentrations (1, 5 and 
500ng/ml; vehicle control for LPS = PBS) for 4 hours. The cell culture supernatant was 
collected and IL-6 was measured by ELISA. Data shown = mean ± SD. Data was 
statistically analysed using one-way ANOVA followed by Bonferroni multiple 
comparison tests. ***p<0.001 vs. 0ng/ml. 
 
 
The measurement of IL-6 secretion in response to LPS (1ng/ml) in human PBMCs was 
repeated over a 24 hour period to observe the secretion pattern. The secretion of IL-6 is 
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significantly induced at 4 hours initially (consistent with response seen in Figure 3.1) 
and continues to rise with increasing the time of exposure to LPS (Figure 3.2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2. LPS significantly induces IL-6 secretion in human PBMCs over 24 
hours. Human PBMCs were treated with 1ng/ml LPS (vehicle control for LPS = PBS) 
with varying times of exposure (0.5-24 hours). The cell culture supernatant was 
collected and IL-6 was measured by ELISA. Data shown = mean ± SD. Data was 
statistically analysed using AUC followed by Student t tests for each time point 
comparing the cumulative AUC values. *p<0.01 and **p<0.001 vs. untreated controls at 
the same time point.  
  
 
In order to investigate the effect of SF on LPS-induced IL-6 secretion, the time of SF 
exposure required determination. In previous experiments within the research group, 
human PBMCs were pre-treated with SF for 20 hours prior to LPS treatment for 4 hours. 
In terms of what was observed in vivo, Gasper and colleagues found that the 
concentration of SF peaks in the plasma 2 hours after ingestion of broccoli [129]. Based 
on those results, the effect of SF on LPS-induction with both a 2 hour and 20 hour pre-
treatment of SF was compared. In both conditions, SF significantly suppressed LPS 
induction of IL-6 secretion (Figure 3.3A and B). 
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Figure 3.3. SF suppresses LPS-induced IL-6 secretion in PBMCs with a 2 hour pre-
treatment (A) and 20 hour pre-treatment (B). PBMCs were treated with 2µM SF 
(vehicle control for SF = < 0.1% (v/v) DMSO) for 2 hours (A) or 20 hours (B) prior to 
treatment with 1ng/ml LPS (vehicle control for LPS = PBS) for 4 hours. The cell culture 
supernatant was collected and IL-6 was measured by ELISA. Data shown = mean ± SD. 
Data was statistically analysed using one-way ANOVA followed by Bonferroni multiple 
comparison tests.***p<0.001 against LPS or as annotated.  
 
 
The suppression of LPS-induced IL-6 secretion by SF was explored further through 
measuring IL-6 secretion over 24 hours. Additional measurements of IL-1β and TNFα 
secretion were also taken throughout a 24 hour period to determine the specificity of 
SF’s effect. It was found that SF significantly reduced the level of LPS-induced 
secretion of all three cytokines throughout the 24 hours when PBMCs were pre-
incubated with SF for 2 hours (Figure 3.4).  
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Figure 3.4. SF significantly suppresses LPS-induced secretion of IL-6 (A), IL-1β (B) 
and TNFα (C) in PBMCs over time. PBMCs were treated with 2µM SF (vehicle 
control for SF = < 0.1% (v/v) DMSO) at 0 hours. After 2 hours, 1ng/ml of LPS (vehicle 
control for LPS = PBS) was added to the cells. The cell culture supernatant was 
collected after 4, 6, 10 and 26 hours and cytokines were measured by ELISA. Data 
shown = mean ± SD. Data was statistically analysed using AUC followed by Student t 
tests for each time point comparing the cumulative AUC values. **p<0.01 and 
***p<0.001 LPS vs. untreated controls and LPS + SF vs. LPS only.  
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3.2.1.2 Effect of SF on PBMC cell viability 
To ensure that the significant suppression observed with SF on LPS-induced cytokine 
secretion was not due to cytotoxic effects, a WST-1 viability assay (section 2.3) was 
carried out with a wide range of SF concentrations (0-200µM). SF was found to 
significantly reduce the viability of human PBMCs at concentrations of 10µM and above 
(Figure 3.5). The IC50 was calculated at 15.6 ± 6.0µM. Importantly, no significant 
reduction was seen in cell viability as compared to the control with concentrations below 
10µM. This confirms that 2µM SF used in the cytokine secretion experiments was not 
significantly reducing LPS-induced cytokine production as a result of cytotoxic effects. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5. Effect of SF on PBMC cell viability. PBMCs were treated with SF (0-
200µM) for 24 hours (vehicle control for SF = < 0.1% (v/v) DMSO). After treatment 
was complete, 10µl WST-1 reagent was added to each well. The plates were incubated 
at 37°C and measured using a spectrophotometer at 450nm every 15 minutes for 3 
hours. Data shown is from the 2.5 hour measurement at which the levels of absorbance 
were all measurable and consistent. Data shown = mean ± SD.  Data was statistically 
analysed using one-way ANOVA followed by the Bonferroni multiple comparison test. 
***p<0.001 vs. 0µM SF. 
 
 
3.2.2 THP-1 monocytes 
3.2.2.1 Effect of SF on LPS-induced cytokine secretion 
The physiologically relevant concentration of 1ng/ml LPS was sufficient for inducing 
cytokine secretion in human PBMCs (Figure 3.1). Using a range of concentrations from 
1-100ng/ml LPS, it was investigated whether human THP-1 monocytes, a cancerous cell 
line isolated from a sufferer of acute monocytic leukaemia [198], behaved in the same 
way. No induction in IL-6 secretion was observed following LPS treatment for 4 hours 
(data not shown) and subsequently LPS treatment for 24 hours was investigated with the 
THP-1 monocytes. 
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LPS at 1ng/ml was sufficient to significantly induce IL-6 secretion in THP-1 monocytes 
(Figure 3.6), replicating what was seen with PBMCs. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6. Induction of IL-6 secretion with different LPS concentrations in THP-1 
monocytes. THP-1 monocytes were treated with LPS at different concentrations (1, 10 
and 100ng/ml; vehicle control for LPS = PBS) for 24 hours. The cell culture supernatant 
was collected and IL-6 was measured by ELISA. Data shown = mean ± SD. Data was 
statistically analysed using one-way ANOVA followed by Bonferroni multiple 
comparison tests. ***p<0.001 vs. 0ng/ml. 
 
 
LPS induction of IL-6 was further examined over a 24 hour period as was carried out 
with the PBMCs (Figure 3.2). IL-6 secretion was also found to be induced by LPS over 
time with the secretion beginning at 12 hours continuing linearly up to 24 hours (Figure 
3.7).  
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Figure 3.7. LPS significantly induces IL-6 secretion in THP-1 monocytes over 24 
hours. THP-1 monocytes were treated with 1ng/ml LPS (vehicle control for LPS = PBS) 
with varying times of exposure (0.5-24 hours). The cell culture supernatant was 
collected and IL-6 was measured by ELISA. Data shown = mean ± SD. AUC followed 
by Student t tests for each time point comparing the cumulative AUC values. 
***p<0.001 vs. untreated controls at the same time point.  
 
 
To investigate whether SF could suppress LPS-induced IL-6 secretion, THP-1 
monocytes were treated with SF (2, 5 or 10µM) in combination with 1ng/ml LPS for 24 
hours. Concentrations of 5µM and 10µM SF were able to significantly suppress the LPS 
induction of IL-6 secretion in THP-1 monocytes while 2µM, the concentration used with 
the PBMCs, shows a small but non-significant reduction (Figure 3.8). 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8. SF suppresses LPS-induced IL-6 secretion in THP-1 monocytes. THP-1 
monocytes were treated with 1ng/ml LPS (vehicle control for LPS = PBS) for 24 hours 
in the presence or absence of SF (2, 5 and 10µM; vehicle control for SF = < 0.1% (v/v) 
DMSO). The cell culture supernatant was collected and IL-6 was measured by ELISA. 
Data shown = mean ± SD. Data was statistically analysed using one-way ANOVA 
followed by Bonferroni multiple comparison tests. ***p<0.001 vs. LPS (1ng/ml) or as 
annotated.  
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The suppression of LPS-induced IL-6 secretion by SF was further investigated over 
time. 5µM SF completely suppressed LPS induction of IL-6 secretion for up to 72 hours 
with the levels of secretion remaining very close to those of the untreated controls 
(Figure 3.9). IL-6 was induced with LPS from 12 hours, which is consistent with what 
was previously shown (Figure 3.7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9. SF significantly suppresses LPS-induced IL-6 secretion in THP-1 
monocytes over time. THP-1 monocytes were treated with 1ng/ml LPS (vehicle control 
for LPS = PBS) over a range of time points (0.5-72 hours) in the presence or absence of 
5µM SF (vehicle control for SF = < 0.1% (v/v) DMSO). The cell culture supernatant 
was collected and IL-6 was measured by ELISA. Data shown = mean ± SD. Data was 
statistically analysed using AUC followed by Student t tests for each time point 
comparing the cumulative AUC values. *p<0.05 and ***p<0.001 LPS vs. untreated 
controls and LPS + SF vs. LPS only.  
 
 
To ensure that the effect of SF was not limited to IL-6 alone, the effect of LPS and SF 
on the levels of IL-1β and TNFα secretion was also measured. THP-1 monocytes were 
co-treated with 1ng/ml LPS and 5µM SF for 12 hours before measuring the cytokine 
secretion. Both IL-1β and TNFα demonstrated a significant induction with 1ng/ml LPS, 
which was significantly suppressed in the presence of 5µM SF (Figure 3.10). 
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Figure 3.10. SF significantly suppresses LPS-induced IL-1β (A) and TNFα (B) 
secretion in THP-1 monocytes. THP-1 monocytes were treated with 1ng/ml LPS 
(vehicle control for LPS = PBS) in the presence or absence of 5µM SF (vehicle control 
for SF = < 0.1% (v/v) DMSO) for 12 hours. The cell culture supernatant was collected 
and IL-1β and TNFα was measured by ELISA. Data shown = mean ± SD. Data was 
statistically analysed using one-way ANOVA followed by Bonferroni multiple 
comparison tests. ***p<0.001 vs. LPS or as annotated.  
 
 
3.2.2.2. Effect of SF on THP-1 monocyte cell viability 
Due to the significant reduction in LPS-induced IL-6, IL-1β and TNFα secretion in 
THP-1 monocytes, the effect of SF on THP-1 cell viability was investigated to ensure 
that this reduction was not simply due to a cytotoxic effect on the cells. THP-1 
monocytes were treated with concentrations of SF from 0-200µM for 24 hours. 
Concentrations up to 15µM SF did not demonstrate any significant cytotoxic effects in 
THP-1 monocytes (Figure 3.11) with an IC50 calculated at 36.4 ± 5.9µM.  
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Figure 3.11. Effect of SF on THP-1 monocyte cell viability. THP-1 monocytes were 
treated with SF (0-200µM; vehicle control for SF = < 0.1% (v/v) DMSO) for 24 hours. 
After treatment was complete, 10µl WST-1 reagent was added to each well. The plates 
were incubated at 37°C and measured using a spectrophotometer at 450nm every 15 
minutes for 3 hours. Data shown is from the 1 hour measurement at which the levels of 
absorbance were all measurable and consistent. Data shown = mean ± SD.  Data was 
statistically analysed using one-way ANOVA followed by the Bonferroni multiple 
comparison test. *p<0.05, ***p<0.001 vs. 0µM SF. 
 
 
3.2.2.3. Effect of SF on LPS-induced cytokine expression 
In order to evaluate which stage of cytokine production SF was targeting, cytokine 
expression was measured to see whether the induction by LPS and inhibition by SF was 
occurring at a transcriptional level in the THP-1 monocytes. Initially, a time course 
experiment was carried out with 1ng/ml LPS treatment measuring IL-6 expression. After 
2 hours of LPS exposure, there was significant induction of IL-6 expression, with the 
peak level occurring after 12 and 24 hours (Figure 3.12). 
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Figure 3.12. LPS significantly induces IL-6 expression in THP-1 monocytes over 
time. THP-1 monocytes were treated with 1ng/ml LPS for varying amounts of time (0.5-
24 hours; vehicle control for LPS = PBS). The RNA was extracted, quantified and 
analysed by real-time RT-PCR. Data shown = mean ± SD. Data was statistically 
analysed using AUC followed by Student t tests for each time point comparing the 
cumulative AUC values. LPS-treated conditions are compared to their own untreated 
control at each time point. **p<0.01, ***p<0.001 vs. untreated controls. 
 
 
Following these results, a co-treatment of 1ng/ml LPS and 5µM SF was carried out in 
order to monitor IL-6 expression over a 72 hour time period. It was demonstrated that at 
this physiologically relevant concentration of SF, a significant inhibition of IL-6 
expression induced by LPS across all the time points measured was observed, with the 
levels of IL-6 expression being comparable to that found in the untreated controls 
(Figure 3.13). 
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Figure 3.13. SF significantly suppresses LPS-induced IL-6 expression in THP-1 
monocytes over time. THP-1 monocytes were treated with 1ng/ml LPS for varying 
amounts of time (0.5-72 hours; vehicle control for LPS = PBS) in the presence or 
absence of 5µM SF (vehicle control for SF = < 0.1% (v/v) DMSO). The RNA was 
extracted, quantified and IL-6 expression was analysed by real-time RT-PCR. Data 
shown = mean ± SD. Data was statistically analysed using two-way ANOVA followed 
by Bonferroni multiple comparisons tests. ***p<0.001 LPS vs. untreated controls and 
LPS + SF vs. LPS only. 
 
 
To confirm SF can suppress the LPS-induced expression of both IL-1β and TNFα, real-
time RT-PCR was carried out with the RNA from THP-1 monocytes treated for 12 hours 
with 1ng/ml LPS and 5µM SF. IL-1β and TNFα expression were both induced by LPS 
treatment (Figure 3.14). However, while IL-1β expression followed the same trend as 
IL-6 with 5µM SF treatment resulting in a significant suppression of LPS induction 
(Figure 3.14A), the suppression of LPS-induced TNFα expression by SF approached, 
but did not reach statistical significance (Figure 3.14B). 
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Figure 3.14. SF significantly suppresses LPS-induced IL-1β expression (A) and 
shows a trend for suppression of TNFα expression (B) in THP-1 monocytes. THP-1 
monocytes were treated with 1ng/ml LPS (vehicle control for LPS = PBS) in the 
presence or absence of 5µM SF (vehicle control for SF = < 0.1% (v/v) DMSO) for 12 
hours. The RNA was extracted, quantified and IL-1β and TNFα expression was analysed 
by real-time RT-PCR. Data shown = mean ± SD. Data was statistically analysed using 
one-way ANOVA followed by Tukey multiple comparisons tests. 
 
 
3.3. Discussion 
Taking into account the elevated levels of endotoxin and pro-inflammatory cytokines in 
sufferers of chronic disease, this study aimed to establish a relevant cell model of 
chronic inflammation. LPS has been widely used in vitro as an artificial stimulant of 
inflammation. However, it is typically used at concentrations in the high ng/ml to low 
µg/ml range, a level that is higher than that found during acute inflammation such as 
sepsis [197]. The initial requirement of the model was to establish whether levels of LPS 
in the range of that observed in circulation of patients with chronic inflammatory 
diseases was sufficient to induce pro-inflammatory cytokine secretion.  
 
Low-level endotoxin (≤ 1ng/ml) has been shown to significantly induce levels of a 
number of pro-inflammatory mediators including the chemokines interleukin-8 (IL-8) 
and monocyte chemotactic protein-1 (MCP-1), as well as the cell adhesion molecules 
VCAM-1 and ICAM-1 [197, 225-227]. Based on this data, it was investigated whether a 
physiologically relevant concentration of 1ng/ml LPS was sufficient to significantly 
induce the production of pro-inflammatory cytokines. The initial experiments were 
carried out investigating the effect of 1ng/ml LPS on IL-6 secretion, as this is the 
cytokine with the most consistent data supporting its involvement in chronic disease. In 
vivo, levels of IL-6 are commonly elevated in patients suffering from chronic diseases, 
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with the majority of studies find levels of IL-6 to be around 1-15pg/ml in both cases and 
controls [26, 27, 29, 34, 35, 39-41, 43].  
 
PBMCs are an ex vivo model, making them a more suitable representation of what 
occurs in vivo as compared to established cell lines, and are a good candidate to use in a 
model of chronic inflammation. However, they do have their limitations. In vivo, 
monocytes would be subjected to hypoxic conditions and without the influence of the 
blood circulation, there will be a number of growth factors and signalling molecules the 
cells are not exposed to when in culture [228]. While cell lines are not directly from a 
patient and are therefore not as good a representation of what happens in vivo, they have 
distinct advantages for use. This includes their ability to be sub-cultured over a period of 
time in order for the same batch of cells to be used for a number of experiments, 
resulting in lower variation as compared to the use of primary cells from a number of 
individuals. Also, the use of cell lines does not require ethical approval, unlike primary 
cells.  
 
The cell line chosen for comparison to primary PBMCs was the THP-1 monocytic cell 
line. THP-1 cells were derived from a one year old boy suffering from acute monocytic 
leukaemia in 1980, and following characterisation were confirmed as a leukaemic cell 
line with distinct monocytic markers [198]. THP-1 cells have often been used as a model 
of monocytes, and while there are evident differences, Qin and colleagues discuss how 
THP-1 cells behave in a similar way to monocytes from patients suffering from chronic 
disease [229]. One difference that was evident was the exposure time to LPS; while the 
PBMCs respond after around 4 hours of treatment THP-1 monocytes require at least 12 
hours. This is possibly due to the fact that the PBMCs used were from a healthy 
individual, while the THP-1 monocytes are a cancerous cell line and may be more 
resistant to IL-6 induction by LPS. Differences in IL-6 secretion in response to LPS 
treatment in PBMCs and THP-1 monocytes was found previously by Schildberger and 
colleagues [230]. Nevertheless, from the data presented in this chapter, there is 
validation for the use of THP-1 monocytes as well as PBMCs to investigate chronic 
inflammation.  
 
Once the response to LPS was confirmed, the next step was to investigate whether SF 
was able to exert an anti-inflammatory effect to reduce the level of LPS induction of 
cytokine production. SF has been previously shown to have the ability to significantly 
reduce the levels of pro-inflammatory cytokine production in a number of different cell 
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and animal models using varying concentrations [181-187, 190-192, 195, 223, 224]. 
This research led to the hypothesis that SF would reduce LPS-induced cytokine 
expression and secretion in THP-1 monocytes and PBMCs. Based on the study by 
Gasper and colleagues who demonstrate that the peak plasma concentration of SF was 
reached 2 hours following ingestion of broccoli [129], a 2 hour pre-treatment of PBMCs 
with SF was investigated and proved to significantly suppress LPS induction of IL-6 
(Figure 3.3A), leading to a more physiologically relevant model. For the THP-1 
monocytes, a co-treatment design was used with 1ng/ml LPS and 5µM SF, and LPS-
induced IL-6, IL-1β and TNFα expression and secretion was suppressed. The reason for 
the increase in the SF concentration used as compared to the PBMCs was due to a lack 
of a statistically significant suppression with 2µM SF in THP-1 monocytes. For all 
subsequent experiments with the THP-1 cells (including in Chapter 4 and 8), 5µM SF 
was used. 
 
It is important to note that in the experiments with LPS and the PBMCs there was 
evident variation in the absolute level of IL-6 secretion that was induced in response to 
LPS at the same concentration (1ng/ml) and for the same time of exposure. As these 
experiments were carried out with PBMCs from different donors, it is likely that these 
variable levels are as a result of individual differences in the donor. Also with the THP-1 
monocytes the induction in response to 1ng/ml LPS was highly variable from observing 
an increase to 350pg/ml in Figure 3.6 as compared to an increase to only 20pg/ml in 
Figure 3.8 in response to the same concentration of LPS for the same length of time. As 
the THP-1 monocytes are a cell line, these results are not as result of individual 
differences and instead it is likely as a result of varying passage number. Following 
these results, it was ensured that experiments were carried out over a narrow passage 
number range to limit the level of variation.  
  
While there was no significant suppression in cell viability for the chosen concentrations 
of SF used with the PBMCs (2µM) and the THP-1 monocytes (5µM), the IC50s from 
each cell type are significantly different (p<0.001; data not shown) and this could be due 
to several reasons. Being a primary cell type, the PBMCs are likely to be more sensitive 
to the SF treatment not only because they come from a healthy volunteer which will 
have no inherent inflammatory status, but also because they have a limited life span in 
culture before becoming senescent, due to a lack of growth factors and extracellular 
matrix components. The THP-1 monocytes on the other hand are an immortalised cell 
line, isolated from a sufferer of acute monocytic leukaemia and therefore as a cancerous 
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cell line may be able to withstand higher concentrations of the inflammatory stimulus 
LPS, and SF compared to human PBMCs.  
 
Of the previous research investigating the effect of SF on LPS-induced cytokine 
production, a number of publications support the findings reported here. In murine 
macrophages, 5µM SF was found to significantly reduce LPS-induced IL-1β and TNFα 
secretion [185, 192] and in rat glial cells, 5µM SF was sufficient to suppress LPS-
induced IL-1β and IL-6 secretion, while 15µM SF was required for TNFα secretion 
[187]. In all of these publications, LPS was used at a concentration of 0.1-1µg/ml, 
concentrations considerably higher than levels of endotoxin observed in chronic disease. 
  
Research by Guo and colleagues using murine RAW 264.7 macrophage cells 
demonstrated that treatment with very low concentrations of SF (0.3 and 0.6µM) were 
able to suppress the capability of 1µg/ml LPS to induce both IL-1β expression and 
secretion, in addition to TNFα secretion [182]. In contrast, a publication by Cheung and 
colleagues found no significant reduction in LPS-induced IL-1 and TNFα secretion by 
1µM SF when using 1µg/ml LPS [223]. This highlights that even with the use of the 
same experimental design with identical cell models, differing results can be observed.  
 
In research published by Brandenburg and colleagues, a concentration of 1µM SF was 
able to significantly reduce the expression of IL-6, IL-1β and TNFα when induced with 
100ng/ml LPS in primary mice microglia [184]. While the concentration of SF was 
lower than the 5µM used in the present study, the research was carried out in primary 
microglia isolated from rat and therefore species differences in addition to the fact that 
the cell model may have functional differences to the monocytes used in this chapter, 
may account for the differences observed in the SF response. This was supported by the 
fact that a different expression pattern was observed, with SF suppressing the LPS-
induced cytokine expression at 6 hours followed by a much lower level of suppression at 
12 hours before reverting back to almost complete suppression after 24 hours of 
exposure to LPS and SF [184]. Furthermore, it may be more appropriate in this 
experimental design with microglial cells to use a lower concentration of SF, because 
the level of SF that would be biologically available in the brain is not well established. 
  
The publication most relevant to the research presented in this chapter is by Yehuda and 
colleagues who used THP-1 monocytes treated with 500ng/ml LPS and concentrations 
of SF of 1.13µM and 2.26µM, before measuring the expression of IL-1β and TNFα. 
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There were significant reductions in the LPS-induced expression of IL-1β with both 
concentrations of SF, and TNFα expression was suppressed by the higher concentration 
[181]. While the study by Yehuda used the same cell model as was used in this chapter, 
they use a different experimental design, using a concentration of LPS at 500ng/ml, 
rather than 1ng/ml used in this work, which is more representative of an acute 
inflammatory attack. Additionally, they measured the expression and secretion of the 
cytokines in response to LPS in differentiated THP-1 cells, which develop macrophage-
like behaviours. They found that a concentration of 4.5µM was required to significantly 
reduce the levels of IL-6, IL-1β and TNFα expression, which supports my work with the 
monocytes and also lends some support to data shown in Chapter 8 (section 8.2.1) [181].  
 
SF has also been shown to exert effects in vivo with the use of animal models. SF was 
able to significantly reduce the LPS-induced expression of TNFα and IL-6 in the 
hippocampus of mice [224] and the circulating levels of these cytokines in the serum of 
mice [195]. Most recently an epidemiological study was published demonstrating that 
consumption of diets rich in cruciferous vegetables was inversely correlated with a 
decreased level of circulating pro-inflammatory biomarkers [120]. This study provides 
evidence that the in vitro findings presented in this chapter are plausible for translation 
into humans.  
 
All of the previously published data that has been mentioned has focused more on a cell 
model of acute inflammation based on excessive concentrations of LPS used however, 
most find significant anti-inflammatory effects with SF. The data from this chapter 
furthers these previous findings by demonstrating that SF, at concentrations that can be 
achieved via broccoli consumption, is able to significantly suppress LPS-induced 
expression and secretion of fundamental biomarkers in a model more comparable to 
chronic inflammation.  
 
 
3.4. Conclusions 
It is apparent from the experiments performed that 1ng/ml LPS, a level relevant to that 
found in circulation of patients suffering from a prolonged low-grade state of 
inflammation, is sufficient to induce the expression and secretion of the pro-
inflammatory cytokines, IL-6, IL-1β and TNFα in human monocyte cells. When the 
cells were treated with physiologically achievable concentrations of SF (2µM for 
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PBMCs and 5µM for THP-1 monocytes) there was a highly significant suppression of 
the LPS-induced cytokine production, without any effect on cell viability. 
  
These data may help to explain the significant correlations found between consumption 
of a diet rich in cruciferous vegetables and an improved risk of cancer and CVD 
mortality via targeting a common factor in both of these chronic diseases. This study 
provides novel experimental evidence that SF at concentrations achievable by 
consumption of only 100-200g of standard broccoli or less than 100g of high-
glucosinolate broccoli could mitigate chronic inflammation by targeting the response of 
monocytes to the elevated levels of circulating LPS found in sufferers of chronic 
diseases. 
 
This chapter only focuses on a trio of important pro-inflammatory cytokines and so to 
further this research the next chapter will employ whole genome analysis of the THP-1 
monocytes to investigate whether the effect of SF is restricted to a small selection of 
genes or if it is able to target the LPS signalling pathway on a global scale. 
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Chapter Four 
Effect of SF on global gene expression of 
THP-1 monocytes exposed to LPS 
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4.0. Introduction 
In the previous chapter, the hypothesis that 5µM SF would be able to significantly 
suppress LPS-induced expression and secretion in THP-1 monocytes was tested in a 
targeted approach with a selection of three specific cytokines, IL-6, IL-1β and TNFα. In 
this chapter, this work was expanded with the use of a non-targeted approach using 
Affymetrix GeneChip® Human Exon 1.0ST arrays to investigate the effect of 5µM SF 
on global gene expression in THP-1 monocytes treated with or without 1ng/ml LPS. 
Advantages for using this non-targeted approach are the removal of bias on the selection 
of biomarkers studied and also the vast amount of information that can be obtained from 
whole genome analysis. For example, the effect of SF can be investigated on all genes 
that are differentially expressed in response to LPS exposure in THP-1 monocytes to 
gain information on whether SF is able to target the TLR4 pathway as a whole. In 
addition, the genes differentially expressed in response to SF alone can be analysed. 
 
As previously discussed, LPS is the specific agonist for the TLR4 molecule. It behaves 
to activate the receptor with the aid of a number of accessory proteins. LBP carries the 
LPS molecule to the GPI-anchored, N-glycosylated CD14 receptor which in turn, 
transfers LPS to the TLR4-MD2 complex [13]. MD2 is a membrane-associated receptor 
that has high binding affinity for TLR4, and is able to accentuate the ability of LPS to 
bind to TLR4 [13]. LPS binding to the TLR4-MD2 complex induces receptor 
dimerisation, which in turn initiates the downstream signalling cascade [13]. The TLR4 
signalling pathway is summarised in Figure 4.1. Upon stimulation of the TLR4-MD2 
receptor complex, either MyD88-dependent or MyD88-independent pathways can be 
stimulated. Activation of the MyD88-dependent pathway results in rapid activation of 
the transcription factor NF-κB, which subsequently induces the expression of pro-
inflammatory cytokines including IL-6, IL-1β, TNFα and chemokines such as IL-8. 
Activation of MyD88-independent pathway results in the swift activation of IRF3, 
followed later by activation of NF-κB, leading to the release of type 1 IFNs e.g. IFNβ. 
IFNβ activates STAT1 leading to the production of chemokines such IP-10 and many 
other IFN-induced genes [14].  
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Figure 4.1. Overview of the TLR4 signalling pathway. LPS is bound to the TLR4-
MD2 complex via the aid of LBP and CD14 accessory proteins. The binding of LPS to 
the TLR4-MD2 complex results in homodimerisation and activation of an intracellular 
signalling cascade. This can be MyD88-dependent or independent. The MyD88-
dependent pathway activates NF-κB and AP-1 resulting in pro-inflammatory cytokine 
and chemokine expression, while the MyD88-independent pathway results in activation 
of predominantly IRF3 followed later by NF-κB, leading to the expression of type I 
IFNs and IFN-inducible genes [13, 14].  
 
 
It was hypothesised that THP-1 monocytes will have a number of differentially 
expressed genes in response to 5µM SF alone. SF has been studied previously in vitro at 
a range of concentrations in a number of different cell models and global gene 
expression patterns have commonly highlighted an induction in genes encoding phase 2 
enzymes and enzymes involved in xenobiotic metabolism [145, 147, 160, 231, 232]. The 
induction of these genes by SF is controlled by AREs found to be present in their gene 
promoter region. These AREs are recognised by Nrf2, which is sequestered within the 
cytoplasm by Keap1 in unstimulated conditions by directly binding to the Nrf2 
transcription factor and targeting it for proteasomal degradation [154]. When cells are 
exposed to SF, Nrf2 is able to dissociate from Keap1 allowing it to translocate into the 
nucleus where it is able to recognise and bind to AREs to activate the expression of its 
target genes. 
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SF behaves as an electrophile and is able to bind to free cysteine thiol groups within a 
number of proteins to form a thioacyl adduct. Keap1 has 27 cysteines within its structure 
that are readily available to react with electrophiles. SF is able to form thioacyl adducts 
with cysteine residues within the Keap1 protein [156-158] and it is predicted that these 
modifications are responsible for the mechanism by which Keap1 is no longer able to 
target Nrf2 for proteasomal degradation. This results in Nrf2 accumulation within the 
nucleus and subsequent induction of the transcription of its target genes. However, this 
has yet to be shown in cells due to the thioacyl adduct formation being reversible and 
sensitive to hydrolysis and alkylation [157-159]. By investigating the constitutive effect 
of 5µM SF on THP-1 monocytes, it will provide an indication as to whether SF is 
behaving with these cells in agreement with previous literature i.e. a number of the 
phase 2 enzymes and those involved in xenobiotic metabolism would be expected to 
demonstrate up-regulated expression levels [145, 147, 160, 231, 232]. 
 
The main aim of this chapter was to investigate whether 5µM SF is able to affect all 
genes differentially expressed in response to 1ng/ml LPS using Affymetrix GeneChip® 
Human Exon 1.0ST arrays to expand the previous studies of investigating the effect on 
selected biomarkers. 
 
 
4.1. Materials and Methods 
Within this chapter, the THP-1 monocytes have been treated for 12 hours with SF (5µM) 
and LPS (1ng/ml) both alone and as a co-treatment to determine the effects on global 
gene expression. RNA was extracted from treated THP-1 monocytes and subjected to 
whole genome expression analysis using the Affymetrix GeneChip® Human Exon 
1.0ST microarrays (section 2.6). 
 
 
4.2. Results 
4.2.1. Effect of SF on THP-1 monocytes 
To establish the effect of SF on global gene expression in the absence of any 
inflammatory stimulus, the THP-1 monocytes were treated with 5µM SF for 12 hours 
before RNA was extracted and subjected to an Affymetrix GeneChip® Human Exon 
1.0ST array. An initial pairwise comparison was carried out between 5µM SF and 
untreated controls to determine the numbers of genes changed at different adjusted p  
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values (Table 4.1). 
 
 
A total of 407 genes were differentially expressed in response to 5µM SF compared to 
untreated controls (adjusted p < 0.01). Of these 407 genes, 284 had less than a 1.5-fold 
change with a relatively even number of genes being increased (152 genes) and 
decreased in expression (132 genes). Only 38 of the 407 genes that were differentially 
expressed in response to 5µM SF (adjusted p < 0.01) demonstrated more than a 2-fold 
change in expression with 27 genes being up-regulated by SF and 11 genes being down-
regulated (Table 4.1).  
 
The next question addressed was whether there were common functions to the genes that 
were altered in THP-1 monocytes in response to 5µM SF. Based on a large body of 
previous research, it was expected that a number of phase 2 enzymes and xenobiotic 
metabolism genes would be differentially expressed [145, 147, 160, 231, 232]. However, 
very few groups have investigated a concentration of SF as low as the physiologically 
relevant 5µM used in this study. To carry out analysis of the genes differentially 
regulated by SF in terms of the pathways affected, DAVID software was used (Table 
4.2) [202, 203]. Glutathione metabolism had the highest fold enrichment level of 4, 
signifying that four times the amount of genes expected by chance were identified. 
Inflammatory signalling and cancer pathways were also highlighted, in addition to 
carbohydrate metabolism. However, while each of these pathways demonstrated 
significant p values, when adjusted using the Benjamini and Hochberg algorithm used to 
account for the rate of false discoveries, the only pathway that remained significant was 
cytokine-cytokine receptor interactions (Table 4.2).  
  
Table 4.1. Number of genes differentially expressed in response to SF  
Fold change in Gene Expression 
 <1.5 1.5-2.0 2.0-4.0 Total Gene Number 
CTRL v SF*     
< 0.05 699 (335,364) 95 (46,49) 38 (27,11) 832 
< 0.01 284 (152,132) 85 (46,39) 38 (27,11) 407 
< 0.001 76 (43,33) 59 (38,21) 34 (27,7) 169 
The number in bold gives the total number of transcripts changed. In brackets, the number of up-
regulated transcripts is followed by the number of down-regulated transcripts. 
* P values are adjusted for false discovery rates using the Benjamini-Hochberg correction 
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Table 4.2. Pathway analysis of genes differentially expressed in response to SF 
Term Count % P Value Fold 
Enrichment 
Benjamini 
p value* 
Cytokine-cytokine receptor 
interaction 
21 5.30 9.7 x 10
-5
 2.638 0.0136 
Chemokine signalling pathway 14 3.54 0.0039 2.466 0.2414 
p53 signalling pathway 7 1.77 0.0194 3.246 0.3265 
Toll-like receptor signalling 
pathway 
9 2.27 0.0115 2.896 0.3358 
Glutathione metabolism 6 1.52 0.0154 4.025 0.3536 
Glycolysis / Gluconeogenesis 6 1.52 0.0372 3.207 0.3846 
Pathways in cancer 16 4.04 0.0772 1.577 0.5301 
The list of genes used for analysis was SF v CTRL p<0.01. 
*While the initial p values are significant for these pathways, only the cytokine-cytokine receptor 
interaction pathway remained significant after correction with Benjamini-Hochberg. 
 
 
Out of the 407 genes found to be differentially expressed with 5µM SF at p < 0.01, only 
79 were significantly classified into common pathways. For this reason, the data was 
interrogated further to identify related groups of genes. Table 4.3 presents the genes 
encoding phase 2, phase 3 and xenobiotic metabolising enzymes differentially expressed 
in response to 5µM SF. Moreover, a number of genes involved in carbohydrate 
metabolism were identified (Table 4.4).  
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Table 4.3. Genes differentially expressed in response to SF involved in detoxification 
pathways 
Affymetrix 
Transcript 
Cluster ID 
Gene 
Symbol 
Gene 
SF Fold Change 
vs. Control*
 
Xenobiotic metabolising enzymes 
3232979 AKR1C1 Aldo-keto reductase family 1, member C1 2.68
3 
3274758 AKR1C2 Aldo-keto reductase family 1, member C2 2.27
3 
3692701 CES1 Carboxylesterase 1 1.76
3 
2382970 EPHX1 Epoxide hydrolase 1, microsomal (xenobiotic) 1.72
3 
3233049 AKR1C3 Aldo-keto reductase family 1, member C3 1.53
2 
Phase 2 enzymes 
3894322 SRXN1 Sulfiredoxin 1 3.15
3 
3130161 GSR Glutathione reductase 2.58
3 
3696666 NQO1 NAD(P)H dehydrogenase, quinone 1 2.57
3 
2423625 GCLM Glutamate-cysteine ligase, modifier subunit 2.48
3 
3429460 TXNRD1 Thioredoxin reductase 1 2.42
3 
3944129 HMOX1 Hemeoxygenase (decycling) 1 2.08
3 
3406589 MGST1 Microsomal glutathione S-transferase 1 1.35
1 
2892277 NQO2 NAD(P)H dehydrogenase, quinone 2 1.31
1 
3220156 TXN Thioredoxin 1.29
1 
3917851 SOD1 Superoxide Dismutase 1, soluble 1.28
1 
Phase 3 enzymes 
3649890 ABCC1 
ATP-binding cassette, sub-family C (CFTR/MRP), 
member 1 
2.03
3 
3726691 ABCC3 
ATP-binding cassette, sub-family C (CFTR/MRP), 
member 3 
1.86
3 
Adjusted p values of fold change: 
1 
p<0.01; 
2
 p<0.001; 
3 
p<0.0001 
* Data taken from the list SF v CTRL p<0.01 
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All of the genes highlighted as being involved in carbohydrate metabolism encoded 
enzymes involved in important steps of glycolysis and the pentose phosphate pathway 
(Figure 4.2). Several genes did not reach a 1.5-fold change in expression in response to 
SF, nevertheless they remained statistically significant, and due to the fact that these 8 
genes were linked by function they were still included in Figure 4.2. 
 
Table 4.4. Genes differentially expressed in response to SF involved in carbohydrate 
cell metabolism 
Affymetrix 
Transcript 
Cluster ID 
Gene 
Symbol 
Gene SF Fold 
Change vs. 
Control* 
2962820 ME1 Malic enzyme 1, NADP(+)-dependent, cytosolic  2.11
3 
4027416 G6PD Glucose-6-phosphate dehydrogenase  1.81
3 
2319802 PGD Phosphogluconate Dehydrogenase  1.80
3 
3316208 TALDO1 Transaldolase 1   1.48
3 
2676671 TKT Transketolase  1.46
2 
3233605 PFKFB3 6-Phosphofructo-2-kinase/Fructose-2,6-biphosphatase 3  1.27
1 
3631964 PKM2 Pyruvate kinase, muscle  1.18
1 
3215570 FBP1 Fructose-1,6-bisphosphatase 1 -1.32
1 
Adjusted p values of fold change: 
1 
p<0.01; 
2
 p<0.001; 
3 
p<0.0001 
* Data taken from the list SF v CTRL p<0.01 
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Figure 4.2. Effect of SF on expression of genes encoding enzymes involved in glycolysis and the pentose phosphate pathway. Glycolysis is a 
fundamental process in aerobic respiration which is responsible for producing the necessary intermediate, pyruvate, for the TCA cycle in order to produce 
ATP. The pentose phosphate pathway behaves to produce the universal electron donor NADPH and ribose phosphates required for nucleic acid formation. 
These two pathways are linked by the glucose 6-phophate intermediate which is utilised by each pathway depending on the requirements of the cells. SF 
increased the expression of enzymes involved in the forward reactions, and decreased one of the enzymes involved in the reverse reactions.  
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As previously mentioned, THP-1 cells are a cancerous, leukaemic cell line. This means 
they are a suitable model for human monocytes in a chronic inflammatory state, but also 
can be considered as a cancer cell model. Of the 407 genes altered by SF in the THP-1 
monocytes (adjusted p < 0.01), a number of genes were found to be specifically 
associated with pathways involved in cancer and demonstrated more than 1.5-fold 
increase or decrease in expression (Table 4.5).  
 
 
 
 
There were also a number of genes differentially expressed in response to SF in THP-1 
monocytes that were found to be associated with inflammatory signalling pathways, in 
particular, a selection of chemokine ligands and receptors (Table 4.6).  
  
Table 4.5. Genes differentially expressed in response to SF involved in pathways in 
cancer 
Affymetrix 
Transcript 
Cluster ID 
Gene 
Symbol 
Gene SF Fold 
Change vs. 
Control* 
3464747 KITLG KIT ligand 1.92
2 
3790704 PMAIP1 Phorbol-12-myristate-13-acetate-induced protein 1 1.71
3 
2539821 ADAM17 ADAM metallopeptidase 17 1.65
2 
3389077 PDGFD Platelet derived growth factor D -1.52
2 
3059464 SEMA3A Sema domain, immunoglobulin domain (Ig), short 
basic domain, secreted, (semaphorin) 3A 
-1.64
1 
3058944 HGF Hepatocyte growth factor -1.75
1 
2720584 SLIT2 Slit homolog 2 (Drosophila) -1.92
2 
Adjusted p values of fold change: 
1 
p<0.01; 
2
 p<0.001; 
3 
p<0.0001 
* Data taken from the list SF v CTRL p<0.01 
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Table 4.6. Genes differentially expressed in response to SF involved in inflammatory 
signalling pathways 
Affymetrix 
Transcript 
Cluster ID 
Gene 
Symbol 
Gene SF Fold 
Change vs. 
Control*
 
Toll-like receptor and cytokine signalling molecules 
2766262 TLR6 Toll-like receptor 6 1.64
1
 
2853102 PRLR Prolactin receptor -1.56
2 
Chemokine signalling molecules 
2731332 IL-8 Interleukin-8 2.36
3 
2669979 CX3CR1 Chemokine (C-X3-C motif) receptor 1 -1.59
1 
4040063 CCL4 **Chemokine (C-C motif) ligand 4 -2.00
1 
2732508 CXCL13 Chemokine (C-X-C motif) ligand 13 -2.08
1 
3718977 CCL4 **Chemokine (C-C motif) ligand 4 -2.38
2 
3719020 CCL4 **Chemokine (C-C motif) ligand 4 -2.38
1 
2773972 CXCL11 Chemokine (C-X-C motif) ligand 11 -2.44
2 
2876608 CXCL14 Chemokine (C-X-C motif) ligand 14 -2.56
3 
2773958 CXCL10 Chemokine (C-X-C motif) ligand 10 -2.63
2 
Adjusted p values of fold change: 
1 
p<0.01; 
2
 p<0.001; 
3 
p<0.0001 
* Data taken from the list SF v CTRL p<0.01 
** Multiple transcript cluster IDs identify alternative transcripts of the same gene and cannot 
distinguish between them  
 
 
4.2.2. Effect of LPS on THP-1 monocytes 
For analysis of global gene expression changes induced by LPS, THP-1 monocytes were 
treated with 1ng/ml LPS for 12 hours. As with the data for the SF treatment (Table 4.1), 
pairwise comparison tests were carried out to identify the number of differentially 
expressed genes in response to LPS at varying adjusted p values (Table 4.7). 
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Compared to the 407 genes that were differentially expressed in response to SF (Table 
4.1), 1210 genes were differentially expressed in response to 1ng/ml LPS (adjusted p < 
0.01). Interestingly, of those that demonstrate more than a 1.5-fold increase, 84% of the 
genes were up-regulated by LPS (Table 4.7). Pathway analysis was carried out on the 
1210 genes altered in response to 1ng/ml LPS and 20 different pathways were identified 
as being affected, not all of which were significant (data not shown). Nevertheless, there 
was a statistically significant association of genes after the Benjamini-Hochberg 
multiple testing correction with inflammatory signalling pathways including cytokine-
cytokine receptor interaction, TLR signalling pathway, chemokine signalling pathway 
and NOD signalling pathways (Table 4.8).  
 
Table 4.7. Number of genes differentially expressed in response to LPS  
Fold change in Gene Expression 
 <1.5 1.5-2.0 2.0-4.0 >4 Total Gene Number 
CTRL v LPS*      
< 0.05 1695 (595,1100) 247 (179,68) 116 (109,7) 48 (48,0) 2106 
< 0.01 814 (343,471) 233 (174,59) 115 (109,6) 48 (48,0) 1210 
< 0.001 264 (153,111) 202 (154,48) 114 (108,6) 48 (48,0) 628 
The number in bold gives the total number of transcripts changed. In brackets, the number of up-
regulated transcripts is followed by the number of down-regulated transcripts. 
* P values are adjusted for false discovery rates using the Benjamini-Hochberg correction 
Table 4.8. Pathway analysis of genes differentially expressed in response to LPS 
Term Count % P-Value Fold 
Enrichment 
Benjamini  
p value* 
Cytokine-cytokine receptor 
interaction 
51 4.28 5.33 x 10
-8
 2.213 9.22 x 10
-6
 
TLR signalling pathway 25 2.10 4.8 x 10
-6
 2.779 4.21 x 10
-4
 
Chemokine signalling pathway 35 2.94 2.39 x 10
-5
 2.123 0.0013 
Cell adhesion molecules (CAMs) 24 2.02 4.42 x 10
-4
 2.179 0.0189 
RIG-I-like receptor signalling 
pathway 
16 1.34 8.35 x 10
-4
 2.601 0.0285 
NOD-like receptor signalling 
pathway 
15 1.26 9.53 x 10
-4
 2.679 0.0271 
Cytosolic DNA-sensing pathway 13 1.09 0.00144 2.832 0.0350 
The list of genes used for analysis was LPS v CTRL p<0.01. 
*The adjusted p-values for all of the pathways listed are significant p<0.05. 
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4.2.3. Effect of SF on LPS-treated THP-1 monocytes 
Following the findings that many genes were differentially expressed in response to 
1ng/ml LPS, the next major research question was whether 5µM SF was able to target 
all of the LPS-affected genes, or if the effect of SF was specific to particular genes. The 
combined treatment of 1ng/ml LPS and 5µM SF for 12 hours was found to significantly 
alter the expression of 1081 genes when a pairwise comparison was carried out with the 
co-treatment versus LPS alone (adjusted p < 0.01) (Table 4.9). In contrast to the LPS 
treatment alone where the majority of genes with a fold change of more than 1.5-fold 
were up-regulated (Table 4.7), 71% of genes changed by LPS and SF together 
demonstrate a down-regulation compared to the LPS alone (Table 4.9). 
 
Table 4.9. Number of differentially expressed genes in response to LPS and SF co-
treatment 
Fold change in Gene Expression 
 <1.5 1.5-2.0 2.0-4.0 >4 Total Gene Number 
LPS v LPS+SF*      
< 0.05 1502 (945,557) 241 (85,156) 141 (35,106) 25 (0,25) 1909 
< 0.01 688 (393,295) 227 (78,149) 141 (35,106) 25 (0,25) 1081 
< 0.001 200 (107,93) 191 (68,123) 138 (34,104) 25 (0,25) 554 
The number in bold gives the total number of transcripts changed. In brackets, the number of up-
regulated transcripts is followed by the number of down-regulated transcripts. 
* P values are adjusted for false discovery rates using the Benjamini-Hochberg correction 
 
 
While the majority of genes differentially expressed in response to LPS were up-
regulated (Table 4.7) and the genes changed in response to a co-treatment of LPS and 
SF compared to LPS alone were down-regulated, it was not known whether there was a 
commonality between the genes affected. A venn diagram was constructed to investigate 
the overlap between these two pairwise comparisons and 562 genes were found to be 
common to both gene lists (Figure 4.3). Furthermore, of these 562 genes that were 
significantly affected by SF in the presence of LPS, 467 of these genes were specifically 
affected only in the presence of LPS (105/562 genes were affected in CTRL v SF 
treatment, data not shown).   
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Figure 4.3. Effect of LPS in the presence or absence of SF on gene expression. 562 
genes were found to be affected by 1ng/ml LPS alone and in the presence of 5µM SF 
(Genes affected by LPS only = 1210; genes affected by LPS and SF co-treatment = 
1081).  
 
 
To get an idea of the relationship between the genes affected by LPS alone and in 
combination with SF, a regression analysis was conducted with all 1210 genes altered by 
LPS plotted against the effect of SF presence. 5µM SF was able to significantly oppose 
the effect of LPS on all genes differentially expressed in response to 1ng/ml LPS alone 
with a clear inverse relationship seen (Figure 4.3). The gradient of the line of regression 
was -1.068 meaning the overall change seen with LPS is almost identical to the extent 
the gene is oppositely affected by LPS and SF in combination. Because the effects of 
LPS and SF have already been characterised on IL-6, IL-1β and TNFα expression (see 
Chapter 3), these have been annotated on Figure 4.4 to demonstrate that the suppressive 
effect of SF was not selective to these genes alone and many genes were affected to a 
much larger extent than the three cytokines previously studied. 
Overlap of genes (p<0.01)
N unique: xy = 1729; x = 1210; y = 1081
562648 519
CTRL v LPS LPS v LPS&SF
Overlap of genes (p<0.01)
N unique: xy = 1729; x = 1210; y = 1081
562648 519
CTRL v LPS LPS v LPS&SF
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Figure 4.4. 5µM SF suppresses all changes induced by 1ng/ml LPS. 1210 genes 
differentially expressed in response to 1ng/ml LPS were plotted with the LPS effect 
relative to the control (y) against the effect of LPS+SF co-treatment compared to LPS 
alone (x). The regression analysis demonstrates a statistically significant association (p < 
0.0001) with a regression coefficient of -1.07 and an R
2
 value of 0.7. IL-6, IL-1β and 
TNFα are circled to highlight where these previously investigated genes lie within the 
regression (biomarkers chosen for targeted approach in Chapter 3). 
 
 
The genes altered by more than 2-fold in response to LPS alone were selected for further 
analysis to investigate the extent of the effect of SF on these LPS-affected genes. Genes 
were characterised into groups according to their associated inflammatory signalling 
pathways (Table 4.10). In addition, many genes identified had miscellaneous functions 
which were not associated with inflammatory pathways (Tables 4.11).  
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Table 4.10. Effect of SF on genes differentially expressed in response to LPS (with > 2-
fold change) with functions in inflammatory signalling pathways 
Affymetrix 
Transcript 
Cluster ID 
Gene 
Symbol 
Gene LPS Fold 
Change 
vs. 
Control† 
LPS + SF 
Fold Change 
vs. LPS 
alone†† 
Toll like receptor and cytokine signalling pathways 
3275690 IL15RA Interleukin 15 receptor, alpha 2.00
3 
-1.56
1 
3645626 IL32 Interleukin 32 2.01
3 
-1.50
1 
2617563 MYD88 Myeloid differentiation primary 
response gene (88) 
2.09
3 
-1.95
3 
3351166 IL10RA Interleukin 10 receptor, alpha 2.23
3
 -1.94
3 
2690900 CD80 CD80 molecule 2.25
3 
-1.89
3 
2905404 PIM1 Pim-1 oncogene 2.34
3
 -1.19* 
3887302 CD40 CD40 molecule, TNF receptor 
superfamily member 5 
2.35
3
 -1.36
1 
2902416 TNF Tumor necrosis factor 2.40
3
 > 0.01 
3500787 TNFSF13B Tumor necrosis factor (ligand) 
superfamily, member 13B 
2.44
3 
-2.21
3 
2992576 IL-6 Interleukin 6 (interferon, beta 2) 2.49
3 
-1.77
2 
2497161 IL18RAP Interleukin 18 receptor accessory 
protein 
2.59
3
 -2.28
3 
2884301 IL12B Interleukin 12B (natural killer cell 
stimulatory factor 2, cytotoxic 
lymphocyte maturation factor 2, p40) 
2.90
3 
-3.15
3 
2501204 IL1RN Interleukin 1 receptor antagonist 2.96
3 
-2.66
3 
2395146 TNFRSF9 Tumor necrosis factor receptor 
superfamily, member 9 
3.16
3
 -1.79
2 
2806468 IL7R Interleukin 7 receptor 3.90
3
 -2.95
3 
2510464 TNFAIP6 Tumor necrosis factor, alpha-induced 
protein 6 
4.11
3
 -1.51* 
2705706 TNFSF10 Tumor necrosis factor (ligand) 
superfamily, member 10 
4.28
3 
-4.45
3 
2571510 IL1B Interleukin 1, beta 4.45
3 
-1.38* 
2783916 TNIP3 TNFAIP3 interacting protein 3 5.35
3
 -1.89
1 
Chemokine signalling 
2731332 IL8 Interleukin-8 3.19
3
 2.04
2 
3457752 STAT2 Signal transducer and activator of 
transcription 2, 113kDa 
3.36
3 
-2.75
3 
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Chemokine signalling (continued) 
2732508 CXCL13 Chemokine (C-X-C motif) ligand 13 3.39
3 
-5.03
3 
2592268 STAT1 Signal transducer and activator of 
transcription 1, 91kDa 
3.41
3 
-2.41
3 
2773947 CXCL9 Chemokine (C-X-C motif) ligand 9 3.90
3 
-4.02
3 
3754133 CCL3L1 Chemokine (C-C motif) ligand 3-like 1 4.13
3 
-2.29
3 
3754070 CCL3L1 Chemokine (C-C motif) ligand 3-like 1 4.29
3 
-2.20
3 
4040932 CCL3L1 Chemokine (C-C motif) ligand 3-like 1 4.32
3 
-2.07
3 
3754009 CCL3 Chemokine (C-C motif) ligand 3 4.63
3 
-2.20
3 
3756319 CCR7 Chemokine (C-C motif) receptor 7 6.53
3 
-3.79
3 
7385547 CCL2 Chemokine (C-C motif) ligand 2 6.70
3
 -2.50
3 
4040063 CCL4L1 Chemokine (C-C motif) ligand 4-like 1 9.12
3 
-4.01
3 
3718930 CCL4 Chemokine (C-C motif) ligand 4 5.60
3 
-3.29
3 
3718977 CCL4 Chemokine (C-C motif) ligand 4 9.22
3 
-3.93
3 
3719020 CCL4 Chemokine (C-C motif) ligand 4 9.25
3 
-4.61
3
 
2773958 CXCL10 Chemokine (C-X-C motif) ligand 10 13.82
3 
-9.95
3 
2773972 CXCL11 Chemokine (C-X-C motif) ligand 11 18.83
3 
-13.53
3
 
3718191 CCL8 Chemokine (C-C motif) ligand 8 25.33
3 
-13.93
3 
Interferon-induced genes 
4053534 ISG15 ISG15 ubiquitin-like modifier 2.14
2 
-1.88
2 
3357840 IFITM3 Interferon induced transmembrane 
protein 3 (1-8U) 
2.15
3 
-1.86
3 
3579546 WARS Tryptophanyl-tRNA synthetase 2.17
3
 -2.55
3 
3774906 SECTM1 Secreted and transmembrane 1 2.19
3 
-2.75
3 
2421925 GBP7 Guanylate binding protein 7 2.36
3
 -2.27
3 
2403261 IFI6 Interferon, alpha-inducible protein 6 2.38
3
 -1.98
3 
2875348 IRF1 Interferon regulatory factor 1 2.68
3
 -1.89
3 
3722338 IFI35 Interferon-induced protein 35 2.82
3 
-2.29
3 
2584207 IFIH1 Interferon induced with helicase C 
domain 1 
3.29
3
 -2.99
3 
3315675 IFITM1 Interferon induced transmembrane 
protein 1 (9-27) 
3.39
3
 -2.56
3 
2439554 AIM2 Absent in melanoma 2 3.47
3 
-2.88
3 
3474831 OASL 2'-5'-oligoadenylate synthetase-like 3.81
3 
-2.99
3
 
2603051 SP110 SP110 nuclear body protein 3.91
3
 -3.46
3 
3432467 OAS3 2'-5'-oligoadenylate synthetase 3, 
100kDa 
4.01
3 
-2.71
3 
3432514 OAS2 2'-5'-oligoadenylate synthetase 2, 
69/71kDa 
4.12
3
 -2.82
3 
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Interferon-induced genes (continued) 
2362394 IFI16 Interferon, gamma-inducible protein 
16 
4.12
3
 -3.47
3 
2735409 HERC5 Hect domain and RLD 5 4.18
3
 -3.48
3
 
2468351 RSAD2 Radical S-adenosyl methionine 
domain containing 2 
4.28
3
 -3.85
3 
3922037 MX2 Myxovirus (influenza virus) resistance 
2 (mouse) 
4.40
3
 -3.38
3 
3432438 OAS1 2',5'-oligoadenylate synthetase 1, 
40/46kDa 
4.47
3 
-2.76
3
 
3257268 IFIT5 Interferon-induced protein with 
tetratricopeptide repeats 5 
5.59
3
 -3.78
3 
3257192 IFIT2 Interferon-induced protein with 
tetratricopeptide repeats 2 
5.65
3
 -4.06
3 
2421995 GBP4 Guanylate binding protein 4 5.92
3
 -6.30
3
 
3549575 IFI27 Interferon, alpha-inducible protein 27 6.25
3 
-5.63
3 
3318443 TRIM22 Tripartite motif-containing 22 6.26
3
 -4.50
3 
3922100 MX1 Myxovirus (influenza virus) resistance 
1, interferon-inducible protein p78 
(mouse) 
6.29
3 
-4.57
3 
3203086 DDX58 DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 58 
6.49
3 
-4.54
3 
2421883 GBP1 Guanylate binding protein 1, 
interferon-inducible, 67kDa 
7.94
3 
-7.50
3
 
2343511 IFI44 Interferon-induced protein 44 9.53
3
 -6.10
3 
2343473 IFI44L Interferon-induced protein 44-like 11.86
3
 -10.18
3
 
3257246 IFIT1 Interferon-induced protein with 
tetratricopeptide repeats 1 
12.18
3 
-8.54
3 
3257204 IFIT3 Interferon-induced protein with 
tetratricopeptide repeats 3 
14.50
3
 -6.87
3 
Adjusted p values of fold change: 
1 
p<0.01
 2
 p<0.001; 
3 
p<0.0001. 
*These fold changes were not found to be significant at p<0.01 but remain significant at p<0.05. 
† The list of genes used for analysis was LPS v CTRL p<0.01. 
†† The list of genes used for analysis was LPS+SF v LPS p<0.01. 
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Table 4.11. Effect of SF on genes differentially expressed in response to LPS (with > 2-
fold change) with miscellaneous functions 
 Affymetrix 
Transcript 
Cluster ID 
Gene 
Symbol 
Gene LPS Fold 
Change vs. 
Control† 
LPS + SF 
Fold Change 
vs. LPS 
alone†† 
Miscellaneous Function 
3791935 SERPINB2 Serpin peptidase inhibitor, clade B 
(ovalbumin), member 2 
-2.63
3 
1.13** 
3387259 SESN3 Sestrin 3 -2.40
3
 1.51
2 
2428796 PTPN22 Protein tyrosine phosphatase, non-
receptor type 22 (lymphoid) 
-2.22
3 
-1.06** 
3791958 SERPINB10 Serpin peptidase inhibitor, clade B 
(ovalbumin), member 10 
-2.20
3
 -1.48
1 
3466687 HAL Histidine ammonia-lyase -2.13
3 
1.22* 
3466687 VLDLR Very low density lipoprotein receptor -2.04
3 
1.65
3 
3068587 GPR85 G protein-coupled receptor 85 2.01
2 
-2.27
3
 
3489481 PHF11 PHD finger protein 11 2.01
3 
-1.67
2 
2777333 PPM1K Protein phosphatase, Mg2+/Mn2+ 
dependent, 1K 
2.01
3 
-1.98
3 
2698738 XRN1 5'-3' exoribonuclease 1 2.02
3
 -1.92
2 
2709778 BCL6 B-cell CLL/lymphoma 6 2.02
3
 -1.19** 
2951859 ETV7 Ets variant 7 2.04
3 
-2.21
3 
3464860 DUSP6 Dual specificity phosphatase 6 2.05
3
 1.23* 
3442854 SLC2A3 Solute carrier family 2 (facilitated 
glucose transporter), member 3 
2.06
3
 -1.90
3 
3581404 GPR132 G protein-coupled receptor 132 2.09
3
 -1.58
3 
2343231 NEXN Nexilin (F actin binding protein) 2.11
3 
-2.42
2 
3388807 MMP1 Matrix metallopeptidase 1 (interstitial 
collagenase) 
2.11
3
 -2.08
3 
2919669 PRDM1 PR domain containing 1, with ZNF 
domain 
2.14
3
 -1.15** 
3601387 PML Promyelocytic leukemia 2.17
3
 -2.14
3 
3346548 BIRC3 Baculoviral IAP repeat-containing 3 2.19
3
 -1.55
1 
2897172 RNF144B Ring finger protein 144B 2.19
3
 -1.88
3 
3806211 PSTPIP2 Proline-serine-threonine phosphatase 
interacting protein 2 
2.20
3
 -2.84
3 
3140213 MSC Musculin 2.20
3
 1.95
3 
2720145 LAP3 Leucine aminopeptidase 3 2.20
3
 -2.04
3 
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Miscellaneous Function (continued) 
3638188 HAPLN3 Hyaluronan and proteoglycan link 
protein 3 
2.21
3
 -2.12
3 
2362746 SLAMF8 SLAM family member 8 2.22
3
 -1.41
1 
2553970 PNPT1 Polyribonucleotide 
nucleotidyltransferase 1 
2.23
3
 -2.09
3 
3150579 ENPP2 Ectonucleotide 
pyrophosphatase/phosphodiesterase 2 
2.23
3
 -2.07
3 
3971806 SAT1 Spermidine/spermine N1-
acetyltransferase 1 
2.28
3
 -1.14** 
2720584 SLIT2 Slit homolog 2 (Drosophila) 2.30
3 
-3.12
3 
2955827 PLA2G7 Phospholipase A2, group VII (platelet-
activating factor acetylhydrolase, 
plasma) 
2.34
3
 -1.05** 
2729667 STAP1 Signal transducing adaptor family 
member 1 
2.36
1 
-1.89
1 
2796553 ACSL1 Acyl-CoA synthetase long-chain 
family member 1 
2.36
3
 -1.43
1 
3075932 PARP12 Poly (ADP-ribose) polymerase family, 
member 12 
2.36
3
 -2.03
3 
3066818 NAMPT Nicotinamide 
phosphoribosyltransferase 
2.37
3
 -1.94
2 
3049292 IGFBP3 Insulin-like growth factor binding 
protein 3 
2.38
3
 1.11** 
3299469 ANKRD22 Ankyrin repeat domain 22 2.41
3 
-1.85
2 
2677902 HESX1 HESX homeobox 1 2.42
3
 -2.50
3 
3944129 HMOX1 Hemeoxygenase (decycling) 1 2.42
3
 1.09** 
3087703 PDGFRL Platelet-derived growth factor receptor-
like 
2.44
3
 -2.65
3 
3618736 RASGRP1 RAS guanyl releasing protein 1 
(calcium and DAG-regulated) 
2.44
3
 -2.01
3 
3205293 PAX5 Paired box 5 2.44
3
 -2.27
3
 
3185498 SLC31A2 Solute carrier family 31 (copper 
transporters), member 2 
2.47
3
 -2.15
3 
2548402 EIF2AK2 Eukaryotic translation initiation factor 
2-alpha kinase 2 
2.53
3
 -1.97
2 
3818596 EMR1 EGF-like module containing, mucin-
like, hormone receptor-like 1 
2.56
3
 -2.99
3 
3944243 APOL6 Apolipoprotein L, 6 2.59
3
 -2.31
3 
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Miscellaneous Function (continued) 
3161082 CD274 CD274 molecule 2.64
2
 -2.53
2 
3835726 BCL3 B-cell CLL/lymphoma 3 2.66
3
 -1.43
3 
3757602 DHX58 DEXH (Asp-Glu-X-His) box 
polypeptide 58 
2.66
3
 -2.50
3 
2421843 GBP3 Guanylate binding protein 3 2.67
3
 -2.52
3 
2403446 PTAFR Platelet-activating factor receptor 2.68
3
 -2.57
3 
3403754 CLEC6A C-type lectin domain family 6, member 
A 
2.68
2
 -3.11
3 
2699726 PLSCR1 Phospholipid scramblase 1 2.72
3
 -2.08
3 
3331355 SERPING1 Serpin peptidase inhibitor, clade G (C1 
inhibitor), member 1 
2.76
3
 -2.51
3 
2638962 DTX3L Deltex 3-like (Drosophila) 2.77
3
 -2.29
3 
2950214 TAP1 Transporter 1, ATP-binding cassette, 
sub-family B (MDR/TAP) 
2.84
3
 -2.51
3 
2896545 GMPR Guanosine monophosphate reductase 2.85
3
 -2.62
3 
3895614 SIGLEC1 Sialic acid binding Ig-like lectin 1, 
sialoadhesin 
2.92
3 
-2.64
3 
3905875 MAFB v-maf musculoaponeurotic 
fibrosarcoma oncogene homolog B 
(avian) 
2.96
3
 -1.27
1 
2991860 ITGB8 Integrin, beta 8 2.98
3
 -2.29
3 
2539125 CMPK2 Cytidine monophosphate (UMP-CMP) 
kinase 2, mitochondrial 
3.01
3
 -2.50
3 
3360622 TRIM5 Tripartite motif-containing 5 3.02
3
 -3.06
3 
3737274 RNF213 Ring finger protein 213 3.11
3
 -2.22
3 
3737338 RNF213 Ring finger protein 213 3.19
3
 -2.45
3 
2975014 SGK1 Serum/glucocorticoid regulated kinase 
1 
3.15
3
 -1.40* 
2440354 CD48 CD48 molecule 3.20
3 
-2.80
3 
3442941 C3AR1 Complement component 3a receptor 1 3.21
3
 -3.46
3 
2945741 FAM65B Family with sequence similarity 65, 
member B 
3.30
3 
-3.16
3 
2792800 DDX60 DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 60 
3.33
3
 -2.43
3 
3373962 UBE2L6 Ubiquitin-conjugating enzyme E2L 6 3.38
3
 -2.69
3 
3119339 LY6E Lymphocyte antigen 6 complex, locus 
E 
3.47
3
 -2.70
3 
3635198 BCL2A1 BCL2-related protein A1 3.52
3 
-2.25
3 
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Miscellaneous Function (continued) 
3820443 ICAM1 Intercellular adhesion molecule 1 3.55
3
 -1.45
2 
3817380 EBI3 Epstein-Barr virus induced 3 3.59
3
 -1.91
3 
2422035 GBP5 Guanylate binding protein 5 3.66
3
 -2.37
3 
3733275 KCNJ2 Potassium inwardly-rectifying channel, 
subfamily J, member 2 
3.80
3 
-1.62
1 
3061438 SAMD9 Sterile alpha motif domain containing 9 3.86
3 
-3.20
3 
2982319 SOD2 Superoxide dismutase 2, mitochondrial 3.89
3 
-1.44
1 
2639054 PARP14 Poly (ADP-ribose) polymerase family, 
member 14 
3.90
3
 -3.04
3 
2371346 RGL1 Ral guanine nucleotide dissociation 
stimulator-like 1 
4.08
3
 -1.51
2 
2692060 PARP9 Poly (ADP-ribose) polymerase family, 
member 9 
4.19
3
 -2.99
3 
3061456 SAMD9L Sterile alpha motif domain containing 
9-like 
4.19
3
 -3.46
3 
3060332 STEAP4 STEAP family member 4 4.81
3 
-2.39
3 
2735362 HERC6 Hect domain and RLD 6 4.88
3
 -2.91
3 
2707876 LAMP3 Lysosomal-associated membrane 
protein 3 
4.92
3 
-3.88
3 
2363202 SLAMF7 SLAM family member 7 5.68
3 
-4.37
3 
3511698 EPSTI1 Epithelial stromal interaction 1 (breast) 5.97
3
 -3.50
3 
2348992 VCAM1 Vascular cell adhesion molecule 1 6.89
3 
-7.16
3 
3095223 IDO1 Indoleamine 2,3-dioxygenase 1 7.18
3
 -5.78
3 
3936550 USP18 Ubiquitin specific peptidase 18 7.35
3 
-5.88
3 
2749011 TDO2 Tryptophan 2,3-dioxygenase 17.59
3 
-6.46
3 
Adjusted p values of fold change: 
1 
p<0.01; 
2
 p<0.001; 
3 
p<0.0001.
 
*These fold changes were not found to be significant at p<0.01 but remain significant at p<0.05. 
**These fold changes are not found to be statistically significant (p>0.05). 
† The list of genes used for analysis was LPS v CTRL p<0.01. 
†† The list of genes used for analysis was LPS+SF v LPS p<0.01. 
 
 
4.3. Discussion 
In order to expand on the research presented in Chapter 3, a systematic investigation was 
carried out to address the question of whether SF was able to significantly alter the 
expression of all LPS-affected genes, and in addition whether SF was able to induce 
significant changes in global gene expression constitutively.  
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407 gene expression patterns were found to be significantly changed in response to 5µM 
SF as compared to untreated controls. Of these genes, associations were identified with 
xenobiotic and carbohydrate metabolism, cancer and inflammatory signalling pathways. 
One mechanism which is consistently associated with SF is the induction of Nrf2. Under 
normal conditions, Nrf2 is sequestered in the cytoplasm by its negative regulator, Keap1, 
which behaves to target the transcription factor for proteasomal degradation [154]. In the 
presence of SF, the electrophilic nature of the ITC results in it binding to free cysteine 
residues to form thioacyl adducts with Keap1, providing a potential mechanism for the 
up-regulation of Nrf2-controlled gene expression [156-159]. 
 
Global gene expression changes in response to SF have been previously investigated in a 
number of different cell models. Caco-2 cells, a colon adenocarcinoma cell line, were 
exposed to 1, 5, 25 and 50µM SF for 24 hours and a number of significant gene changes 
were found [147]. When exposed to 5µM SF, only 4 gene changes were induced in 
Caco-2 cells with more than a 2-fold change as compared to 38 found in the microarray 
analysis in this study with the THP-1 monocytes. While the concentrations necessary to 
induce the changes were much higher in the Caco-2 study, the genes affected were 
comparable with the results in this chapter [147].  
 
In data from non-cancerous primary prostate epithelial and stromal cells treated with 
15µM SF for 24 hours, 196 genes were found to be altered by more than 1.5-fold in 
epithelial cells, while only 42 genes were altered by more than 1.5-fold in stromal cells 
(adjusted p value < 0.001) [146]. In cancerous LNCaP prostate cells, 2579 transcripts 
were altered in response to 25µM SF and 3061 transcripts were differentially expressed 
in response to 10µM SF compared to controls (p < 0.05) [231]. There are many more 
transcripts changed in the LNCaP cells compared to the previously described data, 
which may be as a result of different arrays and alternative methods of analysis. 
However, of the genes that were differentially expressed in LNCaP cells in response to 
SF, genes that encoded enzymes involved in xenobiotic metabolism and detoxification 
such as NQO1, TXNRD1, MGST1 and SOD1 were altered to the greatest extent [231]. 
Similar results were also recorded in human hepatocytes and normal breast epithelial 
cells [160, 232]. All of these genes were also significantly changed in this chapter with 
THP-1 monocytes (Table 4.3).   
 
When microarray analysis of the human lens epithelial cell line FHL124 was carried out 
following treatment with 1 and 2µM SF for 24 hours, both NQO1 and TXNDR1 were 
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up-regulated [145], consistent with previously reported findings. These results also 
demonstrate that concentrations of SF easily achievable from the diet (1 and 2µM) are 
able to induce phase 2 enzymes and cause differential gene expression. The 
effectiveness of lower concentrations in this cell line may reflect the likelihood that 
concentrations found in systemic circulation may be difficult to achieve within lens cells 
[145].  
 
In addition, a number of genes associated with carbohydrate metabolism in glycolysis 
and the pentose phosphate pathway were also identified. The pentose phosphate pathway 
consists of two distinct branches; an oxidative irreversible pathway that is responsible 
for the production of NADPH and a ribose 5-phosphate molecule, and a non-oxidative 
pathway made up of a number of reversible reactions that interconverts between ribose 
phosphates and glycolytic intermediates depending on the cell’s requirements for 
NADPH, ribose phosphates or ATP (Figure 4.2) [233]. The pentose phosphate pathway 
is able to provide an alternative pathway for glucose oxidation and contributes between 
10-20% of all glucose oxidation while glycolysis is responsible for the remaining 80-
90%. This pathway, unlike glycolysis does not require oxygen and does not produce 
ATP. The production of NADPH from the pentose phosphate pathway is of particular 
importance due to its function as the universal electron donor, behaving as a reducing 
agent in a number of biosynthetic pathways. Table 4.4 shows how SF was able to 
significantly induce the expression of the genes responsible for encoding a number of 
enzymes involved in both glycolysis and the pentose phosphate pathway while Figure 
4.2 depicts the linked pathways and those enzymes that were differentially expressed in 
response to 5µM SF. These results were supported by the previously mentioned results 
from non-cancerous human breast epithelial MCF10A cells [160]. After treatment with 
15µM SF for 24 hours, a significant increase of at least 1.2-fold in the expression of 
PGD, G6PD, TALDO1 and TKT was seen in response to SF [160]. 
 
The importance of potentially increasing NADPH production in response to SF is related 
to the involvement of NADPH in xenobiotic metabolism and the reduction of oxidative 
stress by behaving as a universal electron donor. SF behaves to increase GST activity, 
allowing conjugation of xenobiotics to GSH to allow detoxification enabling safe 
excretion. This is in addition to NADPH donating electrons to reactive oxygen species, 
alleviating oxidative stress. The increase seen in GST activity is likely due to an increase 
in the expression of the GCLM, an enzyme responsible for catalysing the rate-limiting 
step in GSH synthesis and this is supported by SF’s ability to increase intracellular GSH 
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[234]. Once safe excretion of xenobiotics is complete, in order for GSH and TXN to 
continue to conjugate to other xenobiotics they require reduction. This reduction 
reaction uses NADPH as an electron donor. While there are a number of logical 
hypotheses for the importance of increasing NADPH production, it is important not to 
over-interpret the data from the global gene expression analysis. In order to confirm that 
the glycolysis and pentose phosphate pathways are up-regulated, the activity of the 
differentially expressed enzymes should also be measured. 
 
In response to LPS, 1210 genes were found to be significantly differentially expressed, 
with 396 demonstrating more than a 1.5-fold change (adjusted p value < 0.01). The 
genes that were altered in expression were mainly involved inflammatory signalling 
pathways such as TLR signalling, cytokines and chemokines and many induced by 
IFNs. This work is completely novel as there are no previously documented microarray 
studies investigating the effect of physiologically relevant concentration of LPS 
(1ng/ml) on THP-1 monocytic cells. Concentrations in the range of 1ng/ml LPS have 
only been used in studies using bone marrow-derived macrophages from mice 
(Accession Numbers: E-GEOD-53810 and E-GEOD-19941, ArrayExpress) and in both 
of these studies a different strain of LPS (Salmonella minnesota) has been used to that 
used in my study (E.coli 055:B5). This Salmonella strain has been previously found to 
behave to an extent that was significantly different to that seen with LPS from the E.coli 
055:B5 strain in its ability to induce TNFα and MCP-1 [14], so it is likely the results 
from these studies would not be comparable to the present study with THP-1 monocytes.  
Ellertsen and colleagues used THP-1 monocytes and treated them with 10µg/ml LPS 
(E.coli 026:B6) for 24 hours only around 15% of their reported changes were consistent 
with the data presented in this chapter presumably due to the large difference in LPS 
concentration used [235]. 
 
SF was able to significantly affect 562 genes induced by LPS, with only 105 of those 
changes also being recorded in the absence of LPS. When exploring the effect of SF on a 
global scale including all 1210 genes induced by LPS the regression analysis 
demonstrated a significantly inverse linear relationship between the effect of LPS alone 
and the co-treatment of LPS and SF on gene expression with a gradient of the regression 
line calculated as -1.068. Annotated on Figure 4.3 are IL-6, IL-1β and TNFα, the three 
cytokines that were focused on in Chapter 3. While IL-6 is fairly close to the line of best 
fit, IL-1β and TNFα demonstrate a lesser change with the co-treatment of LPS and SF 
compared to LPS alone, as demonstrated with real-time RT-PCR (Figure 3.13 and 
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3.14). This highlights that there are many more genes that are particularly sensitive to 
LPS and to the presence of SF than the biomarkers previously used. It is important to 
note that while some gene expression changes demonstrate a 2-fold change in expression 
and others demonstrate 25-fold changes, the conclusion that should be made from these 
results is the magnitude of the number of changes seen. If SF is able to suppress low-
grade inflammation induced as a result of circulating endotoxin levels in individuals 
with chronic disease, the reduction in the production of pro-inflammatory biomarkers 
that are associated with increased risk of CVD and cancer for example, means there is 
potential to prevent adverse inflammatory effects by consuming 1-2 portions of high-
glucosinolate broccoli, which is achievable within a normal diet. 
  
The results in this chapter provide the first evidence that a physiologically relevant 
concentration of 5µM SF is able to affect the gene expression of all genes induced by 
1ng/ml LPS. Thus, evidence is provided that SF targets the TLR4 pathway as a whole 
and is not restricted to particular genes as investigated in Chapter 3. The next chapter 
will investigate a potential mechanism of direct interaction between SF and the TLR4 
receptor to provide potential insights into how SF, at a concentration of 5µM is able to 
significantly suppress LPS-induced expression on a global scale. 
 
 
4.4. Conclusions 
In summary, the physiologically relevant concentration of 5µM SF was able to exert 
profound effects on global gene expression in THP-1 monocytes. Constitutively, SF was 
able to induce enzymes involved in xenobiotic metabolism and phase 2 enzymes, as has 
been previously shown. 
 
LPS at a concentration of 1ng/ml, relevant to levels found in circulation of sufferers of 
chronic disease, significantly induced the expression of 1210 genes (adjusted p value < 
0.01) and in the presence of 5µM SF, all of these genes were significantly suppressed 
(regression analysis: p < 0.001, R
2
 = 0.7, Y = 0.19 - 1.068x). 
  
These results demonstrate that the anti-inflammatory effects seen with SF in Chapter 3 
can be extended to all genes affected by LPS. The next chapter will aim to address a 
potential mechanism of SF, by investigating direct interactions with the TLR4 receptor. 
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Chapter Five 
Investigations into the mechanism of SF on 
TLR4 signalling 
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5.0. Introduction 
The results presented in Chapter 4 demonstrate the ability of SF, at a physiologically 
relevant concentration of 5µM, to reverse the global effects of LPS at a low 
concentration achieved in vivo during a state of chronic inflammation, in THP-1 
monocytes. Based on these findings, it was hypothesised that SF was able to target the 
TLR4 signalling pathway at an early point within the cascade. Activation of the TLR4 
receptor by the binding of its ligand LPS, results in the downstream activation of not 
only NF-κB and AP-1 responsible for the transcription of pro-inflammatory cytokines, 
but also the IRF3 transcription factor which controls the expression of IFNs and IFN-
inducible genes  
 
A widely recognised function of SF is its inhibitory effects on the activity of the 
transcription factor NF-κB by either targeting its transcriptional activity directly or by 
promoting inhibition or degradation of the inhibitor of NF-κB, which maintains the 
transcription factor in its inactive form within the cytoplasm [184, 189, 191-194]. This 
mechanism of SF is thought to be responsible for the suppression of pro-inflammatory 
cytokine expression. However, in Chapter 4 the effect of SF was not restricted to LPS-
induced genes controlled by the NF-κB transcription factor, but also included many IFN-
induced genes, whose transcription is controlled by IRF3. This would suggest that the 
global effect of SF on LPS signalling is greater than the mechanism of targeting only 
NF-κB.  
 
A paper by Youn and colleagues suggested an alternative function for SF on LPS 
signalling which involved direct targeting of cysteine residues within the TLR4 receptor 
[195]. The publication describes the ability of SF to covalently bind to specific cysteine 
residues within the extracellular domain of the TLR4 and it hypothesised that this 
modification prevented the dimerisation of the receptor required for downstream 
signalling and subsequent activation of transcription factors to occur. However, 
limitations of this research include the use of a recombinant form of the protein, likely 
under reducing conditions and as a result the effects may not be representative of what 
happens with SF in vitro and in vivo. In addition, a concentration of 100µM SF was 
used, which is far in excess of the achievable concentrations following consumption of 
broccoli within the diet.  
 
The structure of SF means it is able to behave as an electrophile and where available, has 
the ability to covalently bind to free thiol groups of cysteine residues. This function has 
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been recognised previously with a number of different proteins including the Keap1 
protein, fundamental in the function of SF on Nrf2 signalling. The known protein targets 
of SF have been summarised by Melchini and colleagues [236].  
 
In order to progress from this previous research, the objectives of this chapter was to 
investigate whether SF was able to bind cysteine residues within a recombinant form of 
the TLR4 extracellular domain using physiologically relevant concentrations of SF 
under non-reducing conditions. In addition, this aim was extended by investigating 
whether these SF-thiol adducts were able to form in vitro using cells exposed to SF in 
the presence or absence of LPS to determine whether cysteine modification was a 
plausible mechanism for the effect of SF on global LPS-induced gene expression at 
physiologically relevant concentrations (Chapter 4).  
 
 
5.1. Materials and Methods 
Within this chapter, the recombinant TLR4 protein was treated with varying doses of SF 
and subjected to enzyme digestion to yield peptide fragments (section 2.8.1). In addition, 
proteins were extracted from HT-29 cells subjected to SF treatments (0-25µM) in the 
presence or absence 1ng/ml LPS for 1 hour, using an extraction kit designed to separate 
the soluble and the membrane fractions. To improve the specificity of the proteins 
present within the sample, IP was carried out on the whole protein extract from cells 
subjected to the same treatments. Both the soluble and membrane fraction samples and 
the IP samples were subjected to gel electrophoresis and immunoblotting with an anti-
TLR4 antibody to identify protein bands for gel digestion. All of the recombinant 
peptides and the gel digest products were subjected to LC-MS/MS analysis to identify 
potential cysteine modifications within the TLR4 (see sections 2.7 and 2.8 for more 
details of the methods used). 
 
  
5.2. Results  
5.2.1. Modification of TLR4 cysteine residues by SF under reducing and 
non-reducing conditions 
In the study by Youn and colleagues, 2µg of the purified extracellular domain of TLR4 
was incubated with SF at a concentration of 100µM for 1 hour. The protein was 
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subjected to in-solution digestion with chymotrypsin, followed by trypsin before being 
quenched by the addition of formic acid. 
 
A common step in proteomic analysis with enzymatic digestion is a step to reduce the 
protein of interest with DTT and alkylate the thiol groups the disulphide bonds to allow 
the enzymes to reach the interior of the protein structure and to prevent any disulphide 
bonds reforming. If the disulphide bridges of the TLR4 extracellular domain were 
reduced, the thiol groups of the cysteine residues would be free and able to be readily 
bound by SF, due to its electrophilic nature, and thus any binding could potentially be an 
artefact. In this experiment, 2µg of recombinant extracellular TLR4 was treated with 
100µM SF for 1 hour in the same way as in the study by Youn. This treatment was 
followed by the addition of 1mM DTT (or Tris-HCl buffer as the vehicle control) for 15 
minutes to compare the extent of SF-cysteine adducts formed under reducing or non-
reducing conditions.  
 
Table 5.1 presents the cysteine residues which were bound by SF with and without DTT 
treatment. A clear increase was found in the amount of cysteines bound by SF with the 
reducing agent treatment. In addition, most of the cysteines identified as SF bound with 
DTT treatment were consistent with those found in the article by Youn and colleagues 
[195].  
 
Table 5.1. Cysteine residues bound by SF with and without DTT treatment 
Non-reducing conditions Reducing conditions 
Cys246 
Cys609 
Cys192 
Cys246 
Cys390 
Cys391 
Cys506 
Cys542 
Cys583 
Cys585 
Cys609 
 
 
5.2.2. Effect of SF at lower concentrations on TLR4 modification 
The next step was to establish whether this SF-cysteine adduct formation was able to 
occur with concentrations of SF that were more relevant to that physiologically 
Investigations into the mechanism of SF on TLR4 signalling 
 
109 
 
achievable following consumption of broccoli, under non-reducing conditions. 
Concentrations were chosen ranging from 5µM, which was used in my previous in vitro 
experiments with THP-1 monocytes (Chapters 3 and 4), up to 50µM.  
 
As before, Cys609 and Cys246 were consistently found to be modified by SF (Figure 
5.1). For each peptide fragment identified, the amount of detected b and y ions of the 
fragment were recorded. The b ions contain the N-terminus of the amino acid, while the 
y ions contain the C-terminus. Identification of more b and y ions increased the 
confidence that this modification was not as a result of a false discovery. Interestingly, 
the abundance of the SF-modified peptides containing the Cys246 and Cys609 residues 
increased dose-dependently (Figure 5.2). A small amount of modified Cys609-
containing peptide was detected at 5µM, and while the abundance increased following a 
steady pattern until 25µM, a larger increase in abundance was observed when treated 
with 50µM SF (Figure 5.2A). For the modification of the peptide containing Cys246, 
the intensity of the peak was much lower than that measured for the peptide containing 
Cys609. There was also a level of modified peptide identified in the control-treated 
conditions suggesting that there was a higher level of background noise (Figure 5.2B). 
However, consistent with the pattern seen with the Cys609-containing peptide, there was 
a much larger level of SF modification of the Cys246 when subjected to 50µM SF 
(Figure 5.2B).  
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Figure 5.1. SF directly modifies Cys609 (A) and Cys246 (B) within the extracellular 
domain of TLR4 under non-reducing conditions. Recombinant extracellular domain 
of TLR4 (24-631 residues) was treated with SF (5-50µM; vehicle control for SF = < 
0.1% (v/v) DMSO) for 1 hour at 37°C prior to enzymatic digestion and micro-LC-
MS/MS analysis using the LTQ Orbitrap. Data was analysed using Mascot against the 
Uniprot protein database to identify cysteine-bound SF modifications and oxidised 
methionine. Following analysis of the fragments using Peaks software the modified 
fragments were analysed. Sequences Met607-Lys615 (A) and Thr245-Arg257 (B) were 
identified as containing a SF-modified cysteine and b (blue) and y (red) fragment ions 
were assigned. Lower case m indicates oxidised methionine modification and lower case 
c represents SF-modified cysteine residue. The b and y ions are annotated in the spectra.  
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Figure 5.2. Intensity of SF-modified peptides containing Cys609 (A) or Cys246 (B) 
in response to varying SF concentrations under non-reducing conditions. 
Recombinant extracellular domain of TLR4 (24-631 residues) was treated with SF (5-
50µM; vehicle control for SF = < 0.1% (v/v) DMSO) for 1 hour at 37°C prior to 
enzymatic digestion and micro-LC-MS/MS analysis using the LTQ Orbitrap. Data was 
analysed using Mascot against the Uniprot protein database to identify cysteine-bound 
SF modifications and oxidised methionine. Data was then subjected to analysis with 
Progenesis software to determine the intensity of the SF-modified peptides at each SF 
concentrations. Data shown = mean ± SD, data representative of three independent 
experiments. Data was statistically analysed using one-way ANOVA followed by the 
Bonferroni multiple comparison test. *p<0.05, **p<0.01 and ***p<0.001 vs. 0µM SF.  
 
 
5.2.3. Quantification of TLR4 protein in vitro 
To further progress with this research, the ability of SF to modify cysteine residues 
within the TLR4 was investigated as a plausible mechanism for the results seen with SF 
suppression of LPS-induced transcription on global scale and cytokine secretion in 
human monocyte cells (Chapters 3 and 4).  
 
In the initial stages of optimisation, a western blot analysis was completed with protein 
extracts from THP-1 monocytes, as this was the cell model used in the previous 
experiments in this thesis. However, even after a number of optimisation steps only a 
very faint band for TLR4 was detected from THP-1 monocyte protein extracts and this 
was not reproducible (data not shown). As a result of these difficulties, the HT-29 colon 
cancer cell line was chosen for use. Intestinal cells were used as the positive control for 
the TLR4 antibody utilised in these experiments, and therefore it was suggested that the 
HT-29 cells may be more appropriate. As only a very small band was achieved with the 
THP-1 monocytes using a whole protein extract, a kit was used which was able to 
separate the insoluble membrane fraction from the soluble cytosolic protein fractions. 
TLR4 is anchored at the membrane when it binds to LPS but is also present in the 
cytosol, so by using this more complex protein extraction method, the level of protein 
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expression in both locations can be compared, but also the isolated samples can be used 
for separate subsequent analysis steps. 
 
As with the THP-1 monocytes previously, it was initially difficult to achieve 
reproducible results. However, when the extracts were stored as a number of separate 
aliquots the data was consistently reproducible. For the TLR4 protein, it appeared more 
than one freeze-thaw cycle resulted in the denaturation of the structure so it was no 
longer recognised by the antibody, which explained the non-reproducibility.  
 
HT-29 cells were treated with 5, 10 and 25µM SF for 1 hour in the presence or absence 
of 1ng/ml LPS. These concentrations were chosen based on the results in Figure 5.2, 
where SF-modified TLR4 peptides were identified, and excluding 50µM due to being 
far in excess of physiologically relevant levels. Figure 5.3 displays the western blot 
analysis for TLR4 from both the cytosolic and the membrane protein fractions. A band 
at 93kDa was identified, which was the recommended molecular weight for TLR4 with 
this antibody. A number of additional bands were seen in the blots and were possibly 
due to fragmentation of the receptor during the protein extraction method.  
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Figure 5.3. TLR4 is expressed as a soluble and membrane bound protein. (A) HT-
29 cells were treated with SF (5, 10 and 25µM; vehicle control for SF = < 0.1% (v/v) 
DMSO) in the presence or absence of 1ng/ml LPS (vehicle control for LPS = PBS) for 1 
hour. Proteins were extracted using a two-step kit that involved isolating the soluble 
protein fractions from the insoluble membrane protein fraction. The proteins were then 
separated using gel electrophoresis on a NuPage® 10% Bis-tris gel with NuPage® 
MOPS running buffer under non-reducing conditions. The proteins were transferred to a 
nitrocellulose membrane before being probed with anti-TLR4 at 2µg/ml in 2% (w/v) 
BSA/TBST followed by anti-mouse HRP-linked secondary antibody. Following the 
addition of a chemiluminescent substrate the blots were visualised. Representative of 
four blots from three independent protein extractions. (B). The 93kDa bands from the 
blots in (A) are represented here against the appropriate loading controls for soluble 
proteins (GAPDH) and for membrane proteins (Na-K ATPase).  
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5.2.4. Investigations into SF modifications of TLR4 from HT-29 cells treated with 
SF in the presence or absence of LPS  
The next step was to carry out a gel digestion of the protein fragment around 93kDa 
(highlighted in Figure 5.3) followed by LC-MS/MS analysis to aim to identify potential 
SF modifications of cysteine residues within the TLR4, as with the cell-free recombinant 
protein studies.  
 
HT-29 cells were treated with SF (5, 10 and 25µM) for 1 hour in the presence or absence 
of 1ng/ml LPS before proteins were extracted in the same way as in section 5.2.3. A 
duplicate of each protein sample was run on a gel. A duplicate was used to maximise the 
total amount of protein yield and hence give an increased likelihood of identifying TLR4 
in both the membrane and the cytosolic fraction. The gels were stained with a coomassie 
blue stain to allow visualisation of all of the proteins present in the sample. As seen in 
Figure 5.3, the TLR4 band was identified at approximately 93kDa and so for enzymatic 
digestion, the area of the gel that was selected was between the 80 and 100kDa marker 
bands (Figure 5.4).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4. Densitometry blots of the gels for digestion. HT-29 cells were treated with 
SF (5, 10 and 25µM; vehicle control for SF = < 0.1% (v/v) DMSO) in the presence or 
absence of 1ng/ml LPS (vehicle control for LPS = PBS) for 1 hour. Proteins were 
extracted using a two-step kit that involves isolating the soluble protein fractions from 
the membrane protein fraction (section 2.7.2). The proteins were then separated using 
gel electrophoresis on a NuPage® 10% Bis-tris gel with NuPage® MOPS running buffer 
under non-reducing conditions and each sample was run in duplicate. The gels were 
stained and digested according to details in section 2.8.2. Data shown is representative 
of the four gels produced (two from the cytosolic samples and 2 from the membrane 
fractions). The red box surrounds the area of the gel excised for analysis via LC-
MS/MS. 
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Following enzymatic digestion of the peptides within the gel pieces, the samples were 
subjected to LC-MS/MS analysis to aim to identify TLR4 peptide fragments with or 
without SF modifications. When data was analysed using Mascot software, TLR4 was 
not identified. Table 5.2 lists the 12 most highly scored proteins identified within the 
membrane fraction from HT-29 cells treated with 10µM SF with 1ng/ml LPS. The 
results from this sample demonstrated the most representative results for all the 
membrane and cytosolic fraction samples. Across the different treatments, the findings 
were fairly consistent with the most highly scored proteins identified in all samples. 
Based on the majority of proteins identified being within the 80-110kDa molecular 
weight, this data confirms that the positioning of the gel digest for identifying a 93kDa 
TLR4 protein was correct.  
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Table 5.2. Proteins identified by LC-MS/MS from gel digestion samples* 
Family** Member Accession Name of Gene Score 
Mass 
(Da) 
# of 
peptide 
matches 
# of 
significant 
peptide 
matches 
# of 
sequences 
# of 
significant 
sequences 
1 1 O43707 Alpha-actinin-4 1309 105245 66 43 45 31 
1 2 B7Z565 
cDNA FLJ54739, highly similar to Alpha-
actinin-1 
515 95237 35 19 26 15 
1 3 B2RCS5 Alpha-actinin-2 319 104425 18 9 14 7 
2 1 P55072 Transitional endoplasmic reticulum ATPase 942 89950 38 25 29 21 
3 1 P08238 Heat Shock Protein 90-beta 909 83554 54 34 37 23 
3 2 K9JA46 Epididymis luminal secretory protein 52 694 85006 39 23 29 19 
3 3 P14625 Endoplasmin 169 92696 10 4 9 3 
4 1 Q1KLZ0 HCG15971, isoform CRA_a 861 42052 33 28 19 18 
4 2 A8K3K1 
cDNA FLJ78096, highly similar to Homo 
Sapiens actin,alpha, cardiac muscle (ACTC), 
mRNA 
525 42362 23 20 13 13 
5 1 P19338 Nucleolin 716 76625 41 25 27 18 
6 1 P13639 Elongation factor 2 665 96246 38 27 28 20 
7 1 Q14444 Caprin-1 518 78489 21 14 16 11 
*This list of proteins is from the samples of HT-29 membrane proteins subjected to 10µM SF and LPS treatment with a peptide mass tolerance of 5ppm. This is 
representative of all samples measured, both membrane and cytosolic fractions. 
**Proteins are categorised into families when a high level of shared peptide matches are identified. 
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5.2.5. Identification of potential SF-modified TLR4 using immunoprecipitation 
5.2.5.1. Immunoprecipitation and gel electrophoresis 
In an attempt to identify SF-modified TLR4 fragments, the work from the gel digest was 
followed with the use of an IP method prior to gel electrophoresis. This method was 
advantageous compared to the previous gel digest method due to the fact that with IP, the 
TLR4 will be isolated from the crude protein extract and therefore will not compete with the 
large amount of proteins present in the sample at the same molecular weight in terms of 
abundance.  
 
HT-29 cells were treated as before for 1 hour with SF (5, 10 and 25µM) in the presence or 
absence of 1ng/ml LPS. Total proteins were extracted using the lysis buffer provided in the 
Pierce Classic IP kit, therefore combining those proteins present within the membrane of the 
cells but also within the cytosol, unlike in previous experiments where these localised pools 
of protein were separated. It was deemed unnecessary to separate the membrane and 
cytosolic fractions due to the comparable findings of both fractions when analysed by LC-
MS/MS (Table 5.2). 
  
In order to isolate TLR4 from the total protein extract, an immune complex was prepared. 
This involved combining the protein lysate with the anti-TLR4 antibody, before adding this 
to the protein A/G agarose to capture the antibody-bound TLR4 protein. This antibody-
protein complex was then eluted into sample buffer under reducing conditions to subject 
directly to gel electrophoresis. Following gel electrophoresis, the gels were stained with a 
coomassie blue stain to identify proteins present within the samples. In addition, a western 
blot analysis was carried out to compare with the coomassie blue stained gel. The 
densitometry blot of the coomassie blue stained gel and the visualised western blot are 
presented in Figure 5.5. Five bands were annotated as being of interest in Figure 5.5 and 
were subjected to gel digestion. The reasons for this were that bands 2-5 appeared to vary 
with the treatment of the cells while band 1 appeared to be fairly consistently present in all 
the samples. In order to determine whether there was any indication of an effect of the 
treatments, the band volumes were quantified. To give some level of normalisation, the band 
at around 25kDa which is attributed to the anti-TLR4 antibody, was used.  
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Figure 5.5. Analysis of immunoprecipitation product by gel electrophoresis with 
coomassie blue stain (A) and western blot analysis (B) for TLR4. HT-29 cells were 
treated with SF (5, 10 and 25µM; vehicle control for SF = < 0.1% (v/v) DMSO) in the 
presence or absence of LPS (1ng/ml; vehicle control for LPS = PBS) for 1 hour. Proteins 
were extracted from the cells and immunoprecipitated using the Pierce Classic IP kit 
following manufacturer’s instructions. In order to immunoprecipitate the TLR4 protein, the 
mouse monoclonal anti-TLR4 antibody was used. The antigen-antibody complex was eluted 
in sample buffer under reducing conditions and subjected to gel electrophoresis. One gel was 
stained with GelCode Blue Stain overnight (A) and densitometry measured using the GS800 
Calibrated Densitometer. The other gel was subjected to western blot analysis with the same 
anti-TLR4 antibody and chemiluminescence was measured using anti-mouse HRP-linked 
secondary antibody and a chemiluminescent substrate (B). Annotations 1-5 are the bands 
that were identified for gel digestion and analysis via LC-MS/MS.   
 
 
The bands highlighted in Figure 5.5 were quantified using the Quantity One software to get 
some indications as to whether treatment effects were observed. 
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In Figure 5.6, the data presented demonstrates varying effects of SF and LPS on the 
highlighted bands. While band 1 appears to have no consistent pattern in response to SF or 
LPS, band 2 demonstrates a slight reduction in the levels with increasing doses of SF 
(Figure 5.6A-B). Of particular interest are bands 3 and 4 which demonstrate similar patterns 
with a reduction at higher concentrations of SF relative to the control, while both are 
induced by LPS. When subjected to a combined treatment of LPS and SF, 10 and 25µM SF 
treatment results in a large reduction of the levels of bands 3 and 4 (Figure 5.6C-D). Band 5 
follows a different pattern where SF reduces the levels in the absence of LPS and when 
treated with LPS alone, a reduction in the levels relative to the control was observed. When 
treated in combination with LPS and SF, there is a dose-dependent restoration of the level of 
the protein present to that measured in the control condition (Figure 5.6E).  
Figure 5.6. Quantification of the bands of interest from the IP product. Using the 
Quantity One software necessary to visualise both the coomassie blue stained gel and the 
western blot, the individual bands annotated in Figure 5.5 were quantified based on their 
volume and were normalised using the volume of the antibody band for each corresponding 
lane. 
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5.2.5.2. LC-MS/MS analysis of gel digestion fragments 
From the five digested protein bands subjected to gel digestion (Figure 5.5), TLR4 was not 
identified in any of the samples. High levels of keratin was found within the samples 
suggesting a technical contamination during the procedure for preparing samples from the 
stained gel through until the samples were ready for LC-MS/MS analysis. Following the 
staining of the gel, there was a period where the gel had semi-dried and it is possible it was 
at this point that keratins were able to penetrate the gel and following reconstitution the 
keratins remained present within the gel. In order to confirm the identity of the proteins 
present in the bands highlighted in Figures 5.5 and 5.6, this experiment would need to be 
repeated. 
 
 
5.3. Discussion 
In experiments with the recombinant TLR4 receptor, SF at 100µM was able to modify 
Cys246 and Cys609 of the TLR4 molecule under non-reducing conditions, and when carried 
out under reducing conditions, results were comparable with Youn and colleagues with 
many cysteine residues demonstration thiol modification [195]. The modification of Cys609 
was also detected with SF at low concentrations with a dose-dependent increase with 
concentrations of 5µM to 25µM, with a large increase when subjected to treatment with 
50µM SF (Figure 5.1A). With Cys246, there were slightly different findings however a 
significant increase was seen in the levels of modified protein at 50µM (Figure 5.1B). These 
results demonstrated that Cys609 was most sensitive to modification by SF even at the 
lower, physiologically relevant concentrations. These novel findings suggest that Cys246 
and Cys609 are potentially most important for the suppression of LPS-induced gene 
expression, but this hypothesis requires more investigation. 
 
Interestingly, when investigating the Cys609 residue, it was found that it is attributed to a 
disulphide bridge with Cys583 according to the Uniprot database (Accession Number: 
O00206) [8, 237, 238]. While Cys609 was found to be modified under both non-reducing 
and reducing conditions, the other reported cysteine within the disulphide bond, Cys583, 
was only modified by SF following a reduction step using DTT (Table 5.1). To investigate 
the existence of this particular disulphide bond, the literature that was referred to in the 
Uniprot database was reviewed and no evidence of support for the presence of this 
disulphide bridge was found in any of the articles cited [8, 237, 238]. The combination of the 
lack of literature findings with my observations that Cys609 was bound by SF in the absence 
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of a reduction treatment (Table 5.1 and Figure 5.1), does not corroborate the presence of the 
disulphide bonds in the experimental design presented in this chapter.  
 
The mechanism of cysteine modification by SF was not a novel concept [236]. With 
relevance to the ability of SF to significantly suppress LPS-induced gene expression, SF has 
also been identified as being able to modify the Cys133 residue within the mouse MD2 
protein, the co-receptor of TLR4 required for LPS-induced signalling. This modification 
prevents LPS binding to MD2 [196]. Cys133 is freely available while other cysteines present 
within the structure of MD2 are involved in disulphide bonds. Those involved in disulphide 
bonds were not modified by SF, suggesting that in order for SF to covalently modify 
cysteine residues, the thiol group must be free. In combination with the identified TLR4 
modification by SF, this evidence in a cell-free system may support the hypothesis that SF is 
able to significantly suppress LPS-induced gene expression on a global scale as a result of 
targeting the receptor and its interaction with its specific ligand, LPS. 
 
Additionally, modification of cysteine residues by SF has been described as a plausible 
explanation for additional functions of SF such as its role in Nrf2 activation. During a basal 
state, Nrf2 is sequestered within the cytoplasm of the cell via its inhibitory co-factor, Keap1, 
which behaves to target the Nrf2 transcription factor for proteosomal degradation [154]. 
When activated by the presence of an Nrf2 inducer for example SF, Keap1 is no longer able 
to sequester the Nrf2 to the cytoplasm, leaving Nrf2 free to translocate to the nucleus and 
activate the transcription of ARE-controlled genes [155]. SF was identified as being able to 
directly interact with the thiol group of the Cys151 residue within the Keap1 protein, a 
residue essential for the activity of the protein [156-159].  
 
All evidence of direct binding of SF to thiol groups of cysteine residues within target 
proteins has come from LC-MS/MS analysis utilising recombinant forms of the proteins and 
subjecting them to SF treatment, often at concentrations that cannot be achieved in vivo 
following the consumption of broccoli. While a lack of Nrf2 activation was seen in cells 
exposed to SF when Cys151 within the Keap1 protein was substituted with a serine residue, 
this experimental design has not been undertaken with TLR4 or MD2, making it difficult to 
justify the importance of the cysteine modification and the relevance to the anti-
inflammatory effects of SF in vitro and in vivo. For this reason, investigations were carried 
out into whether the modified cysteine residues could be identified within the TLR4 in a cell 
model following exposure to SF.  
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To investigate whether it was possible to demonstrate SF thiol modification of TLR4 in vitro 
HT-29 cells with SF (5, 10 and 25µM) in the presence or absence of 1ng/ml LPS for 1 hour 
prior to extracting the cytosolic and membrane protein pools. These samples were subjected 
to gel electrophoresis and following coomassie blue staining, a band was excised from gels 
covering the region between 80-100kDa, the area at which the TLR4 protein with a 
molecular weight of 93kDa should potentially be found. The proteins present within the 
band were subjected to a chymotrypsin/trypsin double enzyme digestion to yield peptides 
that were subjected to LC-MS/MS analysis. When analysed, the data did not identify the 
TLR4 protein as present within the band. Reasons for the lack of identifying TLR4 within 
these samples include the fact that the TLR4 is likely to be expressed at very low levels 
compared to actin proteins found within the samples (Table 5.2) and therefore the TLR4 
would have to compete for identification. When exposed to the enzymes during digestion, 
TLR4 would also have to contest with the other proteins present within the band to be 
digested and in addition, when analysed via LC-MS/MS there would be competition 
between the peptides for ionisation and subsequent identification. If the experiment was to 
be repeated, a band over a more narrow range could be excised to try and increase the 
probability of TLR4 identification. 
 
IP techniques were subsequently used with the cell lysate to try and improve the probability 
of identifying SF-modified TLR4 and when a western blot was carried out a number of 
interesting bands were discovered that appeared to change with LPS and SF treatment. 
However, whether these results were a true effect of SF and LPS remain to be determined as 
LC-MS/MS analysis did not identify the TLR4 protein within any of the samples analysed 
and instead the highest scoring proteins were keratins (data not shown). This was thought to 
be due to contamination following the drying of the gel which occurred after the staining 
procedure. While the gel remained intact following rehydration, it is possible keratins from 
the environment were able to penetrate the gel and hence were present within the digested 
peptides. However, due to the identification of protein bands within the IP product which 
were thought to be specific interactions with the TLR4 molecule, in combination with bands 
that demonstrated differing effects with SF and LPS treatments in some cases, it is important 
that this experiment be repeated in future work, ensuring stricter experimental procedures 
are used. 
 
While there were a fairly large number of treatments used with the IP experimental design 
which may result in difficulties when trying to further the work, it would be necessary to 
repeat these experiments with the same conditions as it is important to investigate the effect 
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of SF both with and without LPS. In the absence of LPS, the potential modifications 
between TLR4 and SF in a resting state can be investigated, while in the presence of LPS, 
investigation can be carried out into whether SF is able to modify the TLR4 and prevent LPS 
binding in addition to addressing the question of whether SF is able to bind to TLR4 and 
prevent downstream activation following ligand binding.  
 
Within Chapters 3 to 5, all the research focused on the TLR4 signalling pathway. In the next 
chapter, the scope of the research was broadened to investigate whether the effect of SF was 
restricted to TLR4 signalling or whether SF was also able to target TLR2 and NOD2 
pathways, which are also of fundamental importance in chronic inflammatory signalling.  
 
 
5.4 Conclusion 
To summarise, it was demonstrated that physiologically relevant concentrations of SF, as 
low as 5µM, were able to modify Cys609 and Cys246 present in the extracellular domain of 
recombinant TLR4. These residues remained modified under non-reducing conditions, 
suggesting these may be of larger importance to a potential mechanism.  
 
To investigate whether this was a plausible mechanism to explain the global effects on the 
TLR4 pathway seen in vitro, a gel digest was carried out from both a crude total protein 
sample and an IP product with the aim to enrich the presence of TLR4. In both experimental 
designs, there was no identification of TLR4. This is likely as a result of technical 
drawbacks and while indications of proteins dependent on both LPS and SF treatments were 
identified from the IP product, the lack of LC-MS/MS confirmation means this experiment 
would need to be repeated with an optimised protocol. 
 
Thus far, the TLR4 signalling pathway has been the sole focus of this thesis. The next 
chapter will aim to address whether SF has the ability to target other inflammatory signalling 
pathways, namely TLR2 and NOD2, and whether common polymorphisms in the TLR4 and 
NOD2 receptors implicated in Crohn’s disease, affect the response to their ligands or SF.  
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Chapter Six 
Effect of SF on NF-κB in PRR-expressing cell 
models 
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6.0. Introduction 
In the previous chapter, evidence was provided to demonstrate that SF at physiologically 
relevant concentrations could directly target and modify cysteine residues within the TLR4 
(Chapter 5). Furthermore, this mechanism may be able to explain the global effect SF can 
exert on LPS signalling (Chapter 4). However, until this point only the TLR4 pathway has 
been focused on. This chapter aimed to address whether the suppressive effect of SF was 
specific to TLR4 signalling, or whether SF was able to target other important signalling 
pathways involved in chronic inflammation. Additionally, investigations were carried out 
into whether any differences were observed in the effect of SF when comparing L-SF and 
DL-SF forms.  
 
 
6.0.1. L-SF versus DL-SF 
Both L-SF and DL-SF compounds have been widely investigated in vitro, and throughout 
this thesis, the DL-SF form was used. L-SF is isolated from broccoli and is known to be 
biologically active. SF is a chiral molecule meaning it has two non-superimposable mirror-
image compounds, L-SF and the stereoisomer D-SF. DL-SF is the racemic mixture and is 
available commercially as a synthetic analogue of the naturally occurring L-SF [239]. Its 
synthetic nature has advantages e.g. it is cheaper to produce and is potentially a more 
consistent product, whereas L-SF is derived from broccoli which is advantageous due to 
being the biologically active breakdown product found in circulation following broccoli 
consumption [239]. The stereoisomer of L-SF, D-SF is also commercially available, 
however due to the low natural abundance in broccoli, no research has been carried out 
investigating the biological activity of this form. The hypothesis was that no significant 
differences in the biological activity of the naturally occurring L-SF and the synthetic DL-SF 
will be observed. Support for this hypothesis includes a study by Zhang and colleagues who 
found equipotent levels of quinone reductase induction when comparing L-SF and DL-SF in 
vitro [239]. 
 
 
6.0.2. Chronic inflammatory signalling pathways 
In recent years it has become more widely accepted that a state of low-grade inflammation is 
a contributing common factor to many chronic diseases such as cancer, atherosclerosis and 
IBDs [205]. The importance in trying to prevent the development of these chronic diseases, 
the leading causes of mortality throughout the world, and improving potential treatment 
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options, is crucial. With chronic inflammation as a mutual factor in these diseases, this has 
become an increasingly attractive target for dietary and pharmaceutical interventions. 
 
Inflammatory signalling in chronic diseases is controlled by an array of PRRs which behave 
to recognise specific PAMPs, resulting in the activation of their associated signalling 
pathways [240]. The main classes of PRRs are the TLRs, NLRs and RLRs [241] and within 
this chapter TLR4, TLR2 and NOD2 have been investigated. The TLR4, TLR2 and NOD2 
pathways are individually activated in response to their specific ligands but ultimately, these 
pathways converge with NF-κB activation common to all (Figure 6.1). As mentioned in 
previous chapters, TLR4 responds specifically to LPS and can follow one of two different 
pathways: a MyD88-independent pathway which results in the activation of the transcription 
factor IRF3 followed by NF-κB, or a MyD88-dependent pathway that results in the 
activation of NF-κB and AP-1. This MyD88-dependent pathway is also common to the 
TLR2 signalling pathway, which is activated in response to lipopeptides. NOD2 signalling is 
triggered in response to MDP binding and also results in the activation of NF-κB and AP-1. 
While NOD2 signalling doesn’t involve MyD88, adaptors common to the TLR4, TLR2 and 
NOD2 pathways prior to NF-κB transcription factor activation, including RIP1 and MAPKs, 
are necessary for signalling to occur [240]. 
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Figure 6.1. Overview of the TLR4, TLR2 and NOD2 signalling pathways. In the TLR4 
signalling pathway, LPS binds to the TLR4-MD2 complex via the aid of LBP and CD14 
accessory proteins. The binding of LPS to the TLR4-MD2 complex results in 
homodimerisation and activation of an intracellular signalling cascade. This can be MyD88-
independent or dependent. The MyD88-independent pathway results in the activation of 
IRF3 followed later by NF-κB. This leads to the expression of type I IFNs and IFN-
inducible genes. The MyD88-dependent pathway stimulates NF-κB and AP-1 resulting in 
pro-inflammatory cytokine and chemokine expression [13, 14]. The MyD88-dependent 
pathway is also activated as a result of lipopeptides binding to TLR2. In addition, adaptor 
proteins downstream of MyD88 can be activated by MDP binding to the intracellular NOD2 
receptor, again resulting in the activation of NF-κB and AP-1 [240].  
 
 
The reason for focusing on the TLR4, TLR2 and NOD2 signalling pathways is due to 
identified associations with chronic inflammatory pathologies. Increased TLR4 and TLR2 
expression levels have been linked to chronic diseases including IBDs [48-50], cancer [30], 
metabolic syndrome [242, 243], atherosclerosis [36], obesity [44] and T2DM [44]. Identified 
polymorphisms within TLR4, namely D299G where an aspartate residue at position 299 has 
been substituted with a glycine and T399I where a threonine at position 399 has been 
replaced with an isoleucine residue, have also been investigated in patients with IBDs with 
contradictory results reported [54-62]. Conversely, these polymorphisms have been 
associated with a protective function against T2DM [244]. 
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NOD2 has been widely studied in Crohn’s disease and three SNPs have been commonly 
associated with IBDs. One SNP results in a frameshift mutation within the NOD2 receptor 
sequence, which leads to the introduction of an early stop codon. As a result, a truncated 
NOD2 protein is produced with the final 33 amino acids of the protein missing [53]. The 
other two commonly associated SNPs are missense mutations, G908R where a glycine 
residue at position 908 has been replaced with an arginine residue and R702W, where an 
arginine residue at position 702 is replaced with a tryptophan [245]. Approximately 15% of 
Crohn’s disease patients are found to have at least one of these mutations in the NOD2 
receptor and these three polymorphisms described account for 82% of the mutations in 
NOD2 found in patients suffering from Crohn’s disease or UC [51, 52]. These NOD2 
polymorphisms have also been found at higher prevalence in patients with coronary artery 
disease [246] and some cancers [247], however, further research needs to be carried out to 
firmly establish a link as seen with Crohn’s disease. 
 
Based on previously published data and the results from earlier chapters, the hypothesis 
within this chapter was that both the L-SF and DL-SF compounds would significantly 
suppress NF-κB activity induced in response to appropriate TLR4, TLR2 and NOD2 
ligands, with the same extent of suppression observed with each form, was tested. In 
addition, mutations within these receptors that are commonly associated with IBDs were 
studied to determine if they affected the response to either the ligand or SF treatments. 
 
 
6.1. Materials and Methods 
For the experiments within this chapter HEK-Blue
TM 
cells or HEK cells transfected in-house, 
either stably or transiently transfected, were used (section 2.2.2). These cell lines were 
subjected to various treatments with their appropriate ligands in the presence or absence of 
SF (2, 5 and 10µM) for 24 hours before the cell culture supernatant was used to determine 
the level of NF-κB activity indirectly via the use of a QUANTI-BlueTM assay that measures 
the level of AP enzyme activity (section 2.9). To investigate the effect of SF on the viability 
of these HEK cells, a WST-1 cell viability assay was used (section 2.3).  
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6.2. Results 
6.2.1. Effect of SF on cell viability of HEK293 cells 
To determine which concentration of L-SF and DL-SF to use for the experiments to test the 
effect of SF on NF-κB activity, HEK-Blue
TM
 TLR4, TLR2, NOD2 (wildtype and G908R 
mutant) cells were treated with L-SF or DL-SF (0-200µM) for 24 hours and a WST-1 cell 
viability assay was carried out. The data was analysed collectively because HEK293 cells 
were used consistently, with only the receptor they were transfected with changing. L-SF 
caused a significant reduction in cell viability at concentrations of 15µM and above (Figure 
6.2A) while with DL-SF, concentrations of 10µM and above resulted in significant 
reductions in cell viability (Figure 6.2B). 
 
Figure 6.2. Effect of SF on viability of HEK293 cells. HEK-Blue
TM
 cells were treated with 
A) L-SF or B) DL-SF (0-200µM; vehicle control for L-SF and DL-SF = < 0.1% (v/v) 
DMSO) for 24 hours. After treatment was complete, 10µl WST-1 reagent was added to each 
well. The plates were incubated at 37°C and measured using a spectrophotometer at 450nm 
every 30 minutes for 3 hours. Data shown is from the 1.5 hour measurement at which the 
levels of absorbance were all measurable and consistent. Data shown = mean ± SEM, n = 4. 
Data was statistically analysed using one-way ANOVA followed by the Bonferroni multiple 
comparison test. **p<0.01 and ***p<0.001 vs. 0µM. 
 
 
To determine whether there were any differences in the level of cytotoxicity between the L-
SF and DL-SF compounds, the IC50 for each compound was calculated. Using a t-test, no 
significant difference was found in the levels of cytotoxicity with L-SF and DL-SF (Table 
6.1). 
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6.2.2. Effect of SF on NF-κB activity in TLR4-expressing cells 
To determine whether 1ng/ml LPS (the concentration used in previous chapters) was 
sufficient to induce NF-κB activity in TLR4-expressing cells, HEK-BlueTM-hTLR4 cells 
were treated with 1, 5 and 10ng/ml LPS for 24 hours and level of SEAP was analysed as a 
measure of NF-κB activity. A significant induction of NF-κB activity was seen in response 
to 1, 5 and 10ng/ml LPS (Figure 6.3).  
 
 
 
 
 
 
 
 
 
 
Figure 6.3. LPS significantly induces NF-κB activity in HEK-BlueTM-hTLR4 cells. 
HEK-Blue
TM
-hTLR4 cells were treated with LPS (1, 5 and 10ng/ml; vehicle control for LPS 
= PBS) for 24 hours. Cell culture supernatant was added to QUANTI-Blue
TM
 solution until 
colour change was evident (pink to purple blue, caused by the activity of SEAP). The colour 
change induced by SEAP was analysed as a measure of NF-κB activity at 650nm using a 
spectrophotometer. Data shown = mean ± SEM, n = 4. Data was statistically analysed using 
one-way ANOVA followed by the Bonferroni multiple comparison test. ***p<0.001 vs. 
0ng/ml. 
 
 
Based on the findings in Figure 6.2, concentrations of both L-SF and DL-SF up to 10µM 
were chosen for use in further experiments, where cell viability would be maintained at 
above 80%. This was to ensure that any effects observed on NF-κB activity were not as a 
result of cytotoxic effects induced by SF. Both L-SF and DL-SF at concentrations of 5 and 
10µM were able to significantly suppress NF-κB induction seen in response to 1ng/ml LPS 
(Figure 6.4). 
Table 6.1. IC50 for L-SF and DL-SF on HEK293 cells 
 IC50 (µM) SEM P value 
L-SF 23.92 3.94 
0.148
 
DL-SF 17.01 1.35 
The IC50 values were compared using the Student’s T-test, p > 0.05 = non-
significant.  
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Figure 6.4. L-SF and DL-SF significantly suppress LPS-induced NF-κB activity in 
HEK-Blue
TM
-hTLR4 cells. HEK-Blue
TM
-hTLR4 cells were treated with A) L-SF or B) DL-
SF (0.5, 2, 5 or 10µM; vehicle control for L-SF and DL-SF = < 0.1% (v/v) DMSO) in the 
presence or absence of LPS (1ng/ml; vehicle control for LPS = PBS) for 24 hours. Cell 
culture supernatant was added to QUANTI-Blue
TM
 solution until colour change was evident 
(pink to purple blue, caused by the activity of SEAP). The colour change induced by SEAP 
was analysed as a measure of NF-κB activity at 650nm using a spectrophotometer. Data 
shown = mean ± SEM, n = 4. *p<0.05, **p<0.01 and ***p<0.001, comparison to 0µM + 
LPS. 
 
 
6.2.3. Effect of SF on NF-κB activity in transiently transfected TLR4 cells 
In Crohn’s disease, a higher prevalence of two SNPs within the TLR4 receptor, D299G and 
T399I, have been reported, though it is controversial [54-62]. These TLR4 variants were 
investigated to determine if the mutations resulted in a different response to either their 
ligand LPS, or to SF. HEK293 cells were transiently transfected with either the wildtype or 
mutant TLR4 receptors in addition to the NF-κB-controlled SEAP reporter gene. Cells were 
treated with LPS (1, 5 and 10ng/ml) for 24 hours before NF-κB activity was measured to 
determine whether the transiently transfected TLR4 cells responded to the same extent to 
LPS as the stably transfected cells previously used (section 6.2.2). A concentration of 
1ng/ml LPS was sufficient to significantly induce NF-κB activity in cells expressing the 
wildtype TLR4 receptor (Figure 6.5A) and the mutant receptors, D299G and T399I (Figure 
6.5B-C). The extent of the response to LPS was compared across cells expressing the 
wildtype and the mutant TLR4 receptors and no significant differences were seen in the 
level of NF-κB activity induced in response to LPS (Figure 6.5D).  
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Figure 6.5. LPS significantly induces NF-κB activity in cells transiently transfected 
with wildtype or mutant TLR4. 293-hMD2-CD14 cells transiently transfected with either 
the wildtype or mutant TLR4 receptor (A. wildtype, B. D299G and C. T399I) were treated 
with LPS (1, 5 and 10ng/ml; vehicle control for LPS = PBS) for 24 hours. Cell culture 
supernatant was added to QUANTI-Blue
TM
 solution until colour change was evident (pink to 
purple blue, caused by the activity of SEAP). The colour change induced by SEAP was 
analysed as a measure of NF-κB activity at 650nm using a spectrophotometer. D) shows the 
response of wildtype, D299G and T399I cells collectively. Data shown = mean ± SEM, n = 
4. Data was statistically analysed using one-way ANOVA followed by the Bonferroni 
multiple comparison test. **p<0.01 and ***p<0.001 vs. 0ng/ml. 
 
 
The effect of L-SF and DL-SF on LPS induction of NF-κB activity was investigated. At 
concentrations of both 5 and 10µM, L-SF and DL-SF were able to demonstrate a significant 
suppression of LPS-induced NF-κB activity in cells expressing either the wildtype or mutant 
TLR4 receptors (Figure 6.6). 
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Figure 6.6. L-SF and DL-SF significantly suppress LPS-induced NF-κB activity in cells 
transiently transfected with wildtype or mutant TLR4. 293-hMD2-CD14 cells 
transiently transfected with either the wildtype or mutant TLR4 receptor (A + B. wildtype, C 
+ D. D299G and E + F. T399I) were treated with L-SF (A, C + E) or DL-SF (B, D + F) at 
concentrations of 0.5, 2, 5 and 10µM (vehicle control for L-SF and DL-SF = < 0.1% (v/v) 
DMSO) in the presence or absence of  LPS (1ng/ml; vehicle control for LPS = PBS) for 24 
hours. Cell culture supernatant was added to QUANTI-Blue
TM
 solution until colour change 
was evident (pink to purple blue, caused by the activity of SEAP). The colour change 
induced by SEAP was analysed as a measure of NF-κB activity at 650nm using a 
spectrophotometer. Data shown = mean ± SEM, n = 4. *p<0.05, **p<0.01 and ***p<0.001, 
comparison to 0µM + LPS. 
 
 
To determine whether the D299G or T399I mutations caused differential responses to SF, a 
comparison was carried out between the cells expressing the three TLR4 variants. No 
significant differences were seen in the level of suppression of NF-κB activity induced by 
LPS in response to either L-SF (Figure 6.7A) or DL-SF (Figure 6.7B). 
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Figure 6.7. No significant differences were seen in the response to L-SF (A) or DL-SF 
(B) by cells transiently transfected with either wildtype or mutant TLR4. 293-hMD2-
CD14 cells transiently transfected with either the wildtype or mutant TLR4 receptor (D299G 
and T399I) were compared in terms of their responses to LPS (1ng/ml; vehicle control for 
LPS = PBS) in the presence or absence of A) L-SF or B) DL-SF (0.5, 2, 5 and 10µM SF; 
vehicle control for L-SF and DL-SF = < 0.1% (v/v) DMSO) after 24 hours of treatment. Cell 
culture supernatant was added to QUANTI-Blue
TM
 solution until colour change was evident 
(pink to purple blue, caused by the activity of SEAP). The colour change induced by SEAP 
was analysed as a measure of NF-κB activity at 650nm using a spectrophotometer. Data 
shown = mean ± SEM, n = 4. Data was statistically analysed using two-way ANOVA 
followed by the Bonferroni multiple comparison test. 
 
 
6.2.4. Effect of SF on NF-κB in TLR2-expressing cells 
Until now, investigations had only been carried out with a focus on the effect of SF in 
response to LPS and thus, specifically, on the TLR4 pathway. As previously mentioned, 
TLR2 is fundamental in chronic inflammatory signalling where it can respond to bacterial or 
mycoplasmal lipopeptides [4, 5]. TLR2, unlike TLR4, undergoes heterodimerisation forming 
complexes with either TLR1 or TLR6. These dimers have different ligand specificities; the 
TLR2/TLR1 complex specifically binds triacylated lipopeptides and the TLR2/TLR6 
complex recognises diacylated lipopeptides [4, 5].  
 
In Chapter 5, TLR2 was also studied as a direct target for SF modification however practical 
implications meant that no direct interactions with thiol groups of cysteine residues were 
observed (data not shown). In this chapter, TLR2-expressing cells were utilised to address 
whether the effect of SF was specific to TLR4 signalling or whether SF was able to target 
additional receptors involved in chronic inflammatory signalling.  
 
In order to measure NF-κB activity in TLR2-expressing cells, activation of both the 
TLR2/TLR1 and TLR2/TLR6 dimeric complexes required investigation. Firstly, activation 
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of NF-κB via the TLR2/TLR1 pathway was explored using a synthetic ligand for the TLR2 
receptor complex, Pam3CSK4, a triacylated lipopeptide that behaves to mimic bacterial 
lipoproteins. To determine the necessary concentration to significantly induce NF-κB 
activity, TLR2-expressing cells were treated with concentrations of Pam3CSK4 (5, 15 and 
50pg/ml) for 24 hours and SEAP levels were analysed as a measure of NF-κB activity. A 
concentration of 50pg/ml Pam3CSK4 significantly induced NF-κB activity (Figure 6.8). 
 
 
 
 
 
 
 
 
 
 
Figure 6.8. Pam3CSK4 significantly induces NF-κB activity in HEK-BlueTM-hTLR2 
cells. HEK-Blue
TM
-hTLR2 cells were treated with Pam3CSK4 (5, 15 and 50pg/ml; vehicle 
control for Pam3CSK4 = endotoxin-free water) for 24 hours. Cell culture supernatant was 
added to QUANTI-Blue
TM
 solution until colour change was evident (pink to purple blue, 
caused by the activity of SEAP). The colour change induced by SEAP was analysed as a 
measure of NF-κB activity at 650nm using a spectrophotometer. Data shown = mean ± 
SEM, n = 3. Data was statistically analysed using one-way ANOVA followed by the 
Bonferroni multiple comparison test. **p<0.01 vs. 0pg/ml. 
 
 
To determine the effect of L-SF and DL-SF on Pam3CSK4-induced NF-κB activity, TLR2-
expressing cells were treated with L-SF and DL-SF (0.5, 2, 5 and 10µM) in the presence or 
absence of 50pg/ml Pam3CSK4 for 24 hours. Both L-SF and DL-SF were able to 
significantly suppress levels of NF-κB activity induced in response to Pam3CSK4 
consistently at concentrations of 5 and 10µM (Figure 6.9).  
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Figure 6.9. L-SF and DL-SF are able to significantly suppress Pam3CSK4-induced NF-
κB activity in HEK-BlueTM-hTLR2 cells. HEK-BlueTM-hTLR2 cells were treated with 
Pam3CSK4 (50pg/ml; vehicle control for Pam3CSK4 = endotoxin-free water) in the 
presence or absence of A) L-SF or B) DL-SF (0.5, 2, 5 or 10µM; vehicle control for L-SF 
and DL-SF = < 0.1% (v/v) DMSO) for 24 hours. Cell culture supernatant was added to 
QUANTI-Blue
TM
 solution until colour change was evident (pink to purple blue, caused by 
the activity of SEAP). The colour change induced by SEAP was analysed as a measure of 
NF-κB activity at 650nm using a spectrophotometer. Data shown = mean ± SEM, n = 3. 
*p<0.05, and ***p<0.001, comparison to 0pg/ml for –Pam3CSK4 and +Pam3CSK4 
conditions separately or as annotated. 
 
 
FSL-1, a diacylated lipopeptide derived from mycoplasma, is specifically recognised by the 
TLR2/TLR6 dimer. The same experimental design used with Pam3CSK4 was repeated with 
FSL-1 in the TLR2-expressing cells to investigate the levels of NF-κB activity as a result of 
activating the TLR2/TLR6 dimer. HEK-Blue
TM
-hTLR2 cells were treated with FSL-1 at 
concentrations of 5, 15 and 50pg/ml and the level of induction of NF-κB activity was 
measured. Levels of 15 and 50pg/ml FSL-1 significantly induced NF-κB activity in HEK-
Blue
TM
-hTLR2 cells (Figure 6.10).  
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Figure 6.10. FSL-1 significantly induces NF-κB activity in HEK-BlueTM-hTLR2 cells. 
HEK-Blue
TM
-hTLR2 cells were treated with FSL-1 (5, 15 and 50pg/ml; vehicle control for 
FSL-1 = endotoxin-free water) for 24 hours. Cell culture supernatant was added to 
QUANTI-Blue
TM
 solution until colour change was evident (pink to purple blue, caused by 
the activity of SEAP). The colour change induced by SEAP was analysed as a measure of 
NF-κB activity at 650nm using a spectrophotometer. Data shown = mean ± SEM, n = 3. 
Data was statistically analysed using one-way ANOVA followed by the Bonferroni multiple 
comparison test. ***p<0.001 vs. 0pg/ml. 
 
 
The effect of both L-SF and DL-SF on FSL-1-mediated NF-κB induction was investigated 
using 15pg/ml FSL-1, the minimum concentration sufficient to significantly induce NF-κB 
activity (Figure 6.10). TLR2-expressing cells were treated with L-SF and DL-SF (0.5, 2, 5 
and 10µM) in the presence or absence of 15pg/ml FSL-1 for 24 hours. Both 5 and 10µM L-
SF and DL-SF consistently demonstrated a significant suppression of NF-κB activity 
induced in response to 15pg/ml FSL-1 (Figure 6.11). 
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Figure 6.11. L-SF and DL-SF are able to significantly suppress FSL-1-induced NF-κB 
activity in HEK-Blue
TM
-hTLR2 cells. HEK-Blue
TM
-hTLR2 cells were treated with FSL-1 
(15pg/ml; vehicle control for FSL-1 = endotoxin-free water) in the presence or absence of 
A) L-SF or B) DL-SF (0.5, 2, 5 or 10µM; vehicle control for L-SF and DL-SF = < 0.1% 
(v/v) DMSO) for 24 hours. Cell culture supernatant was added to QUANTI-Blue
TM
 solution 
until colour change was evident (pink to purple blue, caused by the activity of SEAP). The 
colour change induced by SEAP was analysed as a measure of NF-κB activity at 650nm 
using a spectrophotometer. Data shown = mean ± SEM, n = 3. **p<0.01, and ***p<0.001, 
comparison to 0pg/ml for –FSL-1 and +FSL-1 conditions separately or as annotated. 
 
 
6.2.5. Effect of SF on NF-κB activity in NOD2 wildtype and mutant G908R cells 
As explained previously, NOD2 is another example of a PRR like TLR2 and TLR4, but 
differs in terms of its location. While the TLRs are anchored to the cell membrane and are 
bound by their specific ligands extracellularly, the NOD2 receptor is found intracellularly 
[19]. NOD2 has been commonly implicated in Crohn’s disease and one of the mutants 
commonly found in higher prevalence in patients suffering from the chronic inflammatory 
disease is characterised by the SNP, G908R [51, 53, 54]. 
 
The ligand for the NOD2 receptor is MDP, a breakdown product of PGN which is found in 
the cell walls of both Gram-positive and Gram-negative bacteria [19]. MDP is the minimum 
structure required to activate the NOD2 receptor [19].To determine the concentrations of 
MDP sufficient to induce NF-κB activity via NOD2 signalling, cells expressing either the 
wildtype NOD2 or mutant G908R NOD2 were treated with MDP (0.2, 1 and 4µg/ml) for 24 
hours before measuring NF-κB activity. A concentration of 0.2µg/ml MDP was sufficient to 
induce NF-κB activity in cells expressing the wildtype NOD2 receptor (Figure 6.12A) and 
in cells expressing the mutant G908R NOD2 receptor (Figure 6.12B). 
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Figure 6.12. MDP significantly induces NF-κB activity in cells expressing wildtype (A) 
and mutant G908R (B) NOD2. HEK-Blue
TM
-hNOD2 wildtype cells (A) or HEK293 cells 
stably transfected with NOD2 G908R (B) were treated with MDP (0.2, 1 and 4µg/ml; 
vehicle control for MDP = endotoxin-free water) for 24 hours. Cell culture supernatant was 
added to QUANTI-Blue
TM
 solution (until colour change was evident (pink to purple blue, 
caused by the activity of SEAP). The colour change induced by SEAP was analysed as a 
measure of NF-κB activity at 650nm using a spectrophotometer. Data shown = mean ± 
SEM, n = 3. Data was statistically analysed using one-way ANOVA followed by the 
Bonferroni multiple comparison test.  *p<0.05 and ***p<0.001 vs. 0µg/ml. 
 
 
To establish whether the G908R mutation within the NOD2 receptor had an effect on the 
extent of NF-κB activation in response to MDP, levels of NF-κB activity were compared 
between cells expressing the wildtype NOD2 receptor and the mutant G908R receptor. At 
concentrations of 1 and 4µg/ml, cells expressing the wildtype NOD2 receptor demonstrated 
significantly higher levels of NF-κB activity in response to MDP than in cells expressing the 
mutant G908R receptor (Figure 6.13). 
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Figure 6.13. Mutant G908R NOD2 cells are less responsive to MDP induction of NF-κB 
activity. HEK-Blue
TM
-hNOD2 wildtype cells or HEK293 cells stably transfected with 
NOD2 G908R were treated with MDP (0.2, 1 and 4µg/ml; vehicle control for MDP = 
endotoxin-free water) for 24 hours. Cell culture supernatant was added to QUANTI-Blue
TM
 
solution until colour change was evident (pink to purple blue, caused by the activity of 
SEAP). The colour change induced by SEAP was analysed as a measure of NF-κB activity 
at 650nm using a spectrophotometer. Data shown = mean ± SEM, n = 4. Data was 
statistically analysed using two-way ANOVA followed by the Bonferroni multiple 
comparison test. ****p<0.001 G908R vs. wildtype for 1 and 4µg/ml MDP 
 
 
To establish the effect of L-SF and DL-SF on NOD2 signalling, cells expressing the 
wildtype NOD2 receptor were treated with L-SF or DL-SF (0.5, 2, 5 and 10µM) in the 
presence or absence of 0.2µg/ml MDP for 24 hours. Concentrations of 5 and 10µM of both 
L-SF and DL-SF significantly suppressed MDP-induced NF-κB activity (Figure 6.14). In 
HEK-Blue
TM
-hNOD2 wildtype and G908R cells, 2 and 5µM SF consistently induced a 
significant increase in the constitutive levels of NF-κB activity in cells expressing the 
wildtype NOD2 receptor (Figure 6.14). The absolute change observed with these 
concentrations of SF in the absence of MDP is small and while these changes are statistically 
significant, they are unlikely to be biologically relevant.  
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Figure 6.14. L-SF and DL-SF are able to significantly suppress MDP-induced NF-κB 
activity in HEK-Blue
TM
-hNOD2 wildtype cells. HEK-Blue
TM
-hNOD2 wildtype cells were 
treated with MDP (0.2µg/ml; vehicle control for MDP: endotoxin-free water) in the presence 
or absence of A) L-SF or B) DL-SF (0.5, 2, 5 or 10µM; vehicle control for L-SF and DL-SF 
= < 0.1% (v/v) DMSO) for 24 hours. Cell culture supernatant was added to QUANTI-
Blue
TM
 solution until colour change was evident (pink to purple blue, caused by the activity 
of SEAP). The colour change induced by SEAP was analysed as a measure of NF-κB 
activity at 650nm using a spectrophotometer. Data shown = mean ± SD, representative of 
three independent experiments. Data was statistically analysed using one-way ANOVA 
followed by the Bonferroni multiple comparison test with –MDP and +MDP analysed 
separately. *p<0.05, ** p<0.01, ***p<0.001 comparison to 0µM for –MDP and +MDP 
conditions or as annotated. 
 
 
The effect of L-SF and DL-SF was further investigated in cells expressing the mutant 
G908R NOD2 receptor. G908R-expressing cells were treated with either L-SF or DL-SF 
(0.5, 2, 5 and 10µM) in the presence or absence of 0.2µg/ml MDP for 24 hours. 
Concentrations from 2µM of both L-SF and DL-SF demonstrate consistent significant 
suppressions of MDP-induced NF-κB activity (Figure 6.15). 10µM of L-SF and DL-SF also 
induced a significant decrease in the constitutive levels of NF-κB activity in cells expressing 
the mutant G908R NOD2 receptor (Figure 6.15). 
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Figure 6.15. L-SF and DL-SF are able to significantly suppress MDP-induced NF-κB 
activity in NOD2 G908R cells. HEK293 cells stably transfected with NOD2 G908R were 
treated with MDP (0.2µg/ml; vehicle control for MDP: endotoxin-free water) in the presence 
or absence of A) L-SF or B) DL-SF (0.5, 2, 5 or 10µM; vehicle control for L-SF and DL-SF 
= < 0.1% (v/v) DMSO) for 24 hours. Cell culture supernatant was added to QUANTI-
Blue
TM
 solution until colour change was evident (pink to purple blue, caused by the activity 
of SEAP). The colour change induced by SEAP was analysed as a measure of NF-κB 
activity at 650nm using a spectrophotometer. Data shown = mean ± SD, representative of 
three independent experiments. Data was statistically analysed using one-way ANOVA 
followed by the Bonferroni multiple comparison test with –MDP and +MDP analysed 
separately. ***p<0.001 comparison to 0µM for –MDP and +MDP conditions separately or 
as annotated. 
 
 
Finally, the level of NF-κB activity suppression seen with L-SF and DL-SF was compared in 
cells expressing the wildtype and mutant G908R NOD2 receptor. The comparison identified 
a greater suppression of NF-κB activity in cells expressing the G908R NOD2 receptor with 
both L-SF and DL-SF, compared to the levels of suppression observed in cells expressing 
the NOD2 wildtype receptor (Figure 6.16).  
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Figure 6.16. Significant differences were seen in the response L-SF (A) and DL-SF (B) 
by cells expressing either the wildtype or mutant G908R NOD2 receptor. HEK-Blue
TM
-
hNOD2 wildtype cells or HEK293 cells stably transfected with NOD2 G908R were 
compared in terms of their responses to A) L-SF or B) DL-SF (0.5, 2, 5 and 10µM SF; 
vehicle control for L-SF and DL-SF = < 0.1% (v/v) DMSO) in the presence of 0.2µg/ml 
MDP (vehicle control for MDP = endotoxin-free receptor) for 24 hours. Cell culture 
supernatant was added to QUANTI-Blue
TM
 solution until colour change was evident (pink to 
purple blue, caused by the presence of SEAP). The colour change induced by SEAP was 
analysed as a measure of NF-κB activity at 650nm using a spectrophotometer. Data shown = 
mean ± SD, representative of three independent experiments. Data was statistically analysed 
using two-way ANOVA followed by the Bonferroni multiple comparison test. *p<0.05, 
**p<0.01 and ***p<0.001 as annotated.  
 
 
6.2.6. Comparison of the effects of L-SF and DL-SF on NF-κB activity 
An additional aim for this chapter was to determine whether there were any significant 
differences in the extent of effects seen with the naturally occurring L-SF isomer from 
broccoli and the synthetic analogue, DL-SF. For each of the cell lines, both the L-SF and 
DL-SF forms were able to suppress NF-κB activity induced as a result of ligand treatment. 
When L-SF and DL-SF were compared for all experiments, no significant differences were 
seen in the level of suppression. Figure 6.17 shows a representative example of the 
comparative analysis.  
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Figure 6.17. L-SF and DL-SF show no significant differences between their effects on 
ligand-induced NF-κB activity. Cells were treated with the appropriate ligand in the 
presence or absence of L-SF or DL-SF (0.5, 2, 5 or 10µM; vehicle control for L-SF and DL-
SF = < 0.1% (v/v) DMSO) for 24 hours. Cell culture supernatant was added to QUANTI-
Blue
TM
 solution until colour change was evident (pink to purple blue, caused by the activity 
of SEAP). The colour change induced by SEAP was analysed as a measure of NF-κB 
activity at 650nm using a spectrophotometer. Data shown = mean ± SEM, n = 3. Data is 
from an experiment with HEK-Blue
TM
-hTLR2 cells treated with FSL-1 and is representative 
of all comparative analyses in all cell types. Data was statistically analysed using two-way 
ANOVA followed by the Bonferroni multiple comparison test. 
 
 
6.3. Discussion 
Within this chapter, the effect of L-SF and DL-SF was investigated on the TLR4, TLR2 and 
NOD2 signalling pathways (Figure 6.1). The reason for focusing on the TLR4, TLR2 and 
NOD2 signalling pathways is due to identified associations with chronic inflammatory 
pathologies such as the IBDs Crohn’s disease and UC, CVD, obesity, T2DM, metabolic 
syndrome and cancer [36, 44, 48-50, 54-62, 242-244, 246-249].  
 
With the use of a cell model that specifically expressed the TLR4 receptor, more information 
about the effect of SF on TLR4 signalling can be obtained. In Chapters 3 and 4, the effect of 
SF on LPS-induced cytokine production and global gene expression was investigated. In the 
previous chapters, the physiologically relevant concentration of 1ng/ml LPS was used to 
induce cytokine secretion and expression. However, in Chapters 3 and 4, the human 
monocytic THP-1 cell model was used and as this cell type is fundamentally important in the 
rapid response to an inflammatory attack, it was expected that there would be a high level of 
sensitivity to PAMPs such as LPS. Less was known about the HEK293 cells and their ability 
to respond to LPS.  
 
Both L-SF and DL-SF were able to significantly suppress LPS-induced NF-κB activity in 
TLR4-expressing cells. In Chapter 3, SF suppressed LPS-induced cytokine production in 
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THP-1 monocytes to a much greater extent, by almost 100% in some cases. This variability 
in the level of suppression seen with SF may be due to the measurements that were taken 
e.g. NF-κB activity versus ELISA for specific cytokines, the different cell types e.g. HEK-
Blue
TM
 transfected cells versus THP-1 monocytes which endogenously express the PRRs, as 
well as the associated sensitivity levels of the cells. The production of cytokines is controlled 
by NF-κB and AP-1 activity. In this chapter, the activity of NF-κB has been studied alone, 
thus the lesser suppression seen with SF on NF-κB activity compared to in Chapters 3 and 4 
on cytokine expression and secretion, is potentially due to the lack of consideration for 
potential suppression of AP-1 activity. The results from this chapter do however provide 
further support for the hypothesis that SF is able to directly target the TLR4 signalling 
pathway.  
 
As previously mentioned, TLR4 polymorphisms, D299G and T399I have been associated 
with IBDs [54-62], but conversely, there is an indication that these polymorphisms may 
confer protection against T2DM [244]. In HEK293 cells transiently transfected with the 
wildtype or mutant (D299G and T399I) TLR4 receptors, NF-κB activity was significantly 
induced by 1.5-fold in response to 1ng/ml LPS (Figure 6.5). When HEK293 cells were 
stably transfected with TLR4, the response to LPS was greater with around a 3.5-fold 
increase in NF-κB activity (Figure 6.3). This large difference in LPS response is likely a 
result of lower transfection efficiency with the transient transfection method as opposed to 
stable transfection. During transient transfection, the foreign DNA is not integrated into the 
host genome and after several days, expression of the foreign DNA is eliminated from the 
cells through cell division. When cells are stably transfected, the foreign DNA is integrated 
into the host genome meaning the cells can be sub-cultured over time with the transfected 
gene being expressed as an endogenous gene [250]. Thus, cells that are stably transfected 
with TLR4 will demonstrate higher levels of TLR4 expression than the transiently 
transfected TLR4 cells and thus demonstrate a larger induction of NF-κB activity in 
response to LPS (Figures 6.3 and 6.5). 
 
No significant differences were observed in the level of NF-κB induction in response to LPS 
in cells transiently transfected with the D299G and T399I mutants compared to the wildtype 
TLR4 receptor. This disagrees with previous data by Arbour and colleagues who 
demonstrated hypo-responsiveness to LPS inhalation in subjects carrying the D299G and 
T399I mutations and the same was seen with a significantly lower LPS response in THP-1 
cells transfected with the D299G mutant [248]. However, the inconsistency between the 
results in those two experiments and the results presented in this chapter may be due to using 
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a concentration of LPS 100 times lower than in the study by Arbour [248]. In addition, no 
differences were observed in the level of suppression induced by L-SF or DL-SF in cells 
expressing the D299G and T399I TLR4 mutants. This is in support of data shown in Chapter 
5. When a recombinant form of the TLR4 receptor was subjected to SF treatment under non-
reducing conditions, SF was able to target cysteine residues within the receptor at positions 
246 and 609. The D299G and T399I mutations do not involve these cysteine residues and 
the positions of these mutations within the TLR4 receptor are not in close proximity to the 
specific cysteine targets of SF. 
 
To extend the findings from the investigations of SF with the TLR4 signalling pathway, the 
hypothesis that SF was able to additionally exert anti-inflammatory effects on the TLR2 
signalling pathway was tested. As with the TLR4-expressing cells, L-SF and DL-SF were 
able to significantly suppress NF-κB activity induced by Pam3CSK4 (the ligand for 
TLR2/TLR1) and FSL-1 (the ligand for TLR2/TLR6). While in Chapter 5, some evidence 
that SF was able to modify cysteine residues within the extracellular domain of TLR4 was 
produced, similar findings with TLR2 were not observed, likely due to practical 
implications. When the peptide coverage was analysed following LC-MS/MS analysis of the 
enzyme digested TLR2, no cysteines were found within the identified fragments. However, 
based on the data within this chapter, there may be reason for further exploring potential 
interactions between SF and TLR2, which is also supported by previous research [195]. It is 
nevertheless important to note that while the data in this chapter demonstrates a significant 
reduction in NF-κB activity following ligand induction, the suppression could be as a result 
not only of direct interaction of SF with the receptor, but also by SF targeting NF-κB as 
previously reported [184, 189, 191-194], to produce the level of suppression observed. 
 
Finally, the PRR NOD2 was also investigated. In previously published data, HEK293 cells 
transfected with G908R NOD2 receptors have demonstrated a significantly reduced 
response to ligands when compared to cells expressing the wildtype NOD2 receptor [251, 
252]. However, the reduced response to MDP in G908R cells seen in this study is more 
modest than the large reductions seen previously [251, 253]. Another study that monitored 
the NF-κB activity in response to MDP treatment in cells expressing the wildtype or G908R 
mutant receptor by Lecine and colleagues presented more comparable data to the results 
shown in this chapter. Only a small reduction was observed in the response to MDP at a 
concentration of 50ng/ml, a concentration four times smaller than the lowest concentration 
used in the studies presented in this chapter [254]. 
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As reported with TLR4 and TLR2-expressing cells, L-SF and DL-SF were also able to 
suppress MDP-induced NF-κB activity in the wildtype and G908R mutant NOD2 cells, with 
a larger suppression observed in the G908R cells. These differences in the level of 
suppression may be due to the positions of the SNP G908R mutation reducing the affinity of 
a potentially direct interaction with the SF as a result of the large difference in the properties 
of the amino acids involved in the substitution if the mechanism seen with the TLR4 is 
consistent with NOD2 (Chapter 5, [195]). 
 
From a practical standpoint, the results within this chapter have confirmed that it is not 
necessary to use the natural L-SF from broccoli in preference to the synthetic analogue DL-
SF. In all cell models studied, no significant differences were seen in the level of 
suppression of ligand-induced NF-κB activity with the two SF forms tested (Figure 6.17). 
While these results confirm they behave in the same way functionally, there are advantages 
for using each form. While the L-SF is directly relevant to the form found in human 
systemic circulation following the consumption of broccoli, the synthetic DL-SF is 
substantially less expensive to use. 
 
Based on the results presented in this chapter, it can be concluded that SF has the ability to 
target a number of different inflammatory signalling pathways. This chapter has confirmed 
that SF’s ability to significantly suppress the effect of ligand induction on cytokine 
production, global gene expression or NF-κB activity is not restricted to the TLR4 pathway. 
These findings are of critical importance to provide support for the use of SF as a suppressor 
of chronic inflammation due to its breadth of targets which are able to respond to many 
different stimuli.  
 
 
6.4. Conclusions 
In summary, the use of physiologically relevant concentrations of either L-SF or DL-SF was 
able to cause significant suppression of ligand-induced NF-κB activity. This function of SF 
was not restricted to TLR4 signalling, but was also observed with TLR2 and NOD2 
signalling, two additional pathways that are associated with chronic inflammatory 
pathologies such as IBDs, CVD and T2DM. Common TLR4 variants, D299G and T399I, 
which have been identified at a higher prevalence in patients with IBD were not found to 
vary in their response to LPS or SF as compared to cells expressing the wildtype form of 
TLR4. 
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SF was also able to suppress NF-κB activity induced in response to the specific ligands in 
TLR2-expressing cells and NOD2 wildtype or G908R-expressing cells. In cells expressing 
the G908R NOD2 receptor, lower levels of NF-κB activity induction was observed in 
response to higher concentrations of MDP and these cells were significantly more sensitive 
to SF as compared to cells expressing the wildtype NOD2. These results suggest that SF 
would be able to target the inflammatory signalling important in subjects with and without 
mutations within their PRRs, but may be able to selectively target patients with the G908R 
mutation to a greater extent to act as a suppressor of pro-inflammatory signalling associated 
with Crohn’s disease.  
 
In order to further this work, the next chapter investigates the effect of SF in a translational 
in vitro model involving human SGBS adipocyte cells, firstly in terms of the effects SF can 
exert on lipid metabolism in adipocytes (Chapter 7) followed by investigations into the 
effect of SF in response to MaCM treatment of these human adipocytes, a model which 
provides a good representation of the chronic adipose tissue inflammation in individuals 
suffering from obesity (Chapter 8). 
.  
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7.0. Introduction 
In the research presented so far, it has been demonstrated that SF can behave as an anti-
inflammatory agent by targeting a number of inflammatory signalling pathways e.g. TLR4, 
TLR2 and NOD2 in order to suppress NF-κB activity, pro-inflammatory gene expression 
and cytokine secretion. In the final two chapters, this research was translated into a more 
complex model of chronic inflammation with relevance to obesity.  
 
Obesity is characterised by an increase in fat mass as a result of the enlargement and 
hyperplasia of adipocytes within the adipose tissue. In particular, an increase in abdominal 
obesity and visceral fat is significantly associated with an increased risk of developing 
chronic disorders [255, 256]. The enlargement of adipocytes is as a result of an elevation in 
the levels of accumulated triglycerides following increased dietary consumption. In the 
adipose tissue of a lean individual, triglyceride stores within the adipocytes are released into 
circulation where they are transported to organs with increased energy demands. 
Triglycerides are utilised as an energy source, with breakdown resulting in metabolism 
through β-oxidation to produce intermediates for the TCA cycle and electron transport chain 
[84]. In an obese individual, the large increase in accumulation of triglycerides outweighs 
the rate of β-oxidation, which results in the lipolysis of triglycerides and an increase in FFAs 
in circulation [88]. Elevated levels of FFAs have been consistently identified in patients 
suffering from obesity and insulin resistance [85, 86, 257].  
 
To date, there is no commercially available human adipocyte cell line and in much of the 
literature investigating adipose tissue biology, the murine 3T3-L1 cell line is used. In this 
thesis so far, only cell lines of human origin have been studied and thus the aim was to 
continue with the use of human adipocytes, due to the known inconsistencies in the 
behaviours of cells from murine and human origin [258]. Primary human preadipocytes are 
either commercially available or obtained from human subjects if ethical approval is given, 
however there are disadvantages associated: high levels of variability between individuals 
would potentially be observed; primary human preadipocytes have a low differentiation 
capacity after sub-culturing several times; there may be a limited supply of material and 
large costs would be incurred.  
 
In recent studies into adipocyte biology, a human preadipocyte cell line developed by 
Wabitsch and colleagues has become more commonly used [200]. The cells were isolated 
from an infant suffering from Simpson-Golabi-Behmel Syndrome, a condition characterised 
by increased levels of pre- and postnatal growth, and patients often demonstrate large 
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adipose tissue depots [200]. When preadipocytes were isolated, these cells were able to be 
sub-cultured many times and maintained their capacity to differentiate up to generation 50. 
Once fully differentiated, via an insulin-dependent process, (see section 2.2.4), mature fat 
cells that were biochemically and functionally similar to primary human adipocytes were 
obtained [200]. 
 
One particular research question investigated in this chapter was the effect of SF on the 
differentiation of human SGBS preadipocytes. During the differentiation process of 
preadipocytes, there is a distinct increase in the levels of accumulated lipids within the cells. 
SF has been previously shown to reduce the level of lipid accumulation within murine 3T3-
L1 cells at concentrations of 10µM SF and above [162, 164, 259-261]. As yet, no studies 
have been carried out investigating the effect of SF on adipocytes of human origin. One 
study hypothesised that the reduction in lipid accumulation with SF in 3T3-L1 cells was as a 
result of inducing lipolysis [163] and thus in this chapter the aim was to investigate whether 
SF was able to suppress lipid accumulation within adipocytes by inducing lipolysis. It was 
thought that this research question could provide potential support for how supplementation 
with high concentrations of SF was able to suppress weight gain, adipogenesis and liver 
triglyceride accumulation in mice subjected to a high-fat diet [161], but with the use of more 
physiologically relevant concentrations of SF. 
 
 
7.1. Materials and Methods 
The human SGBS adipocyte cells were used throughout this chapter (section 2.2.4). SGBS 
preadipocytes were differentiated in the presence of SF (2, 5 and 10µM) and Oil Red O 
staining and an assay to determine the glycerol concentration within the media was carried 
out to investigate effects on lipid accumulation and lipolysis within the cells (section 2.10). 
Additionally, RNA was extracted at days 10 and 14 of the differentiation process to monitor 
the expression level of CPT1A to investigate if SF had any effects on the metabolism of 
lipids (section 2.5).  
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7.2. Results 
7.2.1. Effect of SF on human SGBS cells 
7.2.1.1. Effect of SF on SGBS preadipocyte and adipocyte cell viability 
To determine the concentrations of SF that were appropriate for use with the SGBS cell line 
as preadipocytes and differentiated adipocytes, a WST-1 cell viability assay was carried out. 
SGBS cells were subjected to SF treatment over a wide range of concentrations (0-200µM) 
for 24 hours before determining the level of cell viability. Concentrations of SF from 15µM 
significantly reduced SGBS preadipocyte cell viability (Figure 7.1A). SGBS adipocytes 
behaved very differently in response to SF with concentrations up to 10µM dramatically 
increasing cell viability in adipocytes relative to the untreated cells. A significant decrease in 
cell viability was not seen until concentrations of SF reached 125µM and above (Figure 
7.1B). The IC50 for the preadipocytes was calculated at 24.4 ± 5.4µM while for the mature 
adipocytes this was much higher at 92.8 ± 15.4µM.  
Figure 7.1. Effect of SF on SGBS cell viability. A) SGBS preadipocytes were treated with 
SF (0-200µM; vehicle control for SF = < 0.1% (v/v) DMSO) for 24 hours. B) SGBS 
preadipocytes were chemically differentiated over 14 days resulting in mature adipocytes 
(see section 2.2.4). On day 14, mature SGBS adipocytes were treated with SF (0-200µM; 
vehicle control for SF = < 0.1% (v/v) DMSO) for 24 hours. Once treatment was complete, 
10µl WST-1 reagent was added to each well (see section 2.3). The plates were incubated at 
37°C and measured using a spectrophotometer every 15 minutes. Data shown is from the 1.5 
hour measurement at which the levels of absorbance were all measurable and consistent. 
Data shown = mean ± SD and is representative of two independent experiments. Data was 
statistically analysed using one-way ANOVA followed by Bonferroni multiple comparison 
tests. *p<0.05, **p<0.01 and ***p<0.001 vs. 0µM SF. 
 
 
7.2.1.2.  Effect of SF on lipid accumulation in SGBS cells  
When SGBS preadipocytes were chemically differentiated, the cells gradually accumulated 
intracellular lipid droplets. This level of lipid accumulation was measured using Oil Red O, 
a dye which is able to enter the cells and stain the intracellular lipids (Figure 7.2). The 
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advantage with using Oil Red O staining is not only that lipid accumulation can be clearly 
seen visually as shown in Figure 7.2, but the stain can be eluted from inside the cells and 
quantified using an absorbance-based assay. Throughout the 14 day differentiation period, 
there was a significant increase in the level of lipid accumulation, demonstrated by an 
increasing level of Oil Red O staining, an observation that is indicative of successful 
differentiation (Figure 7.3).  
 
Figure 7.2. Intracellular lipids accumulate within SGBS cells during differentiation. 
SGBS preadipocytes were chemically differentiated as described in section 2.2.4 and on 
days 0, 4, 7, 11 and 14, cells were fixed with 10% formalin and stained with Oil Red O. 
Photographs were taken using a light microscope following staining at a magnification of 
10X.  
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Figure 7.3. Intracellular lipid accumulation increased over the differentiation process 
of SGBS cells. SGBS preadipocytes were chemically differentiated as described in section 
2.2.4 and on days 0, 4, 8, 11 and 15, cells were fixed with 10% formalin and stained with Oil 
Red O. After excess dye was removed, the stain was eluted from the cells with 100% 
isopropanol and absorbance was measured at 500nm. Absorbance was corrected against 
100% isopropanol from an unstained well. Data shown = mean ± SEM; n = 2. Data was 
statistically analysed using a one-way ANOVA followed by Bonferroni multiple comparison 
tests. **p<0.01 and ***p<0.001 vs. Day 0. 
 
 
 
During the differentiation process, SGBS preadipocytes were treated with SF (2, 5 and 
10µM) and the level of lipid accumulation was measured at day 0, 4, 7, 11 and 14, to 
investigate whether SF could affect adipogenesis. 10µM SF significantly suppressed the 
level of lipid accumulation in SGBS cells from day 11 onwards (Figure 7.4). This 
significant reduction could be seen visually from microscope photographs at days 11 and 14 
(Figure 7.5).  
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Figure 7.4. 10µM SF significantly suppresses lipid accumulation of SGBS cells. SGBS 
preadipocytes were chemically differentiated in the presence or absence of SF (2, 5 and 
10µM; vehicle control for SF = < 0.1% (v/v) DMSO). At days 0, 4, 7, 11 and 14, cells were 
fixed with 10% formalin and stained with Oil Red O. After excess dye was removed, the 
stain was eluted from the cells with 100% isopropanol and absorbance was measured at 
500nm. Absorbance was corrected against 100% isopropanol from an unstained well. Data 
shown = mean ± SD and is representative of two independent experiments. Data was 
statistically analysed using a two way ANOVA followed by Bonferroni multiple comparison 
tests. **** p<0.0001 for 10µM SF compared to the control on each day as annotated. 
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Figure 7.5. Lipid accumulation was reduced in SGBS adipocytes differentiated in the 
presence of 10µM SF. SGBS preadipocytes were chemically differentiated in the presence 
or absence of SF (2, 5 and 10µM; vehicle control for SF = < 0.1% (v/v) DMSO). At days 0, 
4, 7, 11 and 14, cells were fixed with 10% formalin and stained with Oil Red O. Photographs 
were taken using a light microscope following staining at a magnification of 10X. Data 
shown from Control and 10µM SF only at days 11 and 14. 
 
 
7.2.1.3. Effect of SF on CPT1A expression 
The decrease in lipid accumulation induced by 10µM SF at days 11 and 14 of differentiation 
(Figure 7.4 and 7.5) could be due to an increase in lipolysis of the fat droplets that increase 
within the adipocytes during the differentiation process (Figure 7.2 and 7.3). Lipolysis has 
previously been highlighted as a potential mechanism for SF, and if so this would result in 
an increase in the levels of FFAs within the cells [163]. It was hypothesised that in order to 
prevent the FFAs behaving as a pro-inflammatory stimulus within the cells, the SGBS cells 
would metabolise them and use as an energy source. An enzyme fundamental to the fatty 
acid β-oxidation process is CPT1A, which behaves to transfer the long-chain fatty acyl 
group to carnitine allowing the fatty acids to be shuttled into the mitochondria [88, 89]. 
 
SGBS preadipocytes were treated with SF (2, 5 and 10µM) over the 14 day differentiation 
period and RNA was extracted from the cells at days 10 and 14 in order to quantify the 
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levels of CPT1A expression by real-time RT-PCR. 10µM SF significantly induced CPT1A 
expression at both days 10 and 14 (Figure 7.6).  
 
Figure 7.6. 10µM SF significantly induces CPT1A expression in SGBS cells. SGBS 
preadipocytes were chemically differentiated in the presence or absence of SF (2, 5 and 
10µM; vehicle control for SF = < 0.1% (v/v) DMSO). At days 10 (A) and 14 (B), RNA was 
extracted, quantified and analysed by real time RT-PCR. Data shown = mean ± SD. Data 
was statistically analysed using one-way ANOVA followed by Bonferroni multiple 
comparison tests. *** p<0.001 as annotated. 
 
 
7.2.1.4. Effect of SF on glycerol release 
As a result of lipolysis, the glycerol backbone of a triglyceride molecule is secreted by the 
cells and can be measured free in cell culture supernatants [163]. The hypothesis was that 
glycerol would be found at increased levels in the cell culture supernatant from cells treated 
with 10µM SF at days 10 and 14, consistent with SF inducing lipolysis. However, when the 
levels of glycerol were measured, no significant differences were seen with SF treatment at 
days 10 or 14 (Figure 7.7).  
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Figure 7.7. SF caused no significant changes in the levels of glycerol released by SGBS 
cells. SGBS preadipocytes were chemically differentiated in the presence or absence of SF 
(2, 5 and 10µM; vehicle control for SF = < 0.1% (v/v) DMSO). At days 10 (A) and 14 (B), 
cell culture supernatant was collected and cleared by centrifugation before analysis with a 
Glycerol Assay Kit (Cambridge Bioscience Limited, Cat. # 10010755). Data shown = mean 
± SD and is representative of two independent experiments. Data was analysed using one-
way ANOVA followed by Bonferroni multiple comparison tests.  
 
 
7.3. Discussion 
In order to translate results observed in the previous chapters into a translational model of 
chronic inflammation, human SGBS adipocytes were investigated. In this chapter, the effect 
of SF alone on differentiation of the preadipocytes was investigated with measurements 
involved in lipid accumulation.  
 
When the mature SGBS adipocytes were monitored in terms of their response to SF, there 
were very different results. Concentrations up to 10µM were able to induce large significant 
increases in cell viability, with concentrations of 5 and 10µM SF demonstrating a 50% 
increase. Potential reasons for this could be due to the high level of accumulated lipids 
within these cells, which could potentially interfere with absorbance readings. Visually, it 
did not appear that low concentrations of SF led to a larger population of cells relative to the 
control which could increase the cell viability reading, however, absolute cell numbers were 
not measured. It is important to note that the WST-1 assay is not a direct measurement of 
viability even though it is widely used as a representation. It behaves to measure the 
conversion of a tetrazolium salt to a coloured formazan compound (Figure 2.1, see section 
2.3 for more details). This is controlled by mitochondrial dehydrogenase enzymes and 
results in the formation of NADPH. SF has been previously shown to have roles in NADPH 
flux (Chapter 4, Figure 4.2), and therefore, the mature SGBS adipocyte cells may be highly 
sensitive to SF altering NADPH production resulting in an inaccurate reading of metabolic 
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activity. For these reasons it may be more appropriate to use a different assay or method e.g. 
flow cytometry in order to determine the cell viability of the mature adipocyte SGBS 
population in response to SF. 
 
When the SGBS preadipocytes were exposed to SF (2, 5 and 10µM) throughout the 
differentiation period, there was a significant reduction in intracellular lipid accumulation by 
over 40% with 10µM SF at days 11 and 14 (Figure 7.4) and no significant effect on glycerol 
release, a measure of lipolysis (Figure 7.7), but a significant increase in CPT1A expression 
was observed in response to 10µM SF (Figure 7.5). A decrease in Oil Red O staining was 
previously found in research using the mouse fibroblast 3T3-L1 cell line, where 
concentrations of 10µM SF and above are able to significantly suppress differentiation of the 
cells [162, 164, 259-261]. The findings of no effect on glycerol release was in contrast to 
findings in murine 3T3-L1 cells in which an increase in glycerol levels in response to SF at 
concentrations of 5µM and above was demonstrated, however this previous study did 
demonstrate a significant induction in CPT1A expression [163]. These results provide 
support for utilisation of lipids in order to prevent the induction of an inflammatory 
response.  
 
In order to continue investigations into the mechanism of SF an additional method that could 
be used is the measure of intracellular triglycerides, not via Oil Red O staining but with a 
more direct and quantitative method by extracting the intracellular lipids from the cells. SF 
was found to significantly reduce the levels of triglyceride accumulation in murine 3T3-L1 
cells [162, 164, 259-261]. Additionally, similar findings were observed in vivo within the 
livers of CYP2E1 knock-in mice [262] and C57BL/6N mice subjected to a high-fat diet in 
the presence or absence of SF [161].  
 
The subsequent hypothesis was that 10µM SF reduced the level of adipocyte differentiation 
as a result of suppressing lipid accumulation. Previous literature supports this hypothesis, for 
example in the study by Choi and colleagues, there was little effect of SF on lipid 
accumulation if cells were exposed to SF at later stages of adipogenesis, whereas at earlier 
stages, SF completely blocked the differentiation process [164]. The group expanded this 
work with a more recent in vivo study in mice, in which they investigated the effect of SF in 
combination with a high-fat diet over 6 weeks. SF (1g/kg body weight) significantly 
suppressed body weight gain, decreased perirenal and epididymal adipose tissue weight, 
liver weight and fat accumulation in the liver, in addition to total cholesterol, serum glucose 
and leptin when compared to the mice subjected to the high-fat diet alone [161]. While this 
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study provides a convincing argument for the use of SF as an anti-obesity agent, the 
concentration of SF used here is far higher than could be achieved following the 
consumption of broccoli. A previous study by Souza and colleagues used a concentration of 
SF at 1mg/kg body weight, 1000 times lower than the study by Choi and colleagues, and 
found that SF accentuated blood glucose impairments induced by a highly palatable diets in 
Wistar rats [263]. Nevertheless, it is important to remember that it is very difficult to directly 
compare the concentrations of SF administered in rodent models with relevance to broccoli 
consumption in humans. While Souza and colleagues found no significant changes in 
adipogenesis in rats [263], there is a distinct lack of similar studies for comparison, and there 
is no evidence to suggest that lower concentrations could not achieve comparable results to 
those seen in the study by Choi and colleagues. However, it is thought that these findings 
may be largely under-reported, with the hypothesis that the large reductions seen in the study 
by Choi and colleagues may be due to potential toxicity effects.  
 
In terms of the mechanism for how SF may affect adipogenesis, previous research indicated 
a link with the Nrf2 pathway [259-262, 264, 265]. The results in this chapter suggest that 
Nrf2 is an inhibitor of adipogenesis. The discussion of the role of Nrf2 was based on a 
number of studies with largely contradictory arguments [264]. In a study by Pi and 
colleagues, knockdown of Nrf2 in mice fed a high-fat diet resulted in a decrease in adipose 
tissue depots and protected against obesity. With an overexpression of Nrf2 by knockdown 
of Keap1, there was an accelerated response to hormone-induced adipocyte differentiation, 
suggesting that Nrf2 augmented adipocyte differentiation [266]. Conversely, in a study by 
Shin and colleagues there was a significantly accelerated rate of differentiation in 
immortalised mouse embryonic fibroblasts (MEFs) isolated from mice with a knockdown of 
Nrf2. Additionally, a significantly slower rate of differentiation was observed in MEFs 
isolated from mice with a knockdown of Keap1 and hence an increased level of Nrf2 activity 
[267]. The differing findings in this area of research may be as a result of using variations in 
the study models, e.g. primary cultures as opposed to immortalised cells, murine versus 
human cultures, and different methods of activating or inactivating Nrf2 activity. 
 
While the evidence is contradictory, several studies have been discovered to support the 
findings within this chapter however, little of the previous research carried out investigated 
the effect of SF on adipogenesis in cell models of human origin. Based on the research 
published until now, no previous studies have been carried out monitoring the effect of SF 
on lipid accumulation in human adipocytes as presented in this chapter, either with a cell 
line or primary cells. More research should be carried out in this area to determine whether 
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species differences play a role in determining the effect of Nrf2 activation in response to SF 
on adipogenesis and more endpoints studied to try and ascertain the mechanistic details 
involved. 
 
In the final chapter, the ability of SF to target the increased pro-inflammatory state observed 
in obese individuals, was investigated. The effect of SF was investigated on cytokine 
production induced in a model of human adipose tissue inflammation. 
 
 
7.4. Conclusion 
It is apparent from the results in this chapter that 10µM SF was able to suppress 
adipogenesis by reducing the level of lipid accumulation within the SGBS cells during 
differentiation. An elevation in the levels of CPT1A expression, an important enzyme in β-
oxidation was observed and it was hypothesised to be as a result of increased levels of FFA 
release due to an induction of lipolysis. Measurements of free glycerol demonstrated no 
changes in response to SF, suggesting that SF is not inducing lipolysis. A potential 
mechanism for this function of SF is the activation of Nrf2, which in turn controls a number 
of enzymes involved in lipid metabolism.  
 
In the next chapter, the effect of SF will be investigated on cytokine production in a model 
of human adipose tissue inflammation, a condition commonly observed in individuals that 
are obese, using the human SGBS adipocytes exposed to MaCM from the human THP-1 
macrophages.  
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8.0. Introduction 
In the previous chapter, the suppression of lipid accumulation by SF at the concentration of 
10µM in SGBS adipocytes has been described. This effect could be potentially related to the 
up-regulation of Nrf2 signalling and subsequent increase in expression of genes encoding 
enzymes involved in lipid metabolism, such as CPT1A. Obesity is characterised by an 
increased level of lipid accumulation and an elevated pro-inflammatory status. In this 
chapter, the research question investigated was whether SF could exert anti-inflammatory 
effects to target cytokine production in SGBS adipocytes in response to MaCM from human 
THP-1 macrophages, an in vitro model described as the closest representation of human 
adipose tissue inflammation [258, 268-271]. 
 
The low-grade inflammatory state observed in obese individuals is likely as a result of a 
number of factors. There is a large body of scientific evidence reporting that obese subjects 
present with circulating monocytes in a pro-inflammatory status, higher levels of circulating 
pro-inflammatory cytokines and an increased level of macrophage infiltration within the 
adipose tissue [83, 100-102, 272, 273]. As a results of these factors, it is unsurprising that 
obesity is described as an independent risk factor for a number of chronic diseases such as 
cancer [63-65], CVD [66-70] and T2DM [71]. With the incidence of obesity increasing 
worldwide, its association with the listed chronic pathologies provides support for the strong 
need to prevent or treat obesity and its associated comorbidities. Evidence supporting the 
hypothesis that preventing or treating obesity can reduce the risks of developing more severe 
consequences such as cancer and CVD, comes from studies where the inflammatory status 
of obese individuals has been significantly suppressed in response to weight loss [104-108, 
272]. With these findings and the widely accepted notion that a state of low-grade 
inflammation is the common soil to these chronic diseases, chronic inflammatory signalling 
has become a crucial target for dietary, lifestyle and pharmaceutical interventions [205].  
 
The effects of SF on chronic inflammatory diseases has been previously investigated in vivo 
using mouse models of osteoarthritis [179], cancer [274, 275] and obesity induced in 
response to a high-fat diet [161]. SF demonstrated significant suppressions of a low-grade 
inflammatory state and a reduction in the progression of these conditions. When SF was 
administered in mice following exposure to LPS to mimic an inflammatory response, it was 
able to reduce the level of circulating pro-inflammatory cytokines [195]. These studies do 
however have disadvantages. Firstly, the very high concentrations of SF that were 
administered were not relevant to the potential levels of SF that could be achieved through 
diet [161, 195, 274, 275]. Secondly, several studies administer SF via intraperitoneal 
Effect of SF on adipose tissue inflammation 
 
164 
 
injection instead of supplementing diets with pure SF or broccoli as a source, which is a poor 
representation of how SF would be encountered following broccoli consumption within the 
diet [195, 275]. This literature demonstrates the necessity for further in vivo studies, utilising 
physiologically relevant concentrations of SF, both in mouse models and human studies.  
Following a review of the current literature it was ascertained that the effect of 
physiologically relevant concentrations of SF on a model of human adipose tissue 
inflammation had not been previously investigated in vivo or in vitro. The effect of SF on 
adipocyte biology has been primarily investigated using concentrations of 10µM and above 
in murine cell models [162, 164, 259-261]. Therefore, the aim of this chapter was to 
investigate the effect of physiologically relevant concentrations of SF on adipocyte pro-
inflammatory gene expression in a model of human adipose tissue inflammation and SF’s 
potential mechanistic targets. The dietary bioactives investigated on adipose tissue 
inflammation to date are only grape seed extracts and other polyphenol compounds [269-
271, 276]. Thus, investigating the effect of SF at physiologically relevant concentrations on 
human SGBS adipocytes pro-inflammatory gene expression induced by human THP-1 
MaCM is a novel concept.  
 
 
8.1. Materials and Methods 
For the experiments within these chapters the differentiated THP-1 macrophages and the 
human SGBS cells were used (sections 2.2.1 and 2.2.4). For measurement of cytokine 
secretion, an ELISA was carried out for the specific cytokine (section 2.4) and for the 
expression level, real-time RT-PCR was used with the specific primers and probes for each 
target gene (section 2.5). For assessment of cell viability in response to SF or the MaCM, a 
WST-1 cell viability assay was used (section 2.3). To determine the effect of MaCM on lipid 
accumulation with SGBS cells, Oil Red O staining was used (section 2.10). Determination 
of the TCA intermediates within the MaCM was carried out using LC-MS/MS (section 
2.11).  
 
 
8.2. Results 
8.2.1. Characterisation of THP-1 macrophages 
8.2.1.1. Effect of SF on LPS-induced cytokine secretion  
Before beginning experiments using MaCM, the THP-1 macrophages themselves were 
characterised due to potential differences in the behaviours of macrophages compared to the 
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previously used monocytes (Chapters 3 and 4). To induce differentiation, THP-1 monocytes 
were treated with 125ng/ml PMA for 48 hours in serum-free conditions. Differentiation was 
confirmed by monitoring the change in characteristics of the cells; the monocytes are a 
suspension cell line, while the differentiated macrophages are able to adhere to the plastic of 
the culture vessel (Figure 8.1). 
 
 
 
 
 
 
 
 
 
 
Figure 8.1. THP-1 cell morphology. When cultured in the monocytic form, THP-1 cells 
exist as a suspension. When differentiated with 125ng/ml PMA for 48 hours in serum-free 
conditions, the monocytes differentiate into macrophages and they become adherent to the 
culture vessel.  
 
 
To determine whether THP-1 macrophages were able to respond to LPS in the same way as 
THP-1 monocytes (Chapter 3), macrophages were treated with 1ng/ml LPS in the presence 
or absence of 5µM SF. The cell culture supernatant was collected for measuring cytokine 
secretion. 5µM SF significantly suppressed LPS induction of IL-6, IL-1β and TNFα 
secretion with 12 or 24 hours of exposure (Figure 8.2).  
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Figure 8.2. SF significantly suppresses LPS-induced IL-6 (A + B), IL-1β (C + D) and 
TNFα (E + F) secretion in THP-1 macrophages. THP-1 monocytes were treated with 
125ng/ml PMA for 48 hours to allow differentiation to macrophages. THP-1 macrophages 
were treated with 1ng/ml LPS (vehicle control for LPS = PBS) for 12 hours (A, C and E) or 
24 hours (B, D and F) in the presence or absence of 5µM SF (vehicle control for SF = < 
0.1% (v/v) DMSO). The cell culture supernatant was collected and cytokines were measured 
by ELISA. Data shown = mean ± SD. Data was statistically analysed using one-way 
ANOVA followed by Bonferroni multiple comparisons tests. ** p<0.01 and ***p<0.001 as 
annotated; n.d. not detected. 
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8.2.1.2. Effect of SF on THP-1 macrophage cell viability 
To ensure that the significant suppression observed with SF on LPS-induced cytokine 
secretion was not due to cytotoxic effects, THP-1 macrophages were treated with 
concentrations of SF from 0-200µM for 24 hours before determining cell viability using a 
WST-1 assay. SF was found to significantly reduce cell viability at concentrations of 10µM 
and above (Figure 8.3). The IC50 was calculated at 26.9 ± 5.5µM.  
 
 
 
 
 
 
 
 
 
 
 
Figure 8.3. Effect of SF on cell viability of THP-1 macrophages. THP-1 macrophages 
were treated SF (0-200µM; vehicle control for SF = < 0.1% (v/v) DMSO) for 24 hours. 
After treatment was complete, 10µl WST-1 reagent was added to each well (see section 2.3). 
The plates were incubated at 37°C and measured using a spectrophotometer every 15 
minutes. Data shown is from the 45 minute measurement at which levels of absorbance were 
all measurable and consistent. Data shown = mean ± SD and is representative of two 
independent experiments. Data was statistically analysed using one-way ANOVA followed 
by Bonferroni multiple comparison tests. ***p<0.001 vs. 0µM SF. 
 
 
8.2.1.3. Effect of SF on LPS-induced cytokine expression  
In order to determine whether SF was able to act at a transcriptional level, cytokine 
expression was measured. THP-1 macrophages were treated with 1ng/ml LPS in the 
presence or absence of 5µM SF for 12 or 24 hours before IL-6, IL-1β and TNFα expression 
levels were determined. SF significantly suppressed LPS induction of IL-6, IL-1β and TNFα 
expression (Figure 8.4).  
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Figure 8.4. SF significantly suppresses LPS-induced IL-6 (A + B), IL-1β (C + D) and 
TNFα (E + F) expression in THP-1 macrophages. THP-1 macrophages were treated with 
1ng/ml LPS (vehicle control for LPS = PBS) for 12 hours (A, C and E) or 24 hours (B, D 
and F) in the presence or absence of 5µM SF (vehicle control for SF = < 0.1% (v/v) DMSO). 
RNA was extracted, quantified and analysed by real-time RT-PCR. Data shown = mean ± 
SD. Data was statistically analysed using one-way ANOVA followed by Bonferroni 
multiple comparison tests. **p<0.01 and *** p<0.001 as annotated; n.d. not detected. 
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8.2.2. Effect of MaCM in the presence or absence of SF on SGBS cells  
8.2.2.1. Effect of MaCM on SGBS adipocyte cell viability 
To ensure that treating the SGBS adipocytes with MaCM would not result in any cytotoxic 
effects, a WST-1 cell viability assay was carried out. THP-1 monocytes were differentiated 
with 125ng/ml PMA treatment for 48 hours. The medium was replaced after 48 hours with 
serum-free RPMI medium supplemented with 0.5% (w/v) BSA, in order to stabilise 
macrophage-secreted factors and cells were incubated for a further 48 hours. The cell culture 
supernatant was collected and cleared from cell debris with centrifugation and this is the 
MaCM used for subsequent experiments. When SGBS adipocytes were treated with MaCM 
from the THP-1 macrophages, concentrations of 10 and 20% did not induce any significant 
reduction in cell viability, whereas 50% caused a significant reduction with the percentage 
of viable cells remaining at approximately 70% (Figure 8.5).  
 
 
 
 
 
 
 
 
 
 
Figure 8.5. 50% MaCM significantly reduces cell viability of SGBS adipocytes. SGBS 
preadipocytes were chemically differentiated over 14 days (see section 2.2.4) to produce 
mature adipocytes. On day 14 after complete differentiation, SGBS adipocytes were treated 
with MaCM (10, 20 and 50%; vehicle control for MaCM = serum-free RPMI + 0.5% (w/v) 
BSA) for 24 hours. Once treatment was complete, 10µl WST-1 reagent was added to each 
well. The plates were incubated at 37°C and measured using a spectrophotometer every 15 
minutes. Data shown is from the 1.5 hour measurement at which levels of absorbance were 
all measurable and consistent. Data shown = mean ± SEM, n = 2. Data was statistically 
analysed using one-way ANOVA followed by Bonferroni multiple comparison tests. 
*p<0.05 compared to 0% MaCM.  
 
 
8.2.2.2 Effect of MaCM on differentiation of SGBS cells 
In previous literature, MaCM has been found to prevent differentiation of preadipocytes to 
mature adipocytes in a number of murine and human adipocyte cells with MaCM from 
various murine and human macrophages cells [258, 268, 277-281]. To confirm that during 
the differentiation process my experimental model is behaving in the same way as 
previously used models, SGBS preadipocytes were treated with doses of MaCM (10, 20 and 
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50%) and the level of lipid accumulation was measured. At all doses of MaCM, after day 7 
there was a significant reduction in the level of lipid accumulation and this is maintained up 
to day 14 (Figure 8.6).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.6. MaCM significantly suppresses differentiation of SGBS cells. SGBS 
preadipocytes were chemically differentiated in the presence or absence of MaCM (10, 20 
and 50%; vehicle control for MaCM = serum-free RPMI + 0.5% (w/v) BSA). At days 0, 4, 
7, 11 and 14, cells were fixed with 10% formalin and stained with Oil Red O. After the 
excess dye was removed, the stain was eluted and absorbance was measured at 500nm. Data 
shown = mean ± SD and is representative of two independent experiments. 10%, 20% and 
50% MaCM at days 7, 11 and 14 are all significantly different compared to their appropriate 
control for each day (*** p<0.001). 
 
 
8.2.2.3. Effect of MaCM in the presence or absence of SF on SGBS cytokine expression 
In obese subjects, there is a higher level of macrophage infiltration within the adipose tissue 
[83, 100, 101, 272, 282]. In a recent article, THP-1 macrophages and SGBS cells were 
described as the optimum model of human adipose tissue inflammation observed in obesity 
[258]. Using these cell models, the hypothesis was that MaCM from THP-1 macrophages 
was able to significantly induce the expression of pro-inflammatory cytokines e.g. IL-6, IL-
1β and TNFα, and additionally, that SF could target this induction and cause a significant 
suppression. Firstly, when SGBS adipocytes were treated with MaCM (10, 20 and 50%) for 
24 hours, a significant induction in IL-1β expression was observed. SF was able to 
significantly suppress the induction in IL-1β seen with MaCM in a dose-dependent manner 
(Figure 8.7). The same response to MaCM and SF was not seen with SGBS adipocyte IL-6 
expression (Figure 8.8). While an induction in IL-6 expression was seen in response to 
MaCM, in the presence of SF, there was an additional significant increase in IL-6 expression 
when compared to MaCM alone in SGBS adipocytes (Figure 8.8). In addition, TNFα 
expression was measured and found to be below the detection capability in all samples (data 
not shown). 
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Figure 8.7. SF significantly suppresses MaCM-induced IL-1β expression in SGBS 
adipocytes. SGBS preadipocytes were chemically differentiated over 14 days (section 2.2.4) 
to produce mature adipocytes. SGBS adipocytes were treated with MaCM (10, 20 and 50%; 
vehicle control for MaCM = serum-free RPMI + 0.5% (w/v) BSA) for 24 hours in the 
presence or absence of SF (2, 5 and 10µM; vehicle control for SF = < 0.1% (v/v) DMSO). 
Following treatment, RNA was extracted and IL-1β expression was analysed using real-time 
RT-PCR. Data shown = mean ± SD. Data was analysed using one-way ANOVA followed 
by Bonferroni multiple comparison tests. *p<0.05, **p<0.01 and ***p<0.001 compared 
against 0% MaCM (A), MaCM alone or as annotated (B-D). 
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Figure 8.8. SF significantly suppresses MaCM-induced IL-6 expression in SGBS 
adipocytes. SGBS preadipocytes were chemically differentiated over 14 days (section 2.2.4) 
to produce mature adipocytes. SGBS adipocytes were treated with MaCM (10, 20 and 50%; 
vehicle control for MaCM = serum-free RPMI + 0.5% (w/v) BSA) for 24 hours in the 
presence or absence of SF (2, 5 and 10µM; vehicle control for SF = < 0.1% (v/v) DMSO). 
Following treatment, RNA was extracted and IL-6 expression was analysed using real-time 
RT-PCR. Data shown = mean ± SD. Data was analysed using one-way ANOVA followed 
by Bonferroni multiple comparison tests. *p<0.05, **p<0.01 and ***p<0.001 compared 
against 0% MaCM (A), MaCM alone or as annotated (B-D). 
 
 
8.2.3. Analysis of MaCM  
8.2.3.1. LC-MS/MS for TCA intermediate analysis 
Due to a lack of TNFα expression by SGBS adipocytes, it was hypothesised that the 
production of IL-1β and IL-6 expression was controlled by the IL-1β signalling pathway. 
Several of the TCA cycle intermediates have been associated with enhancing the IL-1β 
signalling pathway [283]. It has been hypothesised that the TCA intermediates are able to 
influence pro-inflammatory biomarker production as a result of the activation of the hypoxia 
inducible factor (HIF)-1α pathway [283]. When macrophages are in an inflammatory state, 
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they switch their core metabolism to glycolysis and as a result a number of TCA 
intermediates may be induced which behave to stabilise the HIF-1α, resulting in activation 
of its target genes of which IL-1β is an example [283]. Based on this research, MaCM was 
analysed for a number of TCA cycle intermediates to determine whether these were the 
components of the MaCM were responsible for the effect on IL-1β and IL-6 gene 
expression. 
 
Citrate, succinate, lactate and malate were all identified at measurable concentrations in 
MaCM while the other intermediates described in Table 2.2 were below the limit of 
detection. The levels of citrate, succinate, lactate and malate increased dose-dependently as 
would be expected (Figure 8.9).  
Figure 8.9. TCA intermediate levels increase dose-dependently in MaCM from THP-1 
macrophages. THP-1 monocytes were differentiated to macrophages with a 48 hour 
treatment of 125ng/ml PMA. The macrophage-secreted factors were stabilised by culturing 
the cells with serum-free media + 0.5% (w/v) BSA for a further 48 hours. The MaCM doses 
were produced by diluting in DMEM/F12 + 10% (v/v) FCS (the control media of SGBS 
cells). The 0% MaCM condition is RPMI + 0.5% (w/v) BSA. The samples were measured 
for TCA intermediates using LC-MS/MS and data was analysed using Masshunter software 
(see section 2.11 for more details). Data shown = mean ± SD and is representative of 2 
independent experiments. **p<0.01 and ***p<0.001 compared to 0% MaCM.  
 
 
Effect of SF on adipose tissue inflammation 
 
174 
 
8.2.3.2. Effect of TCA intermediates on SGBS cytokine expression in the presence or 
absence of SF 
Based on the high levels of several TCA intermediates measured in the MaCM, SGBS 
adipocytes were treated with the average levels (from two independent experiments) of the 
pure TCA intermediates found in 50% MaCM, to investigate whether these were responsible 
for the induction in IL-1β and IL-6 expression.  
 
Differentiated SGBS adipocytes were treated with citrate, succinate, lactate and malate alone 
and in combination, however no significant changes were seen in IL-6 except for in response 
to lactate alone and the combination, as a result of the lactate presence (Figure 8.10). This 
significant reduction is likely due to the high millimolar concentration of lactate used and 
visually it could be seen to cause a high level cell death, as determined by detachment of 
cells from the culture vessel and changes in morphology. IL-1β expression was very low in 
the samples, resulting in poor amplification efficiency, preventing extrapolation of the 
relative amounts of IL-1β expression (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.10. TCA intermediates are not responsible for the induction in IL-6 
expression seen in response to MaCM. SGBS preadipocytes were chemically 
differentiated into mature adipocytes (see section 2.2.4). Once differentiation was complete, 
cells were treated with 20µM citrate, 15µM succinate, 5mM lactate and 10µM malate alone 
or in combination (all solubilised in DMEM/F12 medium) for 24 hours. RNA was extracted 
and IL-6 expression was analysed using real-time RT-PCR. Data shown = mean ± SD. Data 
was analysed using one-way ANOVA followed by Bonferroni multiple comparison tests. 
***p<0.001 vs. control.  
 
 
8.2.3.3. Quantification of cytokines in MaCM 
During the differentiation process, the morphological changes from monocytes to 
macrophages are accompanied by a number of functional changes such as the level of 
cytokine expression, which would affect the level available for secretion [268]. A number of 
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independent THP-1 monocyte differentiation experiments were carried out and MaCM from 
four independent experiments were analysed. Levels of IL-6, IL-1β and TNFα were 
quantified by ELISA. TNFα was present at levels almost three times higher than either IL-6 
or IL-1β (Table 8.1). 
 
 
 
 
 
 
 
 
 
 
 
8.2.3.4. Effect of TNFα on SGBS cytokine expression in the presence or absence of SF 
Prior to the analysis of MaCM described in Table 8.1, an individual batch of MaCM was 
analysed to give an indication as to the levels of TNFα. A level of around 1ng/ml was found 
which was significantly lower than the levels calculated in Table 8.1 with the larger sample 
group. However, this lower concentration was used to establish an experimental design 
where SGBS adipocytes were treated with pure TNFα (0.1, 0.2 and 0.5ng/ml) which was 
thought to be representative for 10, 20 and 50% MaCM in the presence or absence of SF (2, 
5 and 10µM) prior to measuring IL-1β and IL-6 gene expression. TNFα treatment 
significantly induced IL-1β gene expression in a dose-dependent manner (Figure 8.11A). SF 
however was unable to suppress this induction with no effect seen at 2 and 5µM, but a 
further significant induction was seen when the SGBS adipocytes were co-treated with 
10µM SF and TNFα (Figure 8.11B-D). The same response to TNFα and SF treatment was 
not observed with IL-6 expression. While TNFα treatment significantly induced IL-6 
expression in a dose-dependent manner, there were no significant effects seen with SF 
treatment (Figure 8.12).  
 
Table 8.1. Levels of cytokines quantified in MaCM 
Cytokine Concentration  
(ng/ml; mean ± SEM*) 
IL-6 8.2 ± 0.6 
IL-1β 6.7 ± 1.7 
TNFα 21.3 ± 1.7 
*Data from four independent experiments 
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Figure 8.11. TNFα induces IL-1β expression in SGBS adipocytes and when co-treated 
with 10µM SF, there is an additional induction. SGBS preadipocytes were differentiated 
for 14 days (section 2.2.4) to produce mature adipocytes. SGBS adipocytes were treated for 
24 hours with TNFα (0.1, 0.2 and 0.5ng/ml; vehicle control for TNFα = PBS) in the 
presence or absence of SF (2, 5 and 10µM; vehicle control for SF = < 0.1% (v/v) DMSO). 
Following treatment, RNA was extracted and IL-1β expression was analysed using real-time 
RT-PCR. Data shown = mean ± SD. Data was analysed using one-way ANOVA followed 
by Bonferroni multiple comparison tests. **p<0.01 and ***p<0.001 compared against 
0ng/ml TNFα (A), TNFα alone or as annotated (B-D). 
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Figure 8.12. TNFα induces IL-6 expression in SGBS adipocytes while SF has no 
significant effect. SGBS preadipocytes were differentiated for 14 days (section 2.2.4) to 
produce mature adipocytes. SGBS adipocytes were treated for 24 hours with TNFα (0.1, 0.2 
and 0.5ng/ml; vehicle control for TNFα = PBS) in the presence or absence of SF (2, 5 and 
10µM; vehicle control for SF = < 0.1% (v/v) DMSO). Following treatment, RNA was 
extracted and IL-6 expression was analysed using real-time RT-PCR. Data shown = mean ± 
SD. Data was analysed using one-way ANOVA followed by Bonferroni multiple 
comparison tests. ***p<0.001 compared against 0ng/ml TNFα (A) or as annotated (B-D). 
 
 
8.2.4. Effect of pre-treating SGBS adipocytes with SF on MaCM-induced 
cytokine expression 
To further characterise the main targets by which SF could exert its anti-inflammatory 
effects, SGBS adipocytes were pre-treated with SF (2, 5 and 10µM) for 24 hours prior to 
being exposed to MaCM. The aim was to investigate whether a different effect was seen 
with IL-1β and IL-6 gene expression using a SF pre-treatment as compared to the previous 
experimental design based on SF co-treatment with MaCM (Figures 8.7 and 8.8). MaCM 
significantly induced IL-1β expression and SF significantly suppressed MaCM induction of 
IL-1β expression seen with 20 and 50% MaCM (Figure 8.13). 
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Figure 8.13. SF significantly suppresses MaCM-induced IL-1β expression in SGBS 
adipocytes when used as a pre-treatment. SGBS preadipocytes were differentiated for 14 
days (section 2.2.4) to produce mature adipocytes. SGBS adipocytes were treated for 24 
hours with SF (2, 5 and 10µM; vehicle control for SF = < 0.1% (v/v) DMSO) before being 
exposed to MaCM (10, 20 and 50%; vehicle control for MaCM = serum-free RPMI + 0.5% 
(w/v) BSA) for a further 24 hours. Following treatment, RNA was extracted and IL-1β 
expression was analysed using real-time RT-PCR. Data shown = mean ± SD. Data was 
analysed using one-way ANOVA followed by Bonferroni multiple comparison tests. 
*p<0.05, **p<0.01 and ***p<0.001 compared against 0% MaCM (A), MaCM alone or as 
annotated (B-D). 
 
 
A significant induction in IL-6 gene expression with MaCM treatment was observed. 
However, SF at 10µM was able to further increase IL-6 expression with 10% MaCM 
(Figure 8.14).  
Effect of SF on adipose tissue inflammation 
 
179 
 
Figure 8.14. SF had no consistent significant effects on MaCM-induced IL-6 expression 
in SGBS adipocytes when used as a pre-treatment. SGBS preadipocytes were 
differentiated for 14 days (section 2.2.4) to produce mature adipocytes. SGBS adipocytes 
were treated for 24 hours with SF (2, 5 and 10µM; vehicle control for SF = < 0.1% (v/v) 
DMSO) before being exposed to MaCM (10, 20 and 50%; vehicle control for MaCM = 
serum-free RPMI + 0.5% (w/v) BSA) for a further 24 hours. Following treatment, RNA was 
extracted and IL-6 expression was analysed using real-time RT-PCR. Data shown = mean ± 
SD. Data was analysed using one-way ANOVA followed by Bonferroni multiple 
comparison tests. *p<0.05, **p<0.01 and ***p<0.001 compared against 0% MaCM (A), 
MaCM alone or as annotated (B-D). 
 
 
8.2.5. Effect of targeting macrophages with SF prior to challenging SGBS 
adipocytes with MaCM  
8.2.5.1. Effect of MaCM from SF pre-treated macrophages on cytokine expression in 
SGBS adipocytes 
To establish whether SF was able to target the macrophages with anti-inflammatory effects, 
THP-1 macrophages were treated with SF (2, 5 and 10µM) for 48 hours when medium was 
replaced with RPMI supplemented with 0.5% (w/v) BSA. MaCM from SF-treated and 
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untreated macrophages was collected and SGBS adipocytes were exposed to MaCM for 24 
hours before IL-1β and IL-6 gene expression was measured.  
 
Treatment with MaCM from SF-treated macrophages resulted in a significantly reduced 
level of IL-1β and IL-6 gene expression induction compared to the levels seen in response to 
MaCM from untreated macrophages (Figure 8.15 and 8.16).  
Figure 8.15. MaCM from SF-treated macrophages demonstrates significantly reduced 
levels of IL-1β gene expression induction. THP-1 monocytes were differentiated into 
macrophages with 125ng/ml PMA treatment for 48 hours. The macrophages were then 
incubated with RPMI + 0.5% (w/v) BSA in the presence or absence of SF (2, 5 and 10µM; 
vehicle control for SF = < 0.1% (v/v) DMSO) for a further 48 hours. SGBS preadipocytes 
were chemically differentiated for 14 days (section 2.2.4) to produce mature adipocytes. 
SGBS adipocytes were treated for 24 hours with MaCM (10, 20 and 50%; vehicle control 
for MaCM = serum-free RPMI + 0.5% (w/v) BSA) from either SF-treated or control-treated 
macrophages. RNA was extracted and IL-1β expression was analysed using real-time RT-
PCR. Data shown = mean ± SD. Data was analysed using one-way ANOVA followed by 
Bonferroni multiple comparison tests. *p<0.05, **p<0.01 and ***p<0.001 compared against 
0% MaCM (A), MaCM alone or as annotated (B-D). 
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Figure 8.16. MaCM from SF-treated macrophages demonstrates significantly reduced 
levels of IL-6 gene expression induction. THP-1 monocytes were differentiated into 
macrophages with 125ng/ml PMA treatment for 48 hours. The macrophages were then 
incubated with RPMI + 0.5% (w/v) BSA in the presence or absence of SF (2, 5 and 10µM; 
vehicle control for SF = < 0.1% (v/v) DMSO) for a further 48 hours. SGBS preadipocytes 
were chemically differentiated for 14 days (section 2.2.4) to produce mature adipocytes. 
SGBS adipocytes were treated for 24 hours with MaCM (10, 20 and 50%; vehicle control 
for MaCM = serum-free RPMI + 0.5% (w/v) BSA) from either SF-treated or control-treated 
macrophages. RNA was extracted and IL-6 expression was analysed using real-time RT-
PCR. Data shown = mean ± SD. Data was analysed using one-way ANOVA followed by 
Bonferroni multiple comparison tests. *p<0.05 and ***p<0.001 compared against 0% 
MaCM (A), MaCM alone or as annotated (B-D). 
 
 
8.2.5.2. Quantification of cytokine levels in MaCM from SF-treated macrophages  
To gain more information about how the pre-treatment of macrophages with SF resulted in a 
significant reduction of both IL-1β and IL-6 gene expression in SGBS adipocytes, the levels 
of IL-1β, IL-6 and TNFα were quantified in the MaCM from SF-treated or control-treated 
macrophages in the same way as described for Table 8.1. SF treatment significantly reduced 
the levels of IL-1β, IL-6 and TNFα secreted by the macrophages dose-dependently (Figure 
8.17). 
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Figure 8.17. SF significantly suppresses cytokine secretion of macrophages. THP-1 
monocytes were treated with 125ng/ml PMA for 48 hours to allow differentiation to 
macrophages. THP-1 macrophages were then treated with SF (2, 5 and 10µM; vehicle 
control for SF = < 0.1% (v/v) DMSO) in RPMI + 0.5% (w/v) BSA to stabilise macrophage-
secreted factors for a further 48 hours. The MaCM was collected and cytokines were 
measured by ELISA. Data shown = mean ± SD. Data was statistically analysed using one-
way ANOVA followed by Bonferroni multiple comparisons tests. * p<0.05 and ***p<0.001 
compared to 0µM SF. 
 
 
8.3. Discussion 
In the previous chapters, it was reported that SF was able to exert anti-inflammatory effects 
at physiologically relevant concentrations by targeting not only the TLR4 signalling 
pathway, but also TLR2 and NOD2 inflammatory signalling pathways. This led to the 
conclusion that SF was able to exert its anti-inflammatory effects as a result of a multi-
targeted approach. Obesity is often characterised by a state of chronic inflammation and is 
an independent risk factor for cancers at several sites [63-65], CVD [66-70] and T2DM [71]. 
Adipose tissue inflammation is common in obese subjects and contributes to the increased 
risk of morbidities associated with obesity. For this reason, the hypothesis of whether SF 
was able to suppress pro-inflammatory cytokine expression in response to macrophage-
secreted factors was explored.  
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SF at a concentration of 5µM was able to suppress LPS-induced cytokine expression and 
secretion in differentiated THP-1 macrophages in a similar way to the results seen in 
Chapter 3 with THP-1 monocytes and previous results from Lin and colleagues [185]. These 
findings support the use of THP-1 macrophages for treatment of SGBS cells with MaCM as 
a highly reproducible and inexpensive in vitro model of adipose tissue inflammation based 
on the research by Keuper and colleagues [258].  
 
The MaCM from THP-1 macrophages was found to significantly prevent preadipocyte 
differentiation at concentrations as low as 10% MaCM. These findings were found to be 
specific to this in vitro model of adipose tissue inflammation [268]. A number of alternative 
models have been used and the most commonly described combination was murine 3T3-L1 
cells and the murine RAW 264.7 macrophages. These murine cell lines have been observed 
to behave differently to similar cell types of human origin [258]. This was demonstrated 
when murine 3T3-L1 cells were subjected to treatment with MaCM from murine J774 
macrophages, where differentiation was only completely suppressed in the presence of 80-
100% MaCM [277-280].  
 
Based on previous findings [258, 281, 284, 285], the hypothesis that SF was able to suppress 
pro-inflammatory gene expression potentially increased in response to THP-1 MaCM in 
human SGBS adipocytes was investigated. Mature SGBS adipocytes that were exposed to a 
co-treatment of SF (2, 5 and 10µM) and MaCM (10, 20 and 50%) demonstrate a significant 
suppression of MaCM-induced IL-1β expression with concentrations from 5µM SF, but a 
further increase in IL-6 expression at the highest SF concentration (Figure 8.7 and 8.8). 
Unlike IL-1β which is widely accepted as a pro-inflammatory cytokine, IL-6 is more 
controversial with reports demonstrating its pleiotropic nature. For example, in reference to 
obesity, which is often associated with insulin resistance, IL-6 can have beneficial effects in 
some cases [286, 287]. Therefore, the additional increase in response to SF may be 
beneficial to consequences of adipose tissue inflammation. Furthermore, this experimental 
design is focusing on the effect SF exerts directly on the SGBS adipocytes due to SF being 
administered as a co-treatment with MaCM.  
 
In addition to IL-1β and IL-6, the levels of TNFα expression was also measured as had been 
carried out in previous chapters. However, no detectable expression was found. In previous 
reports with SGBS cells, a significant increase in IL-6 and IL-1β in response to MaCM has 
been observed, however in the same studies there was no mention of the effect on TNFα 
expression [258, 281, 284, 285]. In this in vitro context where the expression of the 
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adipocytes alone is measured, there may be little relevance in measuring TNFα and this may 
support findings that that the majority of TNFα expression within adipose tissue is as a result 
of the SVF and in particular, ATMs [83, 96, 100, 281, 288] as opposed to the adipocytes 
themselves.  
 
It was hypothesised that the induction in IL-1β and IL-6 in response to MaCM could be 
through the IL-1β pathway. This pathway has been recently investigated in terms of its link 
with TCA intermediates, succinate and malonate which can behave to accentuate the 
inflammatory signalling through this pathway [283]. While levels of citrate, succinate, 
lactate and malate were detected in the MaCM, these compounds were not found to be 
responsible for the induction. This led to the investigations of the cytokines produced by the 
macrophages [281, 284, 285, 289-291]. Non-fat cells within the adipose tissue are described 
as being predominantly responsible for production of these pro-inflammatory mediators [83, 
96, 100, 281, 288]. TNFα was found at the highest level with between 2.5 and 3-fold higher 
than the levels of IL-6 and IL-1β within the MaCM. Gagnon and colleagues presented data 
that measured IL-1β in MaCM also from THP-1 macrophages at a level of 500pg/ml, 
significantly lower than the levels reported in this chapter [289]. This could be as a result of 
Gagnon and colleagues collecting the media after only 24 hours culture (48 hours after 
differentiation in the present study), a lack of BSA presence to stabilise the macrophage-
secreted factors (0.5% (w/v) BSA added to serum-free RPMI in this chapter) and also could 
be affected by the passage number of the THP-1 monocytes used for differentiation  
 
Both IL-1β and IL-6 expression levels were significantly induced in response to all TNFα 
concentrations (Figure 8.11A and 8.12A). This is consistent with previous findings where 
TNFα was able to significantly induce pro-inflammatory gene expression, of which IL-6 was 
consistently an example, in human adipocytes [100, 292, 293]. IL-1β expression was further 
induced when exposed to TNFα in combination with 10µM SF (Figure 8.11B-D), while IL-
6 expression induced by TNFα was unaffected by SF presence (Figure 8.12B-D). 
Surprisingly, these results are completely the opposite to those observed in SGBS adipocytes 
exposed to the co-treatment of MaCM and SF, where IL-1β expression induced in response 
to MaCM was significantly reduced by SF and the IL-6 expression was further induced in 
response to SF (Figure 8.7 and Figure 8.8). Based on these contradictory findings, it was 
concluded that while TNFα present within the MaCM may be partly responsible for the 
significant induction of IL-1β and IL-6 expression levels seen in response to MaCM 
treatment, SF was unable to suppress IL-1β expression and further induce IL-6 expression in 
response to MaCM via targeting of the TNFα signalling pathway.  
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Following these results, the experimental design that was used to answer the research 
question of whether SF was able to target adipose tissue inflammation was re-evaluated. As 
previously stated, the ATMs are derived from circulating monocytes [83, 281, 282], which 
would be in a pro-inflammatory state [273]. Following the consumption of broccoli, these 
pro-inflammatory circulating monocytes would be subjected to free SF at a similar 
concentration to that used in the experiments within this chapter, and would be able to 
significantly reduce the levels of pro-inflammatory gene expression of the circulating 
monocytes. These SF-suppressed monocytes would then extravasate from circulation and 
enter the tissue resulting in differentiation into ATMs. Due to their suppressed inflammatory 
status, the ATMs have the potential to be unable to express or secrete such high levels of 
pro-inflammatory mediators as seen without broccoli consumption and therefore reduce the 
level of adipose tissue inflammation. In further support, SF has been shown to accumulate in 
cells and tissues [294-298] and thus may be able to target the macrophages directly.  
 
Induction of both IL-1β and IL-6 expression was suppressed when SGBS adipocytes were 
exposed to MaCM from SF-treated macrophages compared to MaCM from control-treated 
macrophages (Figure 8.15A and 8.16B). This was presumably as a result of the observed 
significant suppression of IL-6, IL-1β and TNFα when subjected to SF treatment prior to 
collection of MaCM. This provides evidence that the response of adipocytes to MaCM is not 
as a result of individual compounds, but instead is as a result of a collection of molecules, a 
concept that has been previously suggested [279, 299]. To further address the research 
question that SF would primarily target the inflammatory cells rather than the adipocytes to 
suppress adipose tissue inflammation, an additional experimental design could be used. Prior 
to differentiation, the THP-1 monocytes could be exposed to SF at 2, 5 and 10µM before 
continuing with differentiation to macrophages. The SGBS adipocytes would then be 
exposed to MaCM from SF-treated monocytes and it could be investigated whether this is 
sufficient to suppress SGBS pro-inflammatory gene expression as a representation of 
exposure to SF following the consumption of broccoli. 
 
Following a review of relevant literature, only one published study was identified where this 
experimental design of pre-treating macrophages prior to collection of MaCM for human 
adipocyte treatment was used in order to test a grape powder extract, known to be high in the 
polyphenol quercetin [270]. Quercetin was able to suppress pro-inflammatory basal gene 
expression in the macrophages and when human adipocytes were treated with MaCM from 
quercetin-treated macrophages, there was a significantly lower capacity for inducing 
inflammation in the adipocytes [270]. The disadvantage of this study is that quercetin in 
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humans is not readily biologically available unlike SF, but nevertheless these results 
demonstrate an additional dietary factor that may target adipose tissue inflammation. 
Another study carried out investigating the effect of polyphenols on adipose tissue 
inflammation investigated the effect of resveratrol on plasminogen activator inhibitor-1, a 
protein involved in obesity [269]. In that study, they used the same experimental design as 
seen with the results shown in Figures 8.7 and 8.8, where the SGBS adipocytes were co-
treated with THP-1 MaCM (prepared in the same way as in the experiments within this 
chapter) and resveratrol, with the only difference being a 48 hour treatment [269].  
 
From an experimental viewpoint, there was an inconsistency in the method used for the 
production of MaCM in this chapter compared to many other studies. Within this chapter, 
MaCM from human THP-1 cells was prepared by differentiating monocytes with PMA 
(125ng/ml) for 48 hours, followed by replacement of the media with serum-free RPMI 
supplemented with 0.5% (w/v) BSA in order to stabilise the macrophage-secreted factors for 
a further 48 hours, before collecting and using as MaCM. This is in accordance to the 
method used in previous studies [258, 268, 269]. In the study by Bassols and colleagues, 
MaCM was derived from THP-1 cells in a different way by differentiating the monocytes for 
only 24 hours followed by replacement of the medium, without BSA addition, before 
collecting the supernatant as MaCM after a further 24 hours. In addition, this study used LPS 
treatment at a low concentration of 10ng/ml to activate the macrophages and following 
monocyte differentiation, the next 24 hour treatment was supplemented with LPS and 
medium was collected and known as activated MaCM (AcMaCM) [284]. MaCM alone was 
able to induce pro-inflammatory gene expression in primary human adipocytes e.g. IL-6, and 
AcMaCM was able to induce the gene expression at comparable levels [284]. This was in 
disagreement with the study findings from Lacasa and colleagues, who employed the use of 
human primary adipocytes and human primary monocytes that were differentiated to yield 
MaCM. In the same way as Bassols and colleagues, there was a comparison with MaCM 
with no activation of the macrophages and MaCM from macrophages activated with LPS 
(100ng/ml) for 24 hours. Lacasa and colleagues found no induction in IL-6 and IL-1β 
expression in preadipocytes that were treated with MaCM from unactivated macrophages, 
and only saw an induction when cultured with AcMaCM [284]. This study does however 
make use of a very different experimental design in which the preadipocytes are 
differentiated in the presence of MaCM before measuring the inflammatory gene expression 
signature, whereas in the experiments presented in this chapter and previously reported 
studies, it was carried out in mature differentiated adipocytes. Nevertheless, comparable 
results to those found in this study were seen with a significant induction in IL-6 expression 
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in preadipocytes cultured in the presence of MaCM from ATMs [284]. This may further 
support the use of the SGBS adipocytes and THP-1 macrophages as the most advantageous 
in vitro model of adipose tissue inflammation as suggested by [258]. 
 
The data within this chapter has provided some evidence for how SF, at a physiological 
concentration, could exert beneficial effects on an in vitro model of adipose tissue 
inflammation with a multi-targeted approach. At a physiologically relevant concentration, 
SF was able to significantly suppress adipogenesis and the adipocyte inflammatory response 
by targeting the adipocytes directly and also macrophages prior to SGBS adipocytes being 
exposed to the macrophage-secreted factors. While the recent in vivo study with a rodent 
model by Choi and colleagues was able to demonstrate a significant reduction in weight gain 
with SF, as a result of a reduction in the amount of epididymal tissue depots via specifically 
targeting the important PPARγ and C/EBPα transcription factors and adipokines, the 
concentration used was supraphysiological. For this reason and based on the promising 
results seen with the in vitro work in this chapter, this hypothesis could be further 
investigated by designing in vivo studies in rodents using a concentration that is 
physiologically relevant to the consumption of broccoli. To further translate the results, a 
human dietary intervention study could be designed to monitor the effect of broccoli 
consumption on the low-grade inflammatory status commonly found in obese subjects.  
 
 
8.4. Conclusions 
It is apparent from the results in this chapter that SF was able to exert its anti-inflammatory 
effects via a multi-targeted approach, not limited to individually activated signalling 
pathways (Chapters 3-6). Human SGBS adipocytes were subjected to treatment with THP-1 
MaCM in combination with SF. SF was able to significantly suppress the pro-inflammatory 
IL-1β cytokine expression but increase the pleiotropic IL-6 expression. It was discovered 
that although macrophages are responsible for large levels of TNFα production, TNFα alone 
was not solely responsible for the induction seen in IL-1β and IL-6 in response to MaCM 
and in addition, SF does not target the TNFα signalling pathway. It is likely that the 
induction seen with MaCM and the suppression with SF is due to a combination of 
molecules produced by the macrophages.  
 
By targeting the macrophages directly in an improved experimental design representing a 
model of adipose tissue inflammation following consumption of broccoli, there was a 
significant reduction in the levels of IL-1β and IL-6 expression by the SGBS adipocytes 
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presumably as a result of a reduction in the levels of IL-1β, IL-6 and TNFα present within 
the MaCM.  
 
This provides support for continuing this work in vivo, first in a rodent model using a 
physiologically relevant amount of SF which could be further translated into a human 
intervention study where obese subjects with a state of low-grade inflammation could 
consume a diet supplemented with broccoli, before measuring whether this dietary 
intervention resulted in an improvement in their systemic inflammatory status.  
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9.1. Summary of findings 
The overall aim of this study was to establish whether SF, the dietary ITC from broccoli, 
was able to significantly suppress pro-inflammatory signalling in an in vitro model of 
chronic inflammation at a physiologically relevant concentration. It has been well-
documented that SF can behave to induce phase 2 enzymes, halt the cell cycle, alter cell 
metabolism and also affect inflammation [300]. The work in this thesis aimed to shed light 
on whether the effect of SF was targeted to several pro-inflammatory mediators or whether it 
was able to target signalling pathways on a global scale, in addition to investigating potential 
mechanistic explanations before translating the findings into an in vitro model of adipose 
tissue inflammation.  
 
In Chapter 3, the aim was to develop an in vitro model of chronic inflammation. Human 
monocytes (PBMCs and THP-1 monocytes) were the cell models of choice due to their 
importance in the inflammatory response. It was established that very low concentrations of 
LPS could be used with these sensitive cell types, with 1ng/ml being sufficient to induce the 
production of commonly studied pro-inflammatory cytokines IL-6, IL-1β and TNFα. While 
the ex vivo model of PBMCs have their advantages, the THP-1 monocyte cell line was able 
to mimic their response to LPS. At physiological concentrations of SF, a significant 
reduction was seen in the levels of cytokine secretion and expression in both PBMCs and 
THP-1 monocytes induced in response to LPS. 
 
Chapter 4 aimed to determine whether the results seen in Chapter 3 were a specific response 
or whether SF was able to affect the global expression pattern of THP-1 monocytes exposed 
to LPS using Affymetrix GeneChip® Human Exon 1.0ST arrays. In the absence of LPS, SF 
at only 5µM was able to demonstrate a significant induction in genes encoding phase 2 
enzymes and enzymes involved in cell metabolism, findings which were comparable to 
previously published data. A concentration of 5µM SF was able to significantly oppose all 
gene expression changes induced in response to LPS, allowing the conclusion that SF can 
target the TLR4-LPS signalling pathway on a global scale.  
 
As a result of SF demonstrating the ability to target all genes induced by LPS, it was 
hypothesised in Chapter 5 that SF was able to target the TLR4 receptor directly, which had 
also been suggested by previously published research [195]. Experiments were initially 
carried out using a recombinant form of the extracellular domain of TLR4 with varying 
concentrations of SF. Concentrations as low as 5µM were able to modify thiol groups of 
cysteine residues within the TLR4 receptor. While investigations were carried out into 
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whether SF was able to modify the TLR4 in vitro, technical difficulties resulted in this not 
being ascertained.  
 
With all of the experiments thus far being dependent on TLR4 signalling, in Chapter 6 the 
aim was to establish whether the anti-inflammatory effects seen were limited to this 
particular pathway, or if the same suppression could be seen when other important pro-
inflammatory signalling pathways were activated. With the use of HEK293 cells that were 
stably transfected with the TLR4, TLR2 and NOD2 PRRs, in combination with an SEAP 
reporter gene under the control of NF-κB, the effect of SF was investigated with both the L-
SF form derived from broccoli and DL-SF, the synthetic analogue. SF was able to 
significantly suppress ligand-induced NF-κB activity at physiologically relevant 
concentrations in response to the TLR4, TLR2 and NOD2 agonists. In addition, 
polymorphisms within the TLR4 and the NOD2 receptors were investigated which have 
been implicated in the IBD, Crohn’s disease. While the SNPs in TLR4 had no impact on the 
level of response to either LPS or SF, the G908R NOD2 mutant demonstrated a significantly 
lower response to the NOD2 agonist MDP, at higher concentrations. The G908R-expressing 
cells also demonstrated a significantly larger reduction in NF-κB activity in response to SF, 
compared to the response seen in cells expressing the NOD2 wildtype receptor. This 
provides some evidence that SF may be able to have anti-inflammatory effects, to varying 
extents, depending on the genotype, displayed in Crohn’s disease sufferers.  
 
Based on the compiled results thus far, the next step was to translate these findings into a 
more complex in vitro model designed to mimic human adipose tissue inflammation. 
Initially, the effects of SF alone on adipogenesis were explored in human SGBS cells 
(Chapter 7). SF was able to significantly suppress the level of lipid accumulation at a 
concentration of 10µM and concomitantly, induce the level of CPT1A gene expression, a 
fundamental enzyme in fatty acid β-oxidation. With no change seen in glycerol release, it 
was suggested that the reduced level of lipid accumulation was not as a result of an 
induction in lipolysis. 
 
In the final chapter, the ability of SF to suppress cytokine production by human SGBS 
adipocytes in response to MaCM from THP-1 macrophages was tested in an in vitro model, 
aimed to simulate adipose tissue inflammation in humans. While SF was able to 
significantly suppress the levels of IL-1β expression induced in response to MaCM in an 
experimental design where SF was targeting the adipocytes directly, IL-6 expression was 
further increased in response to MaCM and 10µM SF. Following optimisation of the 
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experimental design, both IL-1β and IL-6 expression was significantly suppressed following 
treatment with MaCM from SF-treated macrophages. Investigations were carried out to try 
and conclude the particular targets of SF in the MaCM response, and while the TNFα 
pathway was ruled out, no definitive evidence was determined, with the hypothesis being 
that SF was exerting anti-inflammatory effects in a multi-targeted fashion to suppress 
chronic inflammation.  
 
Much of the work described in this thesis is summarised in Figure 9.1.  
 
Figure 9.1. Targets of SF for suppression of chronic inflammation. SF is able to target 
circulating monocytes that may be exposed to levels of LPS at around 1ng/ml and suppress 
the levels of pro-inflammatory cytokines produced by interacting with the TLR4 directly or 
by suppressing NF-κB activity. Monocytes differentiate into macrophages and infiltrate the 
adipose tissue. SF can target the macrophages directly and lower their inflammatory 
potential, subsequently preventing induction of pro-inflammatory cytokine expression in the 
adipocytes. SF is able to suppress lipid accumulation within adipocytes, a process that 
occurs during obesity and increase triglyceride metabolism. 
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9.2. How do these results compare with previous literature? 
The effect of SF on inflammatory signalling has been investigated previously with variations 
in the experimental designs. In Chapter 3, the experiments initially began with the use of an 
ex vivo model of PBMCs from healthy donors to optimise the appropriate concentration of 
LPS to use in order to simulate an inflammatory response. While the ex vivo models have 
distinct advantages due to their increased relevance to in vivo conditions, experimentally 
they have disadvantages. For this reason, the use of an in vitro monocytic cell line was used 
namely the THP-1 cell line, which had been previously described as a good model for 
human monocytes [229]. Both cell models were able to significantly respond to 
concentrations of 1ng/ml LPS, in terms of cytokine expression and secretion, and these 
levels were significantly suppressed with physiologically relevant concentrations of SF. In 
comparison to other studies, the importance of this data comes from the use of a very low 
concentration of LPS. A concentration approaching 1ng/ml is physiologically relevant to the 
levels of endotoxin that can be achieved in circulation in individuals that are suffering from 
a chronic inflammatory disorder [37, 45, 46], and even when the concentrations of LPS were 
further increased, there was little difference in the level of induction. In many studies, 
concentrations in the µg/ml range have been used which is not representative of the levels 
achieved in circulation following an acute inflammatory attack such as septic shock [197]. 
An additional finding in the comparison with other studies is that many are carried out with 
cell lines of murine origin or with cells from different locations within the body e.g. 
microglial cells and mouse macrophages. This therefore makes comparisons of the results 
difficult due to potential species differences and variations in response to LPS.  
 
When investigated on a global scale (Chapter 4), SF alone was able to significantly affect 
expression of THP-1 monocytes, with a number of phase 2 enzymes being up-regulated in 
addition to a number of genes encoding enzymes involved in carbohydrate cell metabolism. 
The effect of SF on phase 2 enzyme expression has been widely documented at varying 
concentrations. The expression of genes such as NQO1 and TXNRD1 were commonly up-
regulated in cells from a wide range of locations with concentrations as low as 1-2µM 
demonstrating an induction in both global scale microarray analyses and RT-PCR, however 
in some studies concentration as high as 50µM SF were used [140-153, 160, 231, 232, 301].  
 
The investigations with SF and LPS, found that SF was able to oppose the effects of LPS on 
a global scale as demonstrated by a significant linear regression analysis (p < 0.001). To the 
best of my knowledge, the global effect of SF on LPS signalling has not been previously 
investigated. These results demonstrate the importance of untargeted approaches to gain 
General discussion 
 
194 
 
more information about the extent of the effect rather than targeting a selection of specific 
biomarkers.  
 
Based on previous literature and the findings describing the ability of SF to target the whole 
TLR4 pathway, Chapter 5 aimed to investigate potential mechanisms of SF. Youn and 
colleagues demonstrated that SF at a concentration of 100µM was able to directly modify 
cysteine residues within the extracellular domain of the TLR4 [195]. Similar changes were 
found in the investigations in Chapter 5 when the recombinant receptor was exposed to SF at 
the same concentration under reducing conditions. However, to make it more comparable to 
the in vitro and in vivo environment, the experiments were carried out under non-reducing 
conditions and found that Cys609 and Cys246 were modified by much lower concentrations 
of SF. The concept of direct binding of SF to proteins has been previously described with SF 
being able to bind directly to cysteine residues in proteins such as the Keap1 and MD2. This 
function has also been described with other ITC compounds due to the common electrophilic 
nature and was reviewed by Brown and colleagues [302]. In order to determine whether thiol 
modification by SF was a plausible mechanism for the results seen in Chapters 3 and 4, it 
was important to try and model these findings in vitro. While investigations were carried 
out, due to technical difficulties, conclusions could not be made. This is a general difficulty 
in the area of investigating the thiol adduct mechanism, as to the best of my knowledge, 
direct interactions with any proteins by SF via thiol modification has not been demonstrated 
in vitro.  
 
The findings in Chapter 6 which demonstrated that SF was able to target additional 
inflammatory signalling pathways namely TLR2 and NOD2, led to the hypothesis that SF 
was able to suppress inflammatory signalling via multiple targets. In these experiments, 
levels of NF-κB activity were determined by measuring the levels of reporter gene SEAP 
activity. Both L-SF and DL-SF, at physiologically relevant concentrations, were able to 
significantly suppress NF-κB activity in response to agonists specific to the TLR4, TLR2 
and NOD2 receptors. While polymorphisms within the TLR4 receptor had no effect on the 
response to either LPS or SF, the G908R polymorphism resulted in a significantly lower 
response to higher concentrations of MDP and also demonstrated a larger reduction in 
response to SF. This was possibly as a result of the change in amino acid properties, where a 
small aliphatic glycine was replaced with a longer chain, positively charged arginine residue, 
which could potentially alter interactions. In comparison with other studies that have 
investigated the effect of the G908R mutant, there were contrasting views. Much larger 
reductions in the response to MDP have been observed previously [251, 253], however the 
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results in the present study were more comparable to those presented by Lecine and 
colleagues [254].  
 
SF has previously been shown to exert an inhibitory effect on NF-κB activity targeting the 
DNA binding activity of NF-κB or by directly targeting the inhibitor and subsequently 
affecting the translocation of the transcription factor to the nucleus, where it can actively 
affect the transcription of its associated genes. In terms of aiming to suppress chronic 
inflammation, this may be a favoured target due to the fact that a large number of other 
phytochemicals have demonstrated significant suppression on the activity including 
curcumin and resveratrol [240]. 
 
In Chapters 7 and 8, the aim was to translate the findings of the previous chapters into a 
more complex model of chronic inflammation via the use of human SGBS adipocytes, to 
model adipose tissue inflammation. In Chapter 7, it was established that SF at a 
concentration of 10µM was able to significantly reduce the levels of lipid accumulation 
within the cells. During obesity, the levels of lipid accumulation within adipocytes are 
elevated and due to an imbalance between the rate of accumulation and the rate of β-
oxidation, FFAs are released in to systemic circulation. When triglycerides are metabolised, 
the glycerol backbone is released and can be measured as a marker of lipolysis. In the 
present study, no change in the level of glycerol released was observed but a significant 
increase in the level of CPT1A expression was demonstrated. The hypothesis was that there 
would be a reduction in the levels of lipids with SF as a result of an induction in lipolysis as 
previously suggested, but this was not the case [163]. The increase in the level of CPT1A 
expression was however in accordance with the suggestion that SF has an effect on β-
oxidation, a hypothesis also suggested based on findings from a human intervention study 
with high-GSL broccoli [166]. While the effect of lipid accumulation has been previously 
published, the effect has only been determined in 3T3-L1 cells, a mouse fibroblast cell line 
that demonstrates behaviours similar to adipocytes [162, 164, 259]. Therefore, these results 
confirm the importance of investigating the effect of SF on human adipocytes at 
concentrations in a physiologically achievable range.  
 
Finally, the level of pro-inflammatory cytokine production by SGBS adipocytes was 
monitored following treatment with MaCM from THP-1 macrophages. This combination of 
cell models has been previously described as the most representative model for human 
adipose tissue inflammation [258]. When treating the SGBS cells with the MaCM and SF as 
a co-treatment, contrasting results were seen in terms of the effect on IL-1β expression 
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compared to IL-6 expression. Optimisation of the experimental design led to the treatment of 
macrophages with SF prior to collection of the MaCM, in order to produce a more relevant 
in vitro model representing the effect of consuming broccoli on adipose tissue inflammation. 
When SGBS adipocytes were then exposed to MaCM from SF-treated macrophages, there 
was a dose-dependent decrease in the levels of both IL-1β and IL-6 expression.  
 
While these cell models have been used in other studies, only  polyphenol compounds have 
been investigated in terms of their effects on inflammatory cytokine production. In 
particular, only one article that used the same experimental design was identified, where 
macrophages were pre-treated with quercetin [270]. Treatment of SGBS adipocytes with 
MaCM from quercetin-treated macrophages demonstrated a significant reduction in the 
expression of pro-inflammatory mediators. However, quercetin is considerably less bioactive 
than SF and therefore the results seen in the present study with SF may be of increased 
biological relevance for investigating the effects of phytochemicals on pro-inflammatory 
signalling.  
 
 
9.3. Limitations of the research 
The major limitation of this research is that all experiments presented are from in vitro cell 
models or cell-free systems. Results from in vitro studies are difficult to translate to in vivo 
situations for a number of reasons. These include the fact that the cells are isolated in culture 
and do not experience the same conditions as encountered in vivo such as the hypoxic nature 
and without existing in circulation a number of growth factors may not be experienced. 
However, when investigating mechanistic details of the effects of SF, it would be more 
difficult to investigate in an in vivo model. Hence, without these in vitro studies there would 
be less basis for subsequent animal and human studies.  
  
A limitation of Chapter 3 was the varying levels of cytokine production in response to LPS. 
While the LPS used was from the same batch for all experiments in Chapters 3 and 4, the 
cells varied in passage number, which could have affected the response. For this reason, it 
would be more appropriate to carry out experiments using narrower passage number ranges. 
In Chapter 4, a large amount of information from the untargeted approach of a microarray 
analysis was presented. In this chapter, the main conclusion drawn was that SF at a 
physiologically relevant concentration was able to oppose global LPS-induced gene 
expression changes in THP-1 monocytes. However, a great deal of information may have 
been over-looked. For example, in Table 4.10, several genes involved in chemokine 
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signalling were up-regulated in response to LPS with up to a 25-fold induction, which was 
reduced by up to 70% in the presence of SF. Also, the genes differentially expressed in 
response to LPS were only presented when a minimum of 2-fold change in expression due to 
the vast amount of genes altered. This could however result in important collections of genes 
being disregarded that may have had significant functional effects following only small 
changes in their expression level. The potential functional importance of small expression 
changes was hypothesised with SF treatment on carbohydrate cell metabolism, where the 
fold change observed was as low as 1.2-fold, yet due to the fact that a collection of genes 
were linked by pathway interactions, these genes were still included. It may also be 
important to follow up these gene expression differences at a protein level to ensure that 
there are functional consequences.  
 
In Chapter 5, the main limitation was that the research was carried out in a cell-free system 
with the use of a recombinant form of the TLR4 protein. While concentrations of SF were 
used at 5µM and above, the amount of protein used would have been far higher than the 
ratio of SF to TLR4 in vitro and in vivo. It is very difficult to translate the results to the 
potential effects demonstrated in vitro (Chapters 3 and 4) due to the crude experimental 
design. While the modification of the TLR4 by SF was investigated in vitro, no conclusion 
was able to be established as a result of technical difficulties. These experiments would need 
to be repeated, however, it may be difficult to identify potential SF-TLR4 adducts using the 
IP technique due to the reversible nature of SF binding.  
 
 
9.4. Future research  
The data presented in this thesis provides evidence that SF is able to target pro-inflammatory 
signalling at physiologically relevant concentrations by targeting monocytes in circulation 
and also macrophages, which in turn impacted on the inflammatory status of adipocytes 
(Figure 9.1). In terms of furthering this project, a number of extensions could be made to the 
experimental design. Firstly, the in vitro model of adipose tissue inflammation could be 
further improved to increase the level of relevance to in vivo situations by co-culturing the 
SGBS adipocytes with macrophages, either THP-1 or primary human macrophages. This 
experimental design has been previously used in several studies [258, 268]. To further the 
hypothesis that SF is able to significantly suppress adipose tissue inflammation, the SGBS 
adipocytes could be co-cultured with THP-1 macrophages that had been pre-treated with SF 
and measure whether there was a reduction in pro-inflammatory cytokine production by 
adipocytes. However, as previously discussed a limitation of the in vitro work is that it is 
General discussion 
 
198 
 
difficult to translate into an in vivo situation. For this reason, the findings within this thesis 
could be translated into an in vivo study design. An animal study could be carried out using a 
diet-induced obese (DIO) mouse model in which the effect of broccoli as a means of 
providing SF could be investigated. Collection of plasma and PBMCs would establish 
whether SF has any effect on levels of pro-inflammatory cytokines and in addition, 
collection of adipose tissue could allow comparison of the levels of macrophage infiltration 
and the expression levels of pro-inflammatory mediators.  
 
One issue however with animal studies is the concentration of SF hoped to be achieved as 
well as the delivery method of choice. Table 9.1 presents several animal studies that have 
involved SF supplementation, with a delivery method of either diet supplementation or oral 
gavage, to ensure SF is still subjected to the digestive tract. 
 
Table 9.1. Animal studies using SF supplementation 
Study 
SF dose 
(µmols/day)* 
Duration of 
supplementation 
Broccoli 
consumption 
(g/day)** 
Choi et al. 2014 [161] 28.2 6 weeks 22.6 
Davidson et al. 2013 [179] 3 12 weeks 2.4 
Abbaoui et al. 2012 [274] 7.4 2 weeks 5.6 
Traka et al. 2010 [303] 0.5 or 5 4 or 8 weeks 0.4 or 4 
Myzak et al. 2006 [304] 2500 16 weeks 2000 
*In order to calculate µmols/day two assumptions were made; the body weight of a mouse is 
approximately 25g and each mouse consumes around 5g of food per day. 
**Using the assumption that there is 0.8µmol of glucoraphanin per g of broccoli fresh weight with 
100% conversion to SF (according to method used within the research group). 
 
Table 9.1 demonstrates that there is a large amount of variation in the levels of SF used in 
animal studies and when put into perspective of the amount of broccoli that would need to 
be consumed to achieve the levels, it is clear that there is a need for more studies utilising 
physiologically relevant concentrations. Previous studies that have employed more 
physiologically relevant levels of SF such as that by Davidson and colleagues, found 
significant effects on inflammation and the expression of key metalloproteinases implicated 
in osteoarthritis, another example of a chronic inflammatory disease [179]. However, Myzak 
and colleagues investigated the effects of SF on histone deacetylase in vivo using a 
concentration far out of the range of physiological relevance and almost 100 times higher 
than used within the study by Choi and colleagues, who found significant attenuation of 
weight gain and insulin resistance in obese models [161, 304]. 
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The disadvantages of mouse models include the difficulty of translating the dose of SF used 
in the animal to the levels needed for human consumption and also the potential for species 
differences. As discussed by Keuper and colleagues, there are a number of different 
combinations of adipocytes and macrophages used either from mouse or human in order to 
study the effects of adipose tissue inflammation and large differences were seen, suggesting 
it may be difficult to achieve representative effects of human adipose tissue inflammation 
using studies in a mouse model [258]. 
 
Alternatively, a human intervention study could be carried out in which the effect of 
physiologically relevant concentrations of SF could be investigated in a targeted population 
for example, obese individuals compared to lean individuals. This would allow a comparison 
of the effect obesity on the pro-inflammatory state, in addition to any beneficial effects 
following an intervention with broccoli or SF supplements. It may be advantageous to use a 
more elderly population, based on the findings of elevated pro-inflammatory cytokines 
compared to that recorded in younger populations [21]. Study endpoints could include 
collection of plasma to monitor the levels of pro-inflammatory mediators, isolation of 
PBMCS to measure their inflammatory potential ex vivo, plus collection of adipose tissue 
samples to monitor the varying levels of macrophage infiltration between the lean and obese 
subjects and also in response to the supplementation of SF. While the collection of blood 
and PBMCs are less invasive procedures, the collection of adipose tissue from both obese 
and lean subjects would still be possible practically. Obese subjects that were undergoing a 
gastric band procedure, abdominoplasty and breast reductions could be prime candidates and 
similarly, individuals with a normal BMI could also be considered if undergoing routine 
abdominal surgery or indeed cosmetic procedures.  
 
When determining the experimental design for potential human intervention studies, it is 
important to decide upon the method of SF delivery. SF itself is unstable and therefore the 
precursor of SF, glucoraphanin would be the appropriate source. Glucoraphanin could 
potentially be delivered as either a supplement or via the use of broccoli. In the US, a 
number of broccoli extracts are available which are designed to deliver a dose of 
glucoraphanin, and by relying on the myrosinase-like behaviour of the gut microbiota, SF 
could be delivered. By using a supplement it may be possible to potentially deliver higher 
concentrations of SF as opposed to that achieved using broccoli.  
 
Nonetheless, the concentrations of 2-10µM SF used within this thesis would be achievable 
via consumption of broccoli within the diet. With standard broccoli, 2µM SF was achieved 
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in circulation after 2 hours of consuming broccoli [129]. However, with the development of 
a high-GSL broccoli, the possibility to achieve three times the amount of SF at a level of 
7.4µM was achieved with the same portion size as that of standard broccoli [129]. This high-
GSL broccoli, commercially known as Beneforté®, was produced as a result of a selective 
breeding process which results in the expression of a Myb-related protein-28 (Myb28) 
transcription factor from Brassica villosa, enabling increased production of glucoraphanin 
[305]. This provides the ability to deliver higher concentrations of glucoraphanin within the 
same portion size as that usually consumed with standard broccoli.  
 
In conclusion, this thesis provides evidence that physiologically relevant concentrations of 
SF are able to suppress pro-inflammatory signalling in models of a low-grade state of 
inflammation, a condition linked to chronic disease. For this reason, it is logical to progress 
these studies into in vivo models and determine whether a suppression of pro-inflammatory 
signalling can be achieved in humans suffering from chronic inflammation. While a health 
claim is yet to be established for broccoli, these results could provide support for increasing 
the levels of standard broccoli consumption or the commercially available high-GSL 
Beneforté® broccoli within the diet.  
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